

US 20050064462A1

(19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0064462 A1

(10) Pub. No.: US 2005/0064462 A1 (43) Pub. Date: Mar. 24, 2005

Stein et al.

(54) METHODS, COMPOSITIONS, AND KITS FOR PREDICTING THE EFFECT OF COMPOUNDS ON HOT FLASH SYMPTOMS

(76) Inventors: Bernd Stein, San Diego, CA (US);
 Helen Brady, San Diego, CA (US);
 Dan Zhu, San Diego, CA (US)

Correspondence Address: JONES DAY 222 EAST 41ST ST NEW YORK, NY 10017 (US)

- (21) Appl. No.: 10/870,387
- (22) Filed: Jun. 16, 2004

Related U.S. Application Data

(60) Provisional application No. 60/479,570, filed on Jun. 17, 2003.

Publication Classification

- - 514/651

(57) **ABSTRACT**

The present invention provides methods, compositions, and kits, for determining the effects of one or more candidate compounds on hot flash symptoms. In certain aspects, the methods, compositions, and kits can be used to identify compounds that decrease the incidence of hot flash symptoms. In other aspects, the methods, compositions, and kits can be used to determine whether candidate compounds increase the incidence of undesirable hot flash symptoms when administered to a subject.




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 1E

1. REFERENCE TO RELATED APPLICATIONS

HOT FLASH SYMPTOMS

[0001] The present application is entitled to and claims the benefit of U.S. Provisional Application No. 60/479,570, filed Jun. 17, 2003, which application is hereby incorporated by reference in its entirety.

2. FIELD OF THE INVENTION

[0002] The field of the invention generally relates to the identification of the effect of candidate compounds on hot flash symptoms based upon their effect on the regulation of expression of genes associated with hot flash symptoms. More specifically, the invention relates to identification of compounds that decrease hot flash symptoms and/or determining the effects of candidate compounds on hot flash symptoms. In another aspect, the invention provides methods of determining whether candidate compounds increase the incidence of hot flash symptoms as an undesirable side effect.

3. BACKGROUND

[0003] Hot flash symptoms are physical sensations that are experienced by subjects, most commonly by women undergoing menopause. As many as 67% to 75% of women undergoing physiological or surgical menopause report experiencing hot flash symptoms. See Agarwal and Judd, 1995, *Osteoporosis: Etiology, Diagnosis, and Management*, Riggs et al., eds., Ch. 16. "Management of Menopause," pp. 351-354. Such symptoms generally include a sudden sensation of heat radiating from the face, neck, and/or chest; chills; sweating or perspiration; anxiety; tingling; and/or pressure in the head. See id. Hot flash symptoms generally do not present serious medical issues; however, approximately 10% to 15% of menopausal women experience hot flash symptoms of sufficient severity to seek medical treatment. See id.

[0004] Hot flash symptoms can also be caused as a side effect by compounds that modulate the estrogen receptor. For example, raloxifene, commonly administered in the treatment of osteoporosis, causes approximately 11% of subjects to experience hot flash symptoms of sufficient severity to discontinue therapy. See *Drug Facts and Comparisons*, 2003, Wickersham et al., eds., Wolters Lewis Health, St. Louis, Mo., pp. 225-227.

[0005] Hot flash symptoms are believed to be mediated by endocrinological changes occurring in menopausal women that likely involve downward resetting of the central thermoregulatory mechanism. See Kronenberg and Downey, 1987, *Can. J. Physol. Pharmacol.* 65:1312-1324. These changes are believed to be mediated by the hypothalamus and/or the pituitary gland. See id.

[0006] Hot flash symptoms have generally been treated with estrogen replacement therapy. See Agerwal and Judd, supra. Unfortunately, estrogen replacement therapy presents several serious side effects, including an increased risk of endometrial, ovarian, and/or breast cancer; cardiovascular disorders; hypercalcemia; glucose tolerance; depression, and hypothyroidism, among others. *See Drug Facts and*

Comparisons, 2003, Wickersham et al., eds., Wolters Lewis Health, St. Louis, Mo., pp. 217-219.

[0007] Thus, there remains an unmet need for compounds that can be used to treat hot flash symptoms without the deleterious side effects presented by standard estrogen replacement therapy. In addition, rapid, inexpensive methods for determining the effects on hot flash symptoms of compounds indicated for the treatment of, for example, osteoporosis to identify therapeutic agents that do not increase the incidence of hot flash symptoms are also needed.

4. SUMMARY OF THE INVENTION

[0008] The present invention provides methods, compositions, and kits for determining the effects of candidate compounds on hot flash symptoms. Further, the invention provides methods, compositions, and kits for identifying candidate compounds that decrease hot flash symptoms. The methods and kits of the invention are based, in part, on the recognition of a correlation between the regulation of expression of certain genes by a cell and contact by the cell with compounds known to increase or decrease the incidence of hot flash symptoms. The methods and kits are described in reference to the embodiments of the invention that follow.

[0009] In certain aspects, the invention provides a method for determining the effect of a candidate compound on hot-flash symptoms that comprises contacting a first cell that expresses an estrogen receptor or estrogen related receptor with the candidate compound and determining the effect of the candidate compound on the first cell's expression of a panel of genes associated with hot flash symptoms.

[0010] In certain embodiments, the methods further comprise comparing the first cell's expression of the panel of genes associated with hot flash symptoms with a reference expression profile of the panel of genes associated with hot flash symptoms. In certain embodiments, the expression profile of the panel of genes can be the expression profile of the panel of genes following contacting the cell with a compound selected from the group consisting of estradiol, tibolone, raloxifene, and 4-hydroxy tamoxifen.

[0011] In other embodiments, the methods further comprise comparing the first cell's expression of the panel of genes associated with hot flash symptoms with a second cell's expression of the panel of genes associated with hot flash symptoms following contact with a compound that has a known effect on hot flash symptoms. The compound that has a known effect on hot flash symptoms can be any such compound known to one of skill in the art without limitations. In certain embodiments, the compound that has a known effect on hot flash symptoms can be selected from the group that consists of estradiol, tibolone, raloxifene, and 4-hydroxy tamoxifen.

[0012] In certain embodiments, the methods of the invention further comprise determining that the candidate compound decreases the incidence of hot flash symptoms.

[0013] In certain embodiments, the cell that expresses an estrogen receptor can express estrogen receptor α . In other embodiments, the cell that expresses an estrogen receptor can express estrogen receptor β . In certain embodiments, the cell that expresses the estrogen receptor can express both

estrogen receptor a and estrogen receptor β . In certain embodiments, the cell that expresses the estrogen related receptor can express estrogen related receptor α . In other embodiments, the cell that expresses the estrogen related receptor can express estrogen related receptor β . In yet other embodiments, the cell that expresses the estrogen related receptor can express estrogen related receptor γ . In still other embodiments, the cell that expresses the estrogen related receptor can express two or three estrogen related receptors, each of which is selected from the group that consists of estrogen related receptor α , estrogen related receptor β , and estrogen related receptor γ .

[0014] Any cell known by one of skill in the art to express the estrogen receptor or the estrogen related receptor, without limitation, can be used in the methods and kits of the invention. In certain embodiments, the cell that expresses the estrogen receptor or estrogen related receptor can be selected from the group consisting of a pituitary cell and a hypothalamus cell. In further embodiments, the cell that expresses the estrogen receptor can be a GH3 cell, a GH4 cell, a PR1 cell, a MtT/E-2 cell, a alphaT3-1 cell, a D12 cell, an RCF-8 cell, and a GT1-7 cell. In certain embodiments, the cell that expresses the estrogen related receptor can be selected from the group that consists of an A172 glioma cell, a MCF10a cell, a MCF12 cell, a MDA-MB-231 cell, a MDA-MB-435 cell, a MDA-MB-436 cell, a MDA-MB-468 cell, a Hs 578T cell, a BT 20 cell, a BT 474 cell, a BT 549 cell, a SKBr 3 cell, a ZR 75.1 cell, a T47D cell, and a MCF7 cell.

[0015] Any technique known by one of skill in the art to be useful in quantifying expression of a panel of genes associated with hot flash symptoms can be used in the methods of the invention, without limitation. In certain embodiments, the cell's expression of the panel of genes associated with hot flash symptoms can be quantified by a technique selected from the group of reverse transcription real time PCR, quantitative reverse transcription PCR, Northern blot assays, dot blot assays, reverse dot blot assays, RNAse protection assays, 5'-nuclease assays, reporter gene assays, branched DNA assays. In a preferred embodiment, the technique used to quantify the expression of the panel of genes associated with hot flash symptoms is a multiplexed array mRNA assay.

[0016] The panel of genes that is associated with hot flash symptoms can include any gene known by one of skill in the art to be associated with hot flash symptoms, without limitation. In certain embodiments, at least one member of the panel of genes that is associated with hot flash symptoms can be selected from the group consisting of Activin Beta E, Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Argininosuccinate Synthetase, Ribonucleoside Reductase 1, Interleukin-18, ARL gene 4, Calpain, EST196325, CPP32, EST208064, 2-alpha-1 globin, Amiloride Binding Protein, Annexin 1, N27, HBP1, D-binding protein, FE65, Protein Kinase C type I, Glutamate Receptor subunit d1, VAP1, Protein Kinase C subspecies epsilon, EST203549, and Heat Shock Transcription Factor 1.

[0017] In a more preferred embodiment, at least one member of the panel of genes that is associated from hot flash symptoms can be selected from the group consisting of

Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon.

[0018] In certain embodiments, expression of at least one member of the panel of genes can be upregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with the candidate compound. In certain embodiments, expression of at least one member of the panel of genes can be not upregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with the candidate compound. In certain embodiments, expression of at least one member of the panel of genes can be downregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with the candidate compound. In certain embodiments, expression of at least one member of the panel of genes can be not downregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with the candidate compound.

[0019] In certain embodiments, expression of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, and EST196325 can be upregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with the candidate compound. In certain embodiments, expression of Annexin 1, N27, and HBP1 can be not upregulated in a cell that expresses the estrogen related receptor or estrogen related receptor or estrogen related receptor or estrogen related receptor or estrogen related receptor following contact with the candidate compound. In certain embodiments, expression of Protein Kinase C subspecies epsilon can be not downregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with the candidate compound.

[0020] In a preferred embodiment, expression of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, and EST196325 are upregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with the candidate compound; expression of Annexin 1, N27, and HBP1 is not upregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with the candidate compound; and expression of Protein Kinase C subspecies epsilon is not downregulated in a cell that expresses the estrogen related receptor following contact with the candidate compound; and expression of Protein Kinase C subspecies epsilon is not downregulated in a cell that expresses the estrogen receptor following contact with the candidate compound.

[0021] The candidate compound can be any compound known by one of skill in the art without limitation. In certain embodiments, the candidate compound can be an estrogen receptor modulator. In further embodiments, the estrogen receptor modulator can be a selective estrogen receptor modulator.

[0022] The estrogen receptor modulator can be effective to treat any disease, condition, affliction, or disorder known by one of skill in the art to be treatable with an estrogen receptor modulator, without limitation. In certain embodiments, the estrogen receptor modulator can be therapeutically effective to treat or prevent osteoporosis. In other embodiments, the selective estrogen receptor modulator can be therapeutically effective to treat or prevent post-menopausal symptoms. In still other embodiments, the selective estrogen receptor modulator can be therapeutically effective to treat or prevent post-menopausal symptoms. In still other embodiments, the selective estrogen receptor modulator can be therapeutically effective to treat or prevent a proliferative disorder.

[0023] The proliferative disorder can be any proliferative disorder known by one of skill in the art to be treatable with an estrogen receptor modulator without limitation. In certain embodiments, the proliferative disorder can be endometriosis. In other embodiments, the proliferative disorder can be cancer. In certain embodiments, the cancer can be selected from the group consisting of breast cancer, uterine cancer, ovarian cancer, cervical cancer, testicular cancer, and prostate cancer.

[0024] In another aspect, the invention provides a method for rapidly determining the effects of a plurality of compounds on hot-flash symptoms, comprising separately contacting a sample of cells that express an estrogen receptor or estrogen related receptor with each member of the plurality of compounds; and assessing the effect of each member of the plurality of compounds on each of the samples of cells' expression of a panel of genes associated with hot flash symptoms, thereby predicting the effect of each of the compounds on hot-flash symptoms.

[0025] In certain embodiments, the method further comprises comparing the expression of the panel of genes associated with hot flash symptoms by the samples of cells with a reference expression profile of the panel of genes associated with hot flash symptoms. In certain embodiments, the reference expression profile of the panel of genes can be the expression profile of the panel of genes following contacting the cell with a compound selected from the group consisting of estradiol, tibolone, raloxifene, and tamoxifen.

[0026] In other embodiments, the method further comprises comparing the expression of the panel of genes associated with hot flash symptoms by the samples of cells with the expression of the panel of genes associated with hot flash symptoms by a sample of cells following contact with a compound that has a known effect on hot flash symptoms. In certain embodiments, the compound that has a known effect on hot flash symptoms can be selected from the group that consists of estradiol, tibolone, raloxifene, and tamoxifen.

[0027] In certain embodiments, the methods further comprise determining that the compound decreases the incidence of hot flash symptoms.

[0028] In certain embodiments, the sample of cells that expresses the estrogen receptor can estrogen receptor α . In other embodiments, the sample of cells that expresses the estrogen receptor can express estrogen receptor β . In yet other embodiments, the sample of cells that expresses the estrogen receptor can express both estrogen receptor α and estrogen receptor β . In certain embodiments, the sample of cells that expresses the estrogen related receptor can express estrogen related receptor α . In other embodiments, the sample of cells that expresses the estrogen related receptor can express estrogen related receptor β . In yet other embodiments, the sample of cells that expresses the estrogen related receptor can express estrogen related receptor y. In still other embodiments, the sample of cells that expresses the estrogen related receptor can express two or three estrogen related receptors, each of which is selected from the group that consists of estrogen related receptor α , estrogen related receptor β , and estrogen related receptor γ .

[0029] In certain embodiments, the cell that expresses the estrogen receptor can be selected from the group consisting

of a pituitary cell and a hypothalamus cell. In certain embodiments, the cell that expresses the estrogen receptor can be selected from the group consisting of a GH3 cell, a GH4 cell, a PR1 cell, a MtT/E-2 cell, a alphaT3-1 cell, a D12 cell, an RCF-8 cell, and a GT1-7 cell.

[0030] In certain embodiments, the expression of the panel of genes associated with hot flash symptoms by the sample of cells can be quantified by determining the presence and amount of mRNA expressed from the panel of genes. In certain embodiments, the expression of the panel of genes associated with hot flash symptoms by the sample of cells can be quantified by a technique selected from the group of reverse transcription real time PCR, quantitative reverse transcription PCR, Northern blot assays, dot blot assays, reverse dot blot assays, RNAse protection assays, 5'-nuclease assays, reporter gene assays, branched DNA assays, bead array assays, and multiplexed array mRNA assays. In certain embodiments, the expression of the panel of genes associated with hot flash symptoms can be quantified by a multiplexed array mRNA assay.

[0031] In certain embodiments, the expression of the panel of genes associated with hot flash symptoms by the sample of cells can be quantified by determining the presence and amount of protein expressed from the panel of genes. In certain embodiments, the expression of the panel of genes associated with hot flash symptoms can be quantified by a technique selected from the group of a western blot assay, an ELISA assay, a cytokine bead array, multiplexed protein detection assays, and an immunofluorescence assay.

[0032] In certain embodiments, at least one member of the panel of genes can be selected from the group consisting of Activin Beta E, Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Argininosuccinate Synthetase, Ribonucleoside Reductase 1, Interleukin-18, ARL gene 4, Calpain, EST196325, CPP32, EST208064, 2-alpha-1 globin, Amiloride Binding Protein, Annexin 1, N27, HBP1, D-binding protein, FE65, Protein Kinase C type I, Glutamate Receptor subunit d1, VAPI, Protein Kinase C subspecies epsilon, EST203549, and Heat Shock Transcription Factor 1. In certain embodiments, at least one member of the panel of genes can be selected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon, and expression of at least one member of the panel of genes can be upregulated in the cell following contact with the candidate compound.

[0033] In certain embodiments, at least one member of the panel of genes can be selected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon, and expression of at least one member of the panel of genes can be not upregulated in the cell following contact with the candidate compound.

[0034] In certain embodiments, at least one member of the panel of genes cam be selected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon, and expression of at least one member of the panel of genes can be downregulated in the cell following contact with the candidate compound.

[0035] In certain embodiments, at least one member of the panel of genes can be selected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon, and expression of at least one member of the panel of genes can be not downregulated in the cell following contact with the candidate compound.

[0036] In certain embodiments, the panel of genes comprises Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, EST196325, Annexin 1, N27, and HBP1; expression of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, and EST196325 can be upregulated in the cell following contact with the candidate compound; expression of Annexin 1, N27, and HBP1 can be not upregulated in the cell following contact with the candidate compound; and expression of Protein Kinase C subspecies epsilon can be not downregulated in the cell following contact with the candidate compound.

[0037] In another aspect, the invention provides kits for determining the effect of a compound on hot flash symptoms. The kits generally comprise at least one primer or probe that can be used to detect the presence and amount of an expression product of a member of a panel of genes associated with hot flash symptoms. In certain embodiments, the primer or probe can be used to detect an mRNA expressed from a member of a panel of genes associated with hot flash symptoms. In other embodiments, the primer or probe can be used to detect a protein expressed from a member of a panel of genes associated with hot flash symptoms. In other embodiments, the primer or probe can be used to detect a protein expressed from a member of a panel of genes associated with hot flash symptoms.

[0038] In a preferred embodiment, the kits can comprise at least one gene-specific nuclease protection probe that is specific for a member of a panel of genes associated with hot flash symptoms and that can be directly or indirectly detectable; and a surface having multiple spatially discrete regions, at least two of which regions are substantially identical, and wherein the regions are adapted to specifically bind to the gene-specific protection probe(s).

[0039] In yet another aspect, the invention provides compositions suitable for determining the effect of a compound on hot flash symptoms. The compositions may also be used in the methods and kits of the invention. The compositions of the invention generally comprise at least one primer or probe that can be used to detect the presence and amount of an expression product of a member of a panel of genes associated with hot flash symptoms and a suitable buffer, diluent, or excipient. The member of the panel of genes can be any member of a panel of genes associated with hot flash symptoms known by one of skill in the art without limitation.

[0040] In certain embodiments, the primer or probe can be used to detect an mRNA expressed from a member of a panel of genes associated with hot flash symptoms. In other embodiments, the primer or probe can be used to detect a protein expressed from a member of a panel of genes associated with hot flash symptoms. In a preferred embodiment, the composition comprises a plurality of gene-specific nuclease protection probes, wherein each member of the plurality of gene-specific nuclease protection probes hybridizes under stringent conditions to an mRNA expressed from a member of a panel of genes associated with hot flash symptoms.

[0041] In still another aspect, the invention provides arrays useful for the identification of the effect of a plurality of compounds on hot flash symptoms. In certain embodiments, the array can comprise a non-porous surface; and a plurality of different oligonucleotides connected with the surface, wherein at least one of the oligonucleotides hybridizes under stringent conditions to a member of a panel of genes associated with hot flash symptoms, and wherein each of the different oligonucleotides is connected with the surface in a different predetermined region of the surface. The member of the panel of genes can be any member of a panel of genes associated with hot flash symptoms known by one of skill in the art, without limitation.

5. BRIEF DESCRIPTION OF THE FIGURES

[0042] FIG. 1A presents the effects of estradiol, raloxifene, tibolone, and 4-hydroxy tamoxifen on expression of BAD2 and MDR in GH3 cells;

[0043] FIG. 1B presents the effects of estradiol, raloxifene, tibolone, and 4-hydroxy tamoxifen on expression of Prolactin and Parvalbumin in GH3 cells;

[0044] FIG. 1C presents the effects of estradiol, raloxifene, tibolone, and 4-hydroxy tamoxifen on expression of HKII and Calpain in GH3 cells;

[0045] FIG. 1D presents the effects of estradiol, raloxifene, tibolone, and 4-hydroxy tamoxifen on expression of II-18 and Annexin 1 in GH3 cells; and

[0046] FIG. 1E presents the effects of estradiol, raloxifene, tibolone, and 4-hydroxy tamoxifen on expression of N27 (Vdup1) and Protein Kinase C, epsilon subspecies in GH3 cells.

6. DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

[0047] The present invention provides methods, kits, compositions, and arrays for determining the effect of candidate compounds on hot flash symptoms. The methods, kits, compositions, and arrays are described according to the various embodiments of the invention presented in detail below.

6.1. Definitions

[0048] The terms "reference compound(s),""compound(s) known to affect hot flash symptoms," and "compound(s) with a known effect on hot flash symptoms" are used interchangeably and generally refer to compounds that are known by one of skill in the art to increase or decrease the incidence of hot flash symptoms when the compounds are administered to a subject. Exemplary reference compounds include estradiol, tibolone, raloxifene, and 4-hydroxy tamoxifen.

[0049] The terms "candidate compound" or "candidate compounds" refer to one or more compounds whose effects on hot flash symptoms are to be determined according to the methods of the invention. The candidate compound can be any compound known by one of skill in the art without limitation. The candidate compound can be derived from

any source known to one of skill in the art without limitation. For example, and not by way of limitation, the candidate compound can be organic or inorganic; polar or non-polar; neutrally charged, positively charged, negatively charged, or zwitterionic; a small organinc molecule or a large macromolecule, etc. Candidate compounds suitable for the methods of the invention can be obtained from any commercial source, including Aldrich (1001 West St. Paul Ave., Milwaukee, Wis. 53233), Sigma Chemical (P.O. Box 14508, St. Louis, Mo. 63178), Fluka Chemie AG (Industriestrasse 25, CH-9471 Buchs, Switzerland (Fluka Chemical Corp. 980 South 2nd Street, Ronkonkoma, N.Y. 11779)), Eastman Chemical Company, Fine Chemicals (P.O Box 431, Kingsport, Tenn. 37662), Boehringer Mannheim GmbH (Sandhofer Strasse 116, D-68298 Mannheim), Takasago (4 Volvo Drive, Rockleigh, N.J. 07647), SST Corporation (635 Brighton Road, Clifton, N.J. 07012), Ferro (111 West Irene Road, Zachary, La. 70791), Riedel-deHaen Aktiengesellschaft (P.O. Box D-30918, Seelze, Germany), PPG Industries Inc., Fine Chemicals (One PPG Place, 34th Floor, Pittsburgh, Pa. 15272). Further, the effect of any kind of natural product on expression of genes associated with hot flash symptoms may be determined according to the methods of the invention, including microbial, fungal or plant extracts.

[0050] The term "hot flash symptom(s)" refers to one or more symptoms commonly experienced by subjects, typically women, typically at menopause. Hot flash symptoms can include, but are not limited to, a sudden sensation of heat radiating from the face, neck, and/or chest; chills; sweating or perspiration; anxiety; tingling; and/or pressure in the head. Hot flash symptoms can be experienced by subjects for short, e.g., seconds, or long, e.g., hours, durations.

[0051] The term "upregulated" refers to an increase in the expression of one or more genes associated with hot flash symptoms in a cell following contact of the cell with a compound that has an known or unknown effect on hot flash symptoms.

[0052] The term "downregulated" refers to a decrease in the expression of one or more genes associated with hot flash symptoms in a cell following contact of the cell with a compound that has an known or unknown effect on hot flash symptoms.

[0053] The term "panel of genes associated with hot flash symptoms" refers to a plurality of genes, expression of each of which is modulated by a compound that has a known effect on hot flash symptoms. A panel of genes associated with hot flash symptoms can comprise as few as two genes or as many as 30, or more. In certain embodiments, the panel of genes associated with hot flash symptoms comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 22, or 24 genes associated with hot flash symptoms. In a preferred embodiment, the panel of genes associated with hot flash symptoms comprises 10 genes associated with hot flash symptoms.

[0054] The term "high throughput method for determining regulation of gene expression" refers to any method known by one of skill in the art without limitation suitable for determining the effects of a large number of candidate compounds on regulation of expression of genes. Such methods include, for example, but not by way of limitation, the multiplexed array mRNA assays, differential PCR, restriction mediated differential display, AFLP-based transcript profiling, serial expression of gene analysis, Massive

Parallel Signature Sequencing, dot blot assays, reverse dot blot assays, and bead array-based assays.

[0055] The term "reference expression profile," as used herein, refers to the profile of expression of a panel of genes associated with hot flash symptoms in a cell following contact of the cell with a compound that has a known effect on hot flash symptoms. The reference expression profile can be the profile of expression of genes associated with hot flash symptoms in a cell following contact of the cell with any compound with a known effect on hot flash symptoms known by one of skill in the art without limitation. In certain embodiments, the reference expression profile is the profile of expression of genes associated with hot flash symptoms in a cell following contact of the cell with any compound with a known effect on hot flash symptoms known by one of skill in the art without limitation. In certain embodiments, the reference expression profile is the profile of expression of genes associated with hot flash symptoms in a cell following contact of the cell with estradiol, tibolone, raloxifene, or 4-hydroxy tamoxifen.

[0056] As used herein, the terms "nucleic acid,""nucleotide,""polynucleotide" and "oligonucleotide" refer to primers, probes, oligomer fragments to be detected, oligomer controls and unlabeled blocking oligomers and is generic to polydeoxyribonucleotides (containing 2-deoxy-D-ribose), to polyribonucleotides (containing D-ribose), and to any other N-glycoside of a purine or pyrimidine base, or modified purine or pyrimidine bases.

[0057] A nucleic acid, nucleotide, polynucleotide or oligonucleotide can comprise phosphodiester linkages or modified linkages including, but not limited to phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, bridged phosphorothioate or sulfone linkages, and combinations of such linkages.

[0058] A nucleic acid, nucleotide, polynucleotide or oligonucleotide can comprise the five biologically occurring bases (adenine, guanine, thymine, cytosine and uracil) and/ or bases other than the five biologically occurring bases. These bases may serve a number of purposes, e.g., to stabilize or destabilize hybridization; to promote or inhibit probe degradation; or as attachment points for detectable moieties or quencher moieties. For example, a polynucleotide of the invention can contain one or more modified, non-standard, or derivatized base moieties, including, but not limited to, N⁶-methyl-adenine, N⁶-tert-butyl-benzyl-adenine, imidazole, substituted imidazoles, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2thiouracil, beta-D mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5oxyacetic acidmethylester, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, 2,6-diaminopurine, and 5-propynyl pyrimidine. Other examples of modified, non-standard, or derivatized base moieties may be found in U.S. Pat. Nos.

6,001,611, 5,955,589, 5,844,106, 5,789,562, 5,750,343, 5,728,525, and 5,679,785, each of which is incorporated herein by reference in its entirety.

[0059] Furthermore, a nucleic acid, nucleotide, polynucleotide or oligonucleotide can comprise one or more modified sugar moieties including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

[0060] It is not intended that the present invention be limited by the source of a nucleic acid, nucleotide, polynucleotide or oligonucleotide. A nucleic acid, nucleotide, polynucleotide or oligonucleotide can be from a human or non-human mammal, or any other organism, or derived from any recombinant source, synthesized in vitro or by chemical synthesis. A nucleic acid, nucleotide, polynucleotide or oligonucleotide may be DNA, RNA, cDNA, DNA-RNA, locked nucleic acid (LNA), peptide nucleic acid (PNA), a hybrid or any mixture of the same, and may exist in a double-stranded, single-stranded or partially doublestranded form. A nucleic acid may also be a derivative nucleic acid as described in U.S. Pat. No. 5,696,248, which is hereby incorporated by reference in its entirety. The nucleic acids of the invention include both nucleic acids and fragments thereof, in purified or unpurified forms, including genes, chromosomes, plasmids, the genomes of biological material such as microorganisms, e.g., bacteria, yeasts, viruses, viroids, molds, fungi, plants, animals, humans, and the like.

[0061] There is no intended distinction in length between the terms nucleic acid, nucleotide, polynucleotide and oligonucleotide, and these terms will be used interchangeably. These terms include double- and single-stranded DNA, as well as double- and single-stranded RNA, as appropriate for the context.

[0062] The term "primer" refers to an oligonucleotide which is capable of acting as a point of initiation of polynucleotide synthesis along a template nucleic acid strand when placed under conditions that permit synthesis of a primer extension product that is complementary to the template strand. The primer can be obtained from a recombinant source, as in a purified restriction fragment, or produced synthetically. Primer extension conditions typically include the presence of four different deoxyribonucleoside triphosphates and an agent with polymerization activity such as DNA polymerase or reverse transcriptase, in a suitable buffer (a "buffer" can include substituents which are cofactors, or which affect pH, ionic strength, etc.), and at a suitable temperature. The primer is preferably single-stranded for maximum efficiency in amplification.

[0063] The term "hybridize" refers to binding of a singlestranded nucleic acid or a locally single-stranded region of a double-stranded nucleic acid to another single-stranded nucleic acid or a locally single-stranded region of a doublestranded nucleic acid having a complementary sequence. As one of skill in the art is aware, it is not necessary for two nucleic acid strands to be entirely complementary to hybridize to each other. Depending on the hybridization conditions, a nucleic acid can hybridize to its complement even if there are few, some, or many mismatches, deletions, or additions in one or both strands. In certain embodiments, the primers and probes of the invention can hybridize to an at least partially complementary sequence under stringent conditions, as defined below. [0064] The terms "stringent" or "stringent conditions," as used herein, denote hybridization conditions of low ionic strength and high temperature, as is well known in the art; see for example Maniatis et al., 1989, Molecular Cloning: A Laboratory Manual, 2d Edition; Current Protocols in Molecular Biology, 1988, ed. Ausubel et al., J. Wiley & Sons publ., New York, and Tijssen, 1993, Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays," each of which is hereby incorporated by reference. Generally, stringent conditions are selected to be about 5-30° C. lower than the thermal melting point (Tm) for the specified sequence at a defined ionic strength and pH. Alternatively, stringent conditions are selected to be about 5-15° C. lower than the thermal melting point (Tm) for the specified sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm, 50% of the probes are occupied at equilibrium). For example, stringent hybridization conditions can be those in which the salt concentration is less than about 1.0 M sodium (or other salts) ion, typically about 0.01 to about 1 M sodium ion concentration at about pH 7.0 to about pH 8.3 and the temperature is at least about 25° C. for short probes (e.g., 10 to 50 nucleotides) and at least about 55° C. for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be modified with the addition of hybridization destabilizing agents such as formamide.

[0065] The term "highly stringent conditions" is meant to refer to hybridization of a strand of a nucleic acid to a complementary strand of nucleic acid under conditions that permit specific association between the two strands. The nucleic acid strands need not be entirely complementary to hybridize under highly stringent conditions; one of ordinary skill in the art will recognize that nucleic acids can hybridize to each other under highly stringent conditions notwithstanding a certain amount of mismatches, insertions, deletions, etc. One example of "highly stringent conditions" for hybridization of nucleic acids is hybridization in a buffer that comprises 0.5 M NaHPO4, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C., and washing in 0.1×SSC/ 0.1% SDS at 68° C. (Ausubel F. M. et al., eds., 1989, Current Protocols in Molecular Biology, Vol. 1, at p. 2.10.3). Another example of "highly stringent conditions" that can be used for hybridization of an oligonucleotide to another nucleic acid comprises washing in 6×SSC/0.05% sodium pyrophosphate at 37° C. (for 14 base oligos), 48° C. (for 17 base oligos), 55° C. (for 20 base oligos), and 60° C. (for 23 base oligos).

[0066] The term "moderately stringent conditions" is meant to refer to hybridization of a strand of a nucleic acid to a complementary strand of nucleic acid under conditions that permit specific association between the two strands, wherein the strands are less complementary than strands that will associate under highly specific conditions. As one of skill in the art is well aware, "moderately stringent conditions" allow the specific association of nucleic acids that contain sufficient mismatches, insertions, deletions, etc. to prevent specific association under highly stringent conditions, but nonetheless retain sufficient sequence complementarity to specifically associate. One example of "moderately stringent conditions" comprises washing in 0.2×SSC/0.1% SDS at 42° C. (Ausubel et al., 1989, supra). [0067] The "complement" of a nucleic acid sequence, as used herein, refers to an oligonucleotide which, when aligned with the nucleic acid sequence such that the 5' end of one sequence is paired with the 3' end of the other, is in anti-parallel association. The complement of a nucleic acid sequence need not exactly match every nucleotide of the sequence; stable duplexes may contain mismatched base pairs, unmatched bases, insertions, or deletions. Those skilled in the art of nucleic acid technology can determine duplex stability by empirically considering a number of variables including, for example, the length of the oligonucleotide, base composition and sequence of the oligonucleotide, ionic strength, and incidence of mismatched base pairs.

[0068] Stability of a nucleic acid duplex is measured by the melting temperature, or " T_m ." The T_m of a particular nucleic acid duplex under specified conditions is the temperature at which half of the potential base pairs are disassociated.

[0069] The term "detectable moiety" as used herein refers to any atom or molecule which can be used to provide a detectable, quantifiable signal, and which can be attached to a nucleic acid or protein. Detectable moieties may provide signals detectable by fluorescence, radioactivity, colorimetry, gravimetry, X-ray diffraction or absorption, magnetism, enzymatic activity, and the like.

[0070] The term "fluorescent moiety" as used herein refers to a chemical moiety that can emit light under conditions appropriate for the particular moiety. Typically, a particular fluorescent moiety can emit light of a particular wavelength following absorbance of light of shorter wavelength. The wavelength of the light emitted by a particular fluorescent moiety is characteristic of that moiety. Thus, a particular fluorescent moiety can be detected by detecting light of an appropriate wavelength following excitation of the fluorescent moiety with light of shorter wavelength. Examples of fluorescent moieties that can be used in the methods and compositions of the present invention include, but are not limited to, fluorescein-family dyes, polyhalofluoresceinfamily dyes, hexachlorofluorescein-family dyes, coumarinfamily dyes, rhodamine-family dyes, cyanine-family dyes, oxazine-family dyes, thiazine-family dyes, squaraine-family dyes, chelated lanthanide-family dyes, and BODIPY®-family dyes.

[0071] The term "control assay" as used herein refers to a reaction performed as described below with a compound that has a known effect on regulation of genes associated with hot flash symptoms and/or a known effect on hot flash symptoms. The amount of signal emitted by such a reaction can be compared to a reaction performed using a candidate compound to determine the effect of the candidate compound on regulation of genes associated with hot flash symptoms and/or a known effect on hot flash symptoms and/or a known effect on the symptoms.

[0072] To determine "percent complementarity" or "percent identity" of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first nucleic acid sequence for optimal alignment with a second nucleic acid sequence). The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by a complementary nucleotide as the corresponding position in the second sequence, then the molecules are complementary at that position. Likewise, when a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent complementarity (or percent identity) between the two sequences is a function of the number of complementary positions (or identical positions) shared by the sequences divided by the total number of positions compared (i.e., % complementarity=number of complementary overlapping positions/total number of positions of the shorter nucleotide×100%; and % identity=number of identical overlapping positions/total number of positions of the shorter nucleotide×100%).

[0073] The determination of percent identity between two sequences can also be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul, 1990, *Proc. Natl. Acad. Sci. U.S.A.* 87:2264-2268, modified as in Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. U.S.A. 90:5873-5877. Such an algorithm is incorporated into the NBLAST program of Altschul et al., 1990, *J. Mol. Biol.* 215:403.

[0074] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology and recombinant DNA techniques, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook et al., 2001, *Molecular Cloning: A Laboratory Manual*, Third Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Oligonucleotide Synthesis (M. J. Gait, ed., 1984); *Nucleic Acid Hybridization* (B. D. Hames & S. J. Higgins, eds., 1984); *A Practical Guide to Molecular Cloning* (B. Perbal, 1984); and a series, *Methods in Enzymology* (Academic Press, Inc.).

6.2. Methods of Determining the Effect of a Candidate Compound on Hot Flash Symptoms

[0075] The present invention provides a method for determining the effect of a candidate compound on hot flash symptoms. The method generally comprises exposing a cell that expresses an estrogen receptor or estrogen related receptor to a candidate compound and determining the effect of the candidate compound on the cell's expression of a panel of genes associated with hot flash symptoms. In certain embodiments, the method can be used to identify the effect of a single compound on the expression of a panel of genes associated with hot flash symptoms. In other embodiments, the methods can identify the effect of more than one compound on the expression of a panel of genes associated with hot flash symptoms. Thus, the method of the invention can be used to achieve at least two major objectives: the method can be used to identify compounds that decrease the incidence of hot flash symptoms, and the method can be used to determine whether compounds that have some other, useful effect, e.g., compounds effective to treat osteoporosis or breast cancer, undesirably increase the incidence of hot flash symptoms.

6.2.1. Compounds Having a Known Effect on Hot Flash Symptoms

[0076] The present invention is based, in part, on the discovery of a correlation between regulation of expression

of certain genes in a cell that expresses the estrogen receptor or estrogen related receptor and contact of the cell by compounds that have a known effect on hot flash symptoms. Thus, based upon the disclosure of the present invention, one of skill in the art can determine the effect of a candidate compound on hot flash symptoms by contacting a cell with the candidate compound, and determining the effect of the candidate compound on the expression of genes associated with hot flash symptoms. The effects of the candidate compound on hot flash symptoms can be determined by comparing the expression of the panel of genes with a reference expression profile generated by a compound or compounds that has a known effect on hot flash symptoms.

[0077] Any compound, without limitation, that is known by one of skill in the art to have an effect on hot flash symptoms when administered to a subject can be used as a reference compound in the methods of the invention. The reference compound can either increase or decrease the incidence of hot flash symptoms. Gene expression in a cell that expresses the estrogen receptor or estrogen related receptor can be assessed in the presence and absence of the reference compound. Genes that are differentially expressed following contact with a reference compound can thus be identified. The expression of such genes can be upregulated or downregulated following such contact with a reference compound.

[0078] Following identification of genes that are upregulated or downregulated by compounds that have a known effect on hot flash symptoms, the effects of the reference compound on gene expression and on hot flash symptoms can be correlated. For example, estradiol and tibolone are known to decrease the incidence of hot flash symptoms when administered to a subject, while raloxifene and 4-hydroxy tamoxifen are known to increase the incidence of hot flash symptoms when administered to a subject. Thus, a candidate compound that has a similar effect on gene expression to estradiol or tibolone is likely to decrease the incidence of hot flash symptoms when administered to a subject. Conversely, a candidate compound that has a similar effect on gene expression to raloxifene or 4-hydroxy tamoxifen is likely to decrease the incidence of hot flash symptoms when administered to a subject. Any other compound whose effect on hot flash symptoms is known to one of skill in the art can be similarly used in the methods of the invention.

[0079] Accordingly, in certain aspects, the present invention provides methods of determining the effect of a candidate compound or a library of candidate compounds on hot flash symptoms. The methods generally comprise determining the effect of the candidate compound on expression of a panel of genes associated with hot flash symptoms.

[0080] In certain embodiments, the methods further comprise comparing the expression of the panel of genes associated with hot flash symptoms with a reference expression profile of the panel of genes associated with hot flash symptoms. In certain embodiments, the reference expression profile of the panel of genes associated with hot flash symptoms can be the expression profile of the panel of genes following contact of a cell with a compound selected from the group consisting of estradiol, tibolone, raloxifene, and 4-hydroxy tamoxifen. In other embodiments, the reference expression profile of the panel of genes associated with hot flash symptoms can be the expression profile of the panel of genes following contact of a cell with estradiol. In still other embodiments, the reference expression profile of the panel of genes associated with hot flash symptoms can be the expression profile of the panel of genes following contact of a cell with tibolone. In yet other embodiments, the reference expression profile of the panel of genes associated with hot flash symptoms can be the expression profile of the panel of genes following contact of a cell with raloxifene. In still other embodiments, the reference expression profile of the panel of genes associated with hot flash symptoms can be the expression profile of the panel of genes following contact of a cell with 4-hydroxy tamoxifen.

[0081] In other embodiments, the method further comprises comparing the expression profile of a panel of genes associated with hot flash symptoms in a cell following contact with a candidate compound with the expression profile of the panel of genes associated with hot flash symptoms in a cell following contact with a reference compound. In certain embodiments, the reference compound can be selected from the group that consists of estradiol, tibolone, raloxifene, and 4-hydroxy tamoxifen. In other embodiments, the reference compound can be estradiol. In still other embodiments, the reference compound can be raloxifene. In still other embodiments, the reference compound can be raloxifene. In still other embodiments, the reference compound can be raloxifene. In still other embodiments, the reference compound can be raloxifene. In still other embodiments, the reference compound can be raloxifene. In still other embodiments, the reference compound can be raloxifene. In still other embodiments, the reference compound can be raloxifene. In still other embodiments, the reference compound can be raloxifene. In still other embodiments, the reference compound can be raloxifene. In still other embodiments, the reference compound can be raloxifene. In still other embodiments, the reference compound can be raloxifene.

6.2.2. Genes Associated with Hot Flash Symptoms and Their Regulation By Compounds Having a Known Effect on Hot Flash Symptoms

[0082] The present invention provides a large number of genes that are differentially expressed following contact with a compound that has a known effect on hot flash symptoms. The effect on expression of such genes in a cell following contact with a candidate compound can be compared to the effect on expression of these genes following contact with a reference compound, thereby determining the effect of the candidate compound on hot flash symptoms. Genes that can are differentially expressed following contact with a compound known to affect hot flash symptoms are described below.

[0083] The expression of any gene known by one of skill in the art to be associated with hot flash symptoms, without limitation, can be assessed in the methods of the invention. The present invention provides numerous such genes as described in detail, below. Further, additional genes that are associated with hot flash symptoms can readily be identified by one of skill in the art according to the disclosure of the present invention. For example, a cell that expresses the estrogen receptor or estrogen related receptor can be contacted with a reference compound known to affect hot flash symptoms. The overall expression of genes in the cell following contact with the reference compound can be compared to the overall expression of genes in a similar cell that has not been contacted with the reference compound.

[0084] The expression of such genes to identify genes that are differentially expressed following contact with a compound with a known effect on hot flash symptoms can be monitored by any convenient method known by one of skill in the art. Most advantageously, the expression of many genes, e.g., thousands of genes, is monitored at once using a high throughput method for assessing expression of genes in the presence and absence of compounds known to affect hot flash symptoms.

[0085] Using, for example, a gene array from Affymetrix, Inc. (Sunnyvale, Calif.), genes that are differentially expressed following contact with the reference compound can be identified. Affymetrix gene arrays, and methods of making and using such arrays, are described in, for example, U.S. Pat. Nos. 6,551,784, 6,548,257, 6,505,125, 6,489,114, 6,451,536, 6,410,229, 6,391,550, 6,379,895, 6,355,432, 6,342,355, 6,333,155, 6,308,170, 6,291,183, 6,287,850, 6,261,776, 6,225,625, 6,197,506, 6,168,948, 6,156,501, 6,141,096, 6,040,138, 6,022,963, 5,919,523, 5,837,832, 5,744,305, 5,834,758, and 5,631,734, each of which is hereby incorporated by reference in its entirety. In addition, Ausubel et al., eds., Current Protocols in Molecular Biology, 2002, Vol. 4, Unit 25B, Ch. 22, which is hereby incorporated by reference in its entirety, provides further guidance on construction and use of a gene array for identifying genes of interest, e.g., genes associated with hot flash symptoms, that are differentially expressed in different samples of cells.

[0086] Other techniques suitable for such analysis include differential PCR, restriction mediated differential display, AFLP-based transcript profiling, serial expression of gene analysis ("SAGE"), and Massive Parallel Signature Sequencing ("MPSS"). These other techniques and protocols for performing the techniques are well-known in the art and are described in Ausubel et al., eds., Current Protocols in Molecular Biology, 2002, Vol. 4, Unit 25B, Ch. 3-6, except for MPSS, which is described in Brenner et al., 2000, Nat. Biochem. 18:630-634. Each of these references is hereby incorporated by reference in its entirety. Expression of genes that are identified in such a manner can be assessed to determine the effect of candidate compounds on hot flash symptoms.

[0087] Using the above-described methods, a number of genes have been identified that are associated with hot flash symptoms. TABLE 1, below, presents a number of examples of such genes and further, provides examples of effects on regulation of expression of these genes in a cell following contact with reference compounds that have known effects on hot flash symptoms.

			IADLE I			
Gene Name	Abbreviation or Alternative Name	Accession Number	Effect of Estradiol on Expression	Effect of Tibolone on Expression	Effect of Raloxifene on Expression	Effect of 4- hydroxy tamoxifen on Expression
Activin Beta E SEQ ID NO: 1 Type II Hexokinase	нкп	AF089825 D26393	Upregulated Upregulated	Upregulated Upregulated	Down- regulated Down- regulated	Down- regulated Down- regulated
SEQ ID NO: 2 Multi Drug Resistance Gene SEQ ID NO: 3	MDR	M81855	Upregulated	Upregulated	Down- regulated	Down- regulated
Parvalbumin SEQ ID NO: 4		AF022935	Upregulated	Upregulated	Down- regulated	Down- regulated
Protein Tyrosine Phosphatase BAD2 SEQ ID NO: 5	BAD2	U02553	Upregulated	Upregulated	Down- regulated	Down- regulated
Prolactin SEQ ID NO: 6		AI175539	Upregulated	Upregulated	Down- regulated	Down- regulated
Argininosuccinate Synthetase SEQ ID NO: 7		X12459	Upregulated	Upregulated	Down- regulated	Down- regulated
Ribonucleoside Reductase Nuclear Receptor SEQ ID NO: 8	RNR-1	L08595	Upregulated	Upregulated	No Significant Effect	No Significant Effect
Interleukin-18 SEQ ID NO: 9	IL-18	AJ222813	Upregulated	Upregulated	No Significant Effect	No Significant Effect
ARL gene 4 SEQ ID NO: 10		X77235	Upregulated	Upregulated	No Significant Effect	No Significant Effect
Calpain SEQ ID NO: 11		D14478	Upregulated	Upregulated	No Significant Effect	No Significant Effect
EST196325 SEQ ID NO: 12		AA892522	Upregulated	Upregulated	No Significant Effect	No Significant Effect
Interleukin-1 β-converting enzyme-related protease CPP32 SEQ ID NO: 13	CPP32	U84410	Upregulated	Upregulated	No Significant Effect	No Significant Effect
EST208064 SEQ ID NO: 14		AI013389	Upregulated	Upregulated	No Significant Effect	No Significant Effect
Amiloride Binding Protein SEQ ID NO: 15		X73911	Down- regulated	Down- regulated	No Significant Effect	No Significant Effect
2-alpha-1 globin SEQ ID NO: 16		X56325	Upregulated	Upregulated	No Significant Effect	No Significant Effect

TABLE 1

Gene Name	Abbreviation or Alternative Name	Accession Number	Effect of Estradiol on Expression	Effect of Tibolone on Expression	Effect of Raloxifene on Expression	Effect of 4- hydroxy tamoxifen on Expression
Annexin 1 SEQ ID NO: 17	EST 21795	AI171962	No Significant Effect	No Significant Effect	Upregulated	Upregulated
N27 SEQ ID NO: 18	EST 207724	AI014169	No Significant Effect	No Significant Effect	Upregulated	Upregulated
HMG-box containing protein 1 SEQ ID NO: 19	HBP1	U09551	No Significant Effect	No Significant Effect	Upregulated	Upregulated
D-binding protein SEQ ID NO: 20		J03179	No Significant Effect	No Significant Effect	Upregulated	Upregulated
FE65 adaptor protein interacting with beta-amyloid precursor protein intracellular domain SEQ ID NO: 21	FE65	X60469	No Significant Effect	No Significant Effect	Upregulated	No Significant Effect
Protein Kinase C type I SEQ ID NO: 22	PKC type I	M13707	No Significant Effect	No Significant Effect	Upregulated	Upregulated
Glutamate Receptor (d1 subunit) SEQ ID NO: 23		U08255	No Significant Effect	No Significant Effect	Down- regulated	No Significant Effect
Vesicle Associated Protein VAP1 SEQ ID NO: 24	VAP1	AF034582	No Significant Effect	No Significant Effect	Down- regulated	No Significant Effect
Protein Kinase C subspecies epsilon SEQ ID NO: 25		M18331	No Significant Effect	No Significant Effect	Down- regulated	No Significant Effect
EST 203549 SEQ ID NO: 26		AI009098	No Significant Effect	No Significant Effect	Down- regulated	No Significant Effect
Heat Shock Transcription Factor 1 SEQ ID NO: 27		X83094	No Significant Effect	No Significant Effect	Down- regulated	No Significant Effect

TABLE 1-continued

[0088] As shown in TABLE 1, the present invention provides a number of genes that are differentially expressed following contact with compounds that have known effects on hot flash symptoms. By comparing the effects of the reference compounds on expression of genes associated with hot flash symptoms to the effect of a candidate compound on expression of these genes, the effect of the candidate compound on hot flash symptoms can be determined.

[0089] Accordingly, in certain aspects, the invention provides methods of determining the effect of a candidate compound on hot flash symptoms that comprise determining the effect of the candidate compound on expression of a panel of genes associated with hot flash symptoms.

[0090] In certain embodiments, at least one member of the panel of genes that is associated with hot flash symptoms can be selected from the group consisting of Activin Beta E, Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Argininosuccinate Synthetase, Ribonucleoside Reductase 1, Interleukin-18, ARL gene 4, Calpain, EST196325, CPP32, EST208064, 2-alpha-1 globin, Amiloride Binding Protein, Annexin 1, N27, HBP1,

D-binding protein, FE65, Protein Kinase C type I, Glutamate Receptor subunit d1, VAP1, Protein Kinase C subspecies epsilon, EST203549, and Heat Shock Transcription Factor 1. In other embodiments, more than one member of the panel of genes that is associated with hot flash symptoms can be selected from the group consisting of Activin Beta E, Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Argininosuccinate Synthetase, Ribonucleoside Reductase 1, Interleukin-18, ARL gene 4, Calpain, EST196325, CPP32, EST208064, 2-alpha-1 globin, Amiloride Binding Protein, Annexin 1, N27, HBP1, D-binding protein, FE65, Protein Kinase C type I, Glutamate Receptor subunit d1, VAP1, Protein Kinase C subspecies epsilon, EST203549, and Heat Shock Transcription Factor 1. In still other embodiments, each member of the panel of genes that is associated with hot flash symptoms can be selected from the group consisting of Activin Beta E, Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Argininosuccinate Synthetase, Ribonucleoside Reductase 1, Interleukin-18, ARL gene 4, Calpain, EST196325, CPP32, EST208064, 2-alpha-1

globin, Amiloride Binding Protein, Annexin 1, N27, HBP1, D-binding protein, FE65, Protein Kinase C type I, Glutamate Receptor subunit d1, VAP1, Protein Kinase C subspecies epsilon, EST203549, and Heat Shock Transcription Factor 1.

[0091] In more preferred embodiments, at least one member of the panel of genes associated from hot flash symptoms can be selected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon. In still more preferred embodiments, more than one member of the panel of genes associated from hot flash symptoms can be elected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon. In yet more preferred embodiments, each member of the panel of genes associated from hot flash symptoms can be selected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon.

[0092] In certain embodiments, the panel of genes comprises two genes associated with hot flash symptoms. In other, more preferred, embodiments, the panel of genes comprises four genes associated with hot flash symptoms. In other, even more preferred, embodiments, the panel of genes comprises five genes associated with hot flash symptoms. In yet other, even more preferred, embodiments, the panel of genes comprises eight genes associated with hot flash symptoms. In the most preferred embodiment, the panel of genes comprises ten genes associated with hot flash symptoms. In the most preferred embodiment, the panel of genes comprises ten genes associated with hot flash symptoms.

[0093] The expression of the members of the panel of genes associated with hot flash symptoms can be either upregulated or downregulated. As shown above in TABLE 1, reference compounds can characteristically increase or decrease the expression of genes associated with hot flash symptoms. Thus, the nature of the regulation of expression, e.g., upregulation or downregulation, of genes associated with hot flash symptoms can also be used to determine the effect of a candidate compound on hot flash symptoms. For example, contacting a cell that expresses the estrogen receptor with estradiol results in the upregulation of BAD2 and HKII, while contact of the cell with 4-hydroxy tamoxifen results in the downregulation of these genes.

[0094] Accordingly, in certain embodiments, expression of at least one member of the panel of genes associated with hot flash symptoms can be upregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with a candidate compound. In certain embodiments, expression of at least one member of the panel of genes associated with hot flash symptoms can be not upregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with a candidate compound. In certain embodiments, expression of at least one member of the panel of genes associated with hot flash symptoms can be downregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with a candidate compound. In certain embodiments, expression of at least one member of the panel of genes associated with hot flash symptoms can be not downregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with a candidate compound.

[0095] In certain embodiments, expression of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, or EST196325 can be upregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with the candidate compound. In certain embodiments, expression of Annexin 1, N27, or HBP1 can be not upregulated in a cell that expresses the estrogen related receptor or estrogen related receptor or estrogen related receptor following contact with the candidate compound. In certain embodiments, expression of Protein Kinase C subspecies epsilon can be not downregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with the candidate compound. In certain embodiments, expression of Protein Kinase C subspecies epsilon can be not downregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with the candidate compound.

[0096] In other embodiments, expression of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, or EST196325 can be not upregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with the candidate compound. In certain embodiments, expression of Annexin 1, N27, or HBP1 can be upregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with the candidate compound. In certain embodiments, expression of Protein Kinase C subspecies epsilon can be downregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with the candidate compound.

[0097] In a preferred embodiment, expression of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, and EST196325 are upregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with the candidate compound; expression of Annexin 1, N27, and HBP1 is not upregulated in a cell that expresses the estrogen receptor or estrogen related receptor following contact with the candidate compound; and expression of Protein Kinase C subspecies epsilon is not downregulated in a cell that expresses the estrogen related receptor or estrogen related receptor following contact with the candidate compound; and expression of Protein Kinase C subspecies epsilon is not downregulated in a cell that expresses the estrogen receptor following contact with the candidate compound.

[0098] The amount of the change in expression of a panel of genes associated with hot flash symptoms in a cell following contact with a candidate compound can also be assayed in order to determine the effects of the candidate compound on hot flash symptoms. A greater change in expression of genes associated with hot flash symptoms correlates with a more potent effect on hot flash symptoms. Further, the direction of regulation, either up or down, can be compared to the effect of the compounds with a known effect on hot flash symptoms.

[0099] For example, estradiol is the most potent therapeutic agent known to decrease the incidence of hot flash symptoms. If a candidate compound causes the expression of a gene that is upregulated following contact with estradiol, for example, HKII, to increase a similar or greater degree as estradiol, then the candidate compound can be determined to decrease the incidence of hot flash symptoms. The same relationship applies to the effects of tibolone, raloxifene, and 4-hydroxy tamoxifen on regulation of expression of genes associated with hot flash symptoms and the determined effect of a candidate compound on hot flash symptoms. However, even if a candidate compound causes the expression of a gene, for example, HKII, to increase, but to a lesser degree than estradiol, the candidate compound may still decrease the incidence of hot flash symptoms.

[0100] In such situations, the relative amount of increase or decrease in expression of a gene associated with hot flash symptoms following contact with a candidate compound can be determined. For example, a candidate compound may cause the expression of a gene, for example HKII, to increase about two-fold, i.e., by about 100%. Notwithstanding the relative increase or decrease in expression of a given gene following contact with estradiol or tibolone, a candidate compound that results in about a two-fold increase in expression of a gene that is upregulated following contact with estradiol or tibolone is likely to decrease the incidence of hot flash symptoms.

[0101] Similarly, a candidate compound that results in an about two-fold decrease, i.e., by about 50%, in expression of a gene that is downregulated following contact with estradiol or tibolone is likely to decrease the incidence of hot flash symptoms. The converse is also true; a candidate compound that results in an about two-fold increase, i.e., by about 100%, in expression of a gene that is upregulated following contact with raloxifene or 4-hydroxy tamoxifen is likely to increase the incidence of hot flash symptoms. Similarly, a candidate compound that results in an about two-fold decrease, i.e., by about 50%, in expression of a gene that is upregulated following contact with raloxifene or 4-hydroxy tamoxifen is likely to increase the incidence of hot flash symptoms.

6.2.3. Determining the Effect of a Candidate Compound on Hot Flash Symptoms

[0102] The present invention provides methods of determining the effect of a candidate compound on hot flash symptoms based, in part, on the discovery of a correlation between regulation of a panel of genes associated with hot flash symptoms in a cell and contact with the cell by a reference compound with a known effect on hot flash symptoms. The genes associated with hot flash symptoms, reference compounds with known effects on hot flash symptoms, and the effects of such compounds on regulation of such genes are described extensively above. The effects of candidate compounds on hot flash symptoms can be determined by observing the effects of such compounds on the regulation of a panel of genes associated with hot flash symptoms.

[0103] Generally, the methods of the invention provide for exposing a cell that expresses the estrogen receptor or estrogen related receptor to a candidate compound, and determining the effect of the candidate compound on the regulation of one or more genes that are associated with hot flash symptoms. Preferably, the effects of the candidate compound on regulation of more than two, four, five, six, or eight genes that are associated with hot flash symptoms are determined. Most preferably, the effects of the candidate compound on regulation of about ten genes that are associated with hot flash symptoms are determined. Most preferably, the effects of the candidate compound on regulation of about ten genes that are associated with hot flash symptoms are determined.

[0104] In certain embodiments, the effect of a candidate compound on the regulation of genes associated with hot flash symptoms can correlate with the effect of a compound that is selected from the group of estradiol, tibolone, ralox-

ifene, and 4-hydroxy tamoxifen. In other embodiments, the effect of a candidate compound on the regulation of genes associated with hot flash symptoms can correlate with the effect of a compound that is selected from the group of estradiol and tibolone. In still other embodiments, the effect of a candidate compound on the regulation of genes associated with hot flash symptoms can correlate with the effect of a compound that is selected from the group of raloxifene and 4-hydroxy tamoxifen. In yet other embodiments, the effect of a candidate compound on the regulation of genes associated with hot flash symptoms can correlate with the effect of estradiol. In still other embodiments, the effect of a candidate compound on the regulation of genes associated with hot flash symptoms can correlate with the effect of tibolone. In yet other embodiments, the effect of a candidate compound on the regulation of genes associated with hot flash symptoms can correlate with the effect of raloxifene. In still other embodiments, the effect of a candidate compound on the regulation of genes associated with hot flash symptoms can correlate with the effect of 4-hydroxy tamoxifen.

[0105] In certain embodiments, the effect of the candidate compound on the regulation of a panel genes associated with hot flash symptoms can be different from the effect of a compound that is selected from the group consisting of estradiol, tibolone, raloxifene, and 4-hydroxy tamoxifen. Nonetheless, one of skill in the art can still determine the effect of the candidate compound on hot flash symptoms based upon the degree of similarity of effect on hot flash symptoms of the candidate compound to the effects of the reference compounds.

[0106] In general, the effect of the candidate compound on regulation of genes associated with hot flash symptoms, particularly the direction of regulation, can be compared to the effects of the reference compounds on regulation of the same genes. If the candidate compound regulates the expression of at least about half of the genes associated with hot flash symptoms that are tested similar to the manner in which estradiol or tibolone regulate the same genes, but no such genes are regulated similar to the manner in which raloxifene or 4-hydroxy tamoxifen regulate the same genes, the candidate compound can be determined to decrease the incidence of hot flash symptoms. If the candidate compound regulates the expression of at least about half of genes associated with hot flash symptoms that are tested similar to the manner in which raloxifene or 4-hydroxy tamoxifen regulate the same genes, but no such genes are regulated similar to the manner in which estradiol or tibolone regulate the same genes, the candidate compound can be determined to increase the incidence of hot flash symptoms. Preferably, expression of at least ten such genes is tested in determining the effect of the candidate compound, as shown in the following examples. However, as few as five genes associated with hot flash symptoms can be tested in determining the effect of a candidate compound hot flash symptoms.

[0107] For example, a candidate compound could increase the expression of at least about five genes associated with hot flash symptoms that are upregulated in a cell following contact with estradiol and/or tibolone, but not increase the expression of any genes that are upregulated in a cell following contact with raloxifene and/or 4-hydroxy tamoxifen. Such a candidate compound would be determined to decrease the incidence of hot flash symptoms. In another example, a candidate compound that can decrease the expression of at least about five genes associated with hot flash symptoms that are downregulated in a cell following contact with estradiol and/or tibolone, but not increase the expression of any genes that are upregulated in a cell following contact with raloxifene and/or 4-hydroxy tamoxifen would also be determined to decrease the incidence of hot flash symptoms. Other examples of candidate compounds that would be determined to decrease the incidence of hot flash symptoms include those that increase the expression of at least about five genes associated with hot flash symptoms that are upregulated in a cell following contact with estradiol and/or tibolone, but not decrease the expression of any genes that are downregulated in a cell following contact with raloxifene and/or 4-hydroxy tamoxifen and those that can decrease the expression of at least about five genes associated with hot flash symptoms that are downregulated in a cell following contact with estradiol and/or tibolone, but not decrease the expression of any genes that are downregulated in a cell following contact with raloxifene and/or 4-hydroxy tamoxifen.

[0108] In another example, a compound that can increase the expression of at least about five genes that are upregulated in a cell following contact with raloxifene or 4-hydroxy tamoxifen but does not increase the expression of any genes that are upregulated in a cell following contact with estradiol or tibolone would be determined to increase the incidence of hot flash symptoms. In still another example, candidate compounds that decrease the expression of at least about five genes that are downregulated in a cell following contact with raloxifene and 4-hydroxy tamoxifen but do not decrease the expression of any genes that are downregulated in a cell following contact with estradiol or tibolone would be determined to increase the incidence of hot flash symptoms. Other examples of candidate compounds that would be determined to increase the incidence of hot flash symptoms include those that that can increase the expression of at least about five genes that are upregulated in a cell following contact with raloxifene or 4-hydroxy tamoxifen but does not decrease the expression of any genes that are downregulated in a cell following contact with estradiol or tibolone and those that decrease the expression of at least about five genes that are downregulated in a cell following contact with raloxifene and 4-hydroxy tamoxifen but do not increase the expression of any genes that are upregulated in a cell following contact with estradiol or tibolone.

[0109] In certain embodiments, the effect of the candidate compound on regulation of genes associated with hot flash symptoms can be compared to a reference expression profile of the panel of genes associated with hot flash symptoms. The reference expression profile of the panel of genes associated with hot flash symptoms is generally determined by contacting a cell with a compound selected from the group consisting of estradiol, tibolone, raloxifene, and 4-hydroxy tamoxifen. The reference pattern can be predetermined, i.e., known at the time the candidate compound is contacted to the cell to determine the effect of the candidate compound on regulation of hot flash symptoms. The reference pattern can comprise any set of one or more genes and effects on hot flash symptoms listed in TABLE 1.

[0110] In other embodiments, the methods further comprise comparing a cell's expression of the panel of genes associated with hot flash symptoms following contact with a candidate compound with a cell's expression of the panel of genes associated with hot flash symptoms following contact with a compound that has a known effect on hot flash symptoms. The compound that has a known effect on hot flash symptoms can be any such compound known to one of skill in the art without limitations. In certain embodiments, the compound that has a known effect on hot flash symptoms can be selected from the group that consists of estradiol, tibolone, raloxifene, and 4-hydroxy tamoxifen. In such embodiments, the compound or compounds with known effects on hot flash symptoms are contacted with a cell in parallel with one or more candidate compounds as a control assay. The effects of the candidate compounds and reference compounds on regulation of expression of genes associated with hot flash symptoms can be compared to determine the effect of the candidate compound on hot flash symptoms.

6.2.4. Cells and Cell Lines that Express the Estrogen Receptor and Estrogen Related Receptor

[0111] The present invention is based, in part, on assessing the regulation of genes associated with hot flash symptoms in cells that express the estrogen receptor or estrogen related receptor following contact with compounds that can modulate the estrogen receptor or estrogen related receptor. Accordingly, certain aspects of the invention rely on contacting a cell that expresses the estrogen receptor or estrogen related receptor or estrogen related receptor or estrogen related receptor.

[0112] Any cell that is known by one of skill in the art to express the estrogen receptor or estrogen related receptor, without limitation, may be used in the methods of the invention. In certain embodiments, the cell can express the estrogen receptor. In other embodiments, the cell can express the estrogen related receptor. Such cells that express one of these receptors are generally mammalian cells. In certain embodiments, the mammalian cell can be selected from the group that consists of a rat cell, a mouse cell, a monkey cell, a chimpanzee cell, and a human cell.

[0113] Further, the cell can be derived from any organ or tissue that expresses the estrogen receptor or the estrogen related receptor. For example, in certain embodiments, the cell that expresses the estrogen receptor can be a pituitary cell. In other embodiments, the cell that expresses the estrogen receptor can be a hypothalamus cell. In still other embodiments, the cell that expresses the estrogen related receptor can be any central or peripheral nervous system cell that expresses the estrogen related receptor.

[0114] The cell that expresses the estrogen receptor or estrogen related receptor and that is used in the methods of the invention is preferably a cell suitable for propagation in cell culture for an indefinite period of time. Any such cell that is known by one of skill in the art to express the estrogen receptor or estrogen related receptor and to be suitable for propagation in cell culture for an indefinite period of time can be used in the methods of the invention, without limitation. In certain embodiments, the cell that expresses the estrogen receptor can be selected from the group of a GH3 cell, a GH4 cell, a PR1 cell, a MtT/E-2 cell, a alphaT3-1 cell, a D12 cell, an RCF-8 cell, and a GT1-7 cell. In a preferred embodiment, the cell that expresses the estrogen receptor is a GH3 cell. In certain embodiments, the cell that expresses the estrogen related receptor can be selected from the group that consists of an A172 glioma cell, a MCF10a cell, a MCF12 cell, a MDA-MB-231 cell, a

MDA-MB-435 cell, a MDA-MB-436 cell, a MDA-MB-468 cell, a Hs 578T cell, a BT 20 cell, a BT 474 cell, a BT 549 cell, a SKBr 3 cell, a ZR 75.1 cell, a T47D cell, and a MCF7 cell.

[0115] Further, the cell that expresses the estrogen receptor can express any estrogen receptor known by one of skill in the art without limitation. In certain embodiments, the estrogen receptor that is expressed by the cell can be estrogen receptor α . In other embodiments, the estrogen receptor β . In still other embodiments, the cell that expresses the estrogen receptor can express both estrogen receptor a and estrogen receptor β .

[0116] Similarly, the cell that expresses the estrogen related receptor can express any estrogen related receptor known to one of skill in the art without limitation. In certain embodiments, the cell that expresses the estrogen related receptor can express estrogen related receptor α . In other embodiments, the cell that expresses the estrogen related receptor can express estrogen related receptor β . In yet other embodiments, the cell that expresses the estrogen related receptor can express estrogen related receptor β . In yet other embodiments, the cell that expresses the estrogen related receptor can express estrogen related receptor γ . In still other embodiments, the cell that expresses the estrogen related receptors, each of which is selected from the group that consists of estrogen related receptor α , estrogen related receptor β , and estrogen related receptor γ .

6.2.5. High Throughput Methods for Ouantifying the Expression of Genes Associated with Hot Flash Symptoms

[0117] In certain aspects, the present invention provides high throughput methods for determining the effect of a plurality of candidate compounds on hot flash symptoms. High throughput methods for determining the effect of a plurality of compounds on hot flash symptoms generally comprise separately exposing samples of cells that express the estrogen receptor or estrogen related receptor to each member of the plurality of candidate compounds. The effects of each of the plurality of candidate compounds on the regulation of expression of a panel of genes associated with hot flash symptoms can then be determined for each of the samples of cells. Using the above-described correlation between regulation of expression of such genes and the effect of a reference compound on hot flash symptoms, the effects of the plurality of compounds can thus be identified.

[0118] High throughput methods generally rely on simultaneously determining the effects of a large number of compounds on the regulation of expression of a panel of genes associated with hot flash symptoms in a sample of cells. The high throughput methods used in connection with the invention are further described with reference to particular embodiments of such high throughput methods as described below. Further guidance regarding these particular embodiments of the high throughput methods for determining the effect of candidate compounds on hot flash symptoms may be found in U.S. Pat. No. 6,238,869, which is incorporated by reference in its entirety. This patent describes generic methods that can be readily be adapted to determine the effect of candidate compound on regulation of expression of genes associated with hot flash symptoms as described below. However, any high throughput method known to one of skill in the art to be useful in the determination of the effects of a large number of compounds on regulation of gene expression, without limitation, can be used in the methods of the invention.

[0119] Briefly, the preferred high throughput method comprises separately exposing samples of cells to each member of a plurality of candidate compounds. The samples of cells are then lysed. The lysates are exposed to a plurality of gene-specific nuclease protection probes, each of which can hybridize to a member of a panel of genes associated with hot flash symptoms, as described above. The lysates are then contacted with a nuclease with single-stranded nuclease activity, such as, for example, S1 nuclease. Following digestion to completion with this nuclease, the remaining RNA in the lysates can optionally be degraded.

[0120] The remainder of the method comprises detecting the gene specific nuclease protection probes or RNA protected from degradation by the gene-specific nuclease protection probes. In one embodiment, the lysates are contacted with a surface containing regions adapted to specifically associate with each of the gene-specific nuclease protection probes. The presence and amount of each gene-specific nuclease protection probe can be detected by contacting the gene-specific nuclease protection probes with a detection probe that specifically associates with the gene-specific nuclease protection probes. The detection probe can then be detected directly or indirectly.

[0121] In addition, certain other methods for quantifying the expression of genes associated with hot flash symptoms, as described in Section 5.2.6, below, can be adapted by one of skill in the art to identify the effects of a large number of candidate compounds and thus can be used as high throughput methods. Therefore, the high throughput methods for identifying the effects of candidate compounds on hot flash symptoms are not limited to the above-described embodiments, but also include those described below as well. Further, the methods for identifying genes associated with hot flash symptoms can also be adapted to determine the effects of candidate compounds on regulation of expression of genes associated with hot flash symptoms and thus can be used to determine the effects of such candidate compounds on hot flash symptoms.

6.2.6. Other Methods for Quantifying the Expression of Genes Associated with Hot Flash Symptoms

[0122] In certain aspects, the invention provides methods for determining the effect of a candidate compound on hot flash symptoms by determining the effect of the candidate compound on expression of a panel of genes associated with hot flash symptoms. Generally, the effect of the candidate compound on expression of genes associated with hot flash symptoms can be determined by quantifying the amount of mRNA expressed from a gene associated with hot flash symptoms by a cell in the presence and absence of the candidate compound. By comparing the amount of mRNA expressed from a gene associated with hot flash symptoms by a cell that has been exposed to a candidate compound to the amount of mRNA expressed from a gene associated with hot flash symptoms by a cell that has not been exposed to the candidate compound, the effect of the candidate compound on expression of genes associated with hot flash symptoms can be determined.

[0123] Any method known by one of skill in the art to be useful in detecting the presence and amount of an mRNA expressed from a gene associated with hot flash symptoms can be used in the methods of the invention, without limitation. For example, the presence and amount of an mRNA expressed from a gene associated with hot flash symptoms can be detected with a technique that is selected from the group consisting of reverse transcription real time PCR, quantitative reverse transcription PCR, Northern blot assays, dot blot assays, reverse dot blot assays, S1 nuclease protection assays, primer extension, RNAse protection assays, 5'-nuclease assays, reporter gene assays, branched DNA assays, bead array assays, and multiplexed array mRNA assays. In a preferred embodiment, the presence and amount of an mRNA expressed from a gene associated with hot flash symptoms is detected with a multiplexed array mRNA assay, as described above.

[0124] Many of the above referenced techniques, as well as protocols for performing them, are described in Ausubel et al., eds., *Current Protocols in Molecular Biology*, 2002, Vol. 4, Unit 4, Ch. 6-9 and Unit 15, Ch. 5, which is hereby incorporated by reference in its entirety. For example, Northern blot assays, S1 nuclease protection assays, primer extension, RNAse protection assays, and reverse transcription PCR are well known to in the art and are each described in detail in this reference. One of ordinary skill in the art can readily adapt these protocols for detecting the presence and amount of an mRNA that is expressed by genes associated with hot flash symptoms.

[0125] Further, the presence and amount of an mRNA expressed from genes associated with hot flash symptoms can be accomplished using a dot blot format. In the dot blot format, the unlabeled amplified sample is bound to a solid support, such as a membrane, the membrane incubated with labeled probe under suitable hybridization conditions, the unhybridized probe removed by washing, and the filter monitored for the presence of bound probe. When multiple samples are analyzed with a single probe, the dot blot format is quite useful. Many samples can be immobilized at discrete locations on a single membrane and hybridized simultaneously by immersing the membrane in a solution of probe.

[0126] An alternate method that is quite useful when large numbers of different probes are to be used is a "reverse" dot blot format, in which the amplified sequence contains a label, and the probe is bound to the solid support. This format can be especially useful if the assay methods of the present invention is used as one of a battery of methods to be performed simultaneously on a sample. In this format, the unlabeled probes specific for a gene or several genes associated with hot flash symptoms are bound to the membrane and exposed to the labeled sample under appropriately stringent hybridization conditions. Unhybridized labeled sample is then removed by washing under suitably stringent conditions, and the filter is then monitored for the presence of bound sequences.

[0127] Both the forward and reverse dot blot assays can be carried out conveniently in a microtiter plate; see U.S. patent application Ser. No. 695,072, filed May 3, 1991, which is a CIP of U.S. patent application Ser. No. 414,542, filed Sep. 29, 1989, now abandoned, each of which is incorporated herein by reference in its entirety. The probes can be attached to bovine serum albumen (BSA), for example,

which adheres to the microtiter plate, thereby immobilizing the probe. Another example of a method of using one or more oligonucleotides specific for genes associated with hot flash symptoms to detect the presence and amount of mRNA expressed from such genes is described in U.S. Pat. No. 6,383,756, which provides a method for detecting a nucleic acid bound to a membrane, and which is hereby incorporated by reference in its entirety.

[0128] In addition, Bustin, 2002, *J. Mol. Endocrinol.* 29(1):23-39; Bustin, 2000, *J. Mol. Endocrinol.* 25(2):169-93; and Freeman et al., 1999, *Biotechniques.* 26(1):112-22, 124-5; each of which are incorporated by reference in their entirety, review the state of the art of real time reverse transcription PCR and provide methods for performing such reactions. These references also describe quantitative reverse transcription PCR, which is further reviewed by Richards and Poch, 2002, *Mol. Biotechnol.* 21(1):19-37, which is hereby incorporated by reference in its entirety. These references teach reaction conditions and parameters that can easily be adapted by one of skill in the art for detecting the presence and amount of an mRNA expressed from genes that are associated with hot flash symptoms.

[0129] 5'-nuclease assays generally comprise contacting a primer hybridized to the nucleic acid to be detected with an enzyme with 5'-nuclease activity. The enzyme with 5'-nuclease activity then fragments a probe that is also hybridized to the nucleic acid to be detected in a 5'-nuclease reaction. The probe can be labeled with a detectable moiety that enables detection of fragmentation of the probe. Such methods are based on those described in U.S. Pat. Nos. 6,214, 979, 5,804,375, 5,487,972 and 5,210,015, each of which is hereby incorporated by reference in its entirety. One of skill in the art is readily able to recognize suitable probes and primers for detecting a particular nucleic acid of known sequence for use in a 5'-nuclease assay for detecting the presence and amount of an mRNA expressed from genes associated with hot flash symptoms.

[0130] In another example, the presence and amount of mRNA expressed from genes associated with hot flash symptoms can be detected with a branched-DNA assay. In such methods, a dendrimer monomer is constructed of two DNA strands that share a region of sequence complementarity located in the central portion of each strand. When the two strands anneal to form the monomer the resulting structure has a central double-stranded center bordered by four single-stranded ends. A dendrimer can be assembled from monomers by hybridization of the single stranded ends of the monomers to each other, while still leaving many single-stranded ends free. These free single-stranded ends can have the sequences of any nucleic acid that can hybridize to an mRNA expressed from genes associated with hot flash symptoms. A dendrimer can be detectably labeled with any detectable moiety known to one of skill in the art without limitation, as described above in connection with the high throughput methods for quantifying an mRNA expressed from genes associated with hot flash symptoms.

[0131] Dendrimers can then be used as a probe, in, for example, the "dot blot" assays described above. In addition, a dendrimer can be used as a probe in any method known to one of skill in the art in which the probe is directly detected. A probe is directly detected when the presence of the probe can be determined without any subsequent reaction or

modification, such as a dot blot or Northern hybridization. Further guidance on the selection and use of dendrimers as probes to detect the presence and amount of an mRNA expressed from genes associated with hot flash symptoms may be found in U.S. Pat. Nos. 6,261,779 and in Nilsen et al., 1997, *J. Theoretical Biology* 187:273-284, Capaldi et al., 2000, *Nucleic. Acids Res.*, 28(7):21e, Wang et al., 1998, *J. Am. Chem. Soc.* 120:8281-8282, and Wang et al., 1998, *Electroanalysis* 10(8):553-556, each of which is hereby incorporated by reference in its entirety.

[0132] A reporter gene assay can also be used to detect the presence and amount of an mRNA expressed from genes associated with hot flash symptoms. Such assays generally rely on recombinantly linking the transcriptional control region of a gene associated with hot flash symptoms to the coding region of a reporter gene. The presence and amount of expression of the reporter gene can then be determined. The presence and amount of an mRNA expressed by genes associated with hot flash symptoms can then be extrapolated based upon the presence and amount of the reporter gene that is detected. Representative reporter gene assays that can easily be adapted by one of skill in the art for use in the methods of the invention are described by Storz et al., 1999, Anal. Biochem. 276:97-104 and Terstappen et al., 2000, J. Biomol. Screen. 5:255-262, each of which is incorporated by reference in its entirety.

[0133] The presence and amount of an mRNA expressed from genes associated with hot flash symptoms can also be determined using a bead array-based assay. In such assays, oligonucleotides specific for the mRNA to be detected are coupled to fluorescently-detectable beads. The mRNA is then reverse transcribed into labeled cDNA, and hybridized to the detectable beads. The presence and amount of the labeled cDNA can then be detected, revealing the presence and amount of the mRNA expressed from the gene associated with hot flash symptoms. One of ordinary skill in the art can readily adapt the protocols described in Yang et al., 2001, Genome Res. 11:1888-98 and in U.S. Pat. Nos. 6,562,569, 6,514,771, 6,468,811, 6,387,707, 6,376,256, 6,255,116, and 6,251,691, each of which is incorporated by reference in its entirety, to detect the presence and amount of an mRNA expressed from genes associated with hot flash symptoms.

[0134] Of course, the presence and amount of an mRNA expressed from genes associated with hot flash symptoms can be determined by reverse transcribing the mRNA into cDNA and detecting the presence and amount of cDNA product. Thus, any of the above-described methods suitable for the detection of DNA in addition to RNA can be adapted to detect cDNA derived from mRNA expressed from genes associated with hot flash symptoms.

[0135] Similarly, the presence and amount of mRNA expressed from genes associated with hot flash symptoms can also be determined by quantifying the amount of protein translated from the mRNA. As one of skill in the art is aware, the amount of protein translated from a given transcript, absent translational regulation, depends on the amount of mRNA transcript. Thus, the effects of candidate compounds

on regulation of genes associated with hot flash symptoms can also be determined by detecting the presence and amount of proteins expressed from genes associated with hot flash symptoms.

[0136] The presence and amount of protein expressed from genes associated with hot flash symptoms can be determined by any suitable method known by one of skill in the art without limitation. For example, and not by way of limitation, the presence and amount of protein expressed from genes associated with hot flash symptoms can be determined using a western blot assay, an ELISA assay, a cytokine bead array, multiplexed protein detection assays, an immunofluorescence assay, and the like.

[0137] Many of the above-referenced techniques, as well as protocols for performing them, are described in Ausubel et al., eds., *Current Protocols in Molecular Biology*, 2002, Vol. 1, Unit 10, Ch. 3, and Vol. 2, Unit 11 Ch. 1-6., which is hereby incorporated by reference in its entirety. For example, western blot assays, ELISA assays, and immunofluorescence assays are well known to in the art and are each described in detail in this reference. One of ordinary skill in the art can readily adapt these protocols for detecting the presence and amount of protein that is expressed by genes associated with hot flash symptoms.

[0138] In addition, U.S. Pat. No. 6,576,478, which is incorporated by reference in its entirety, describes an array suitable for cytokine bead assays, multiplexed fluorescence assays, and other high throughput assays for determining the presence and amount of protein expressed from genes associated with hot flash symptoms. The device, as well as the device described in U.S. Pat. No. 6,558,960, also incorporated by reference in its entirety, can readily be adapted by one of skill in the art for use in such methods. U.S. Pat. Nos. 6,531,283 and 6,511,802, each of which is hereby incorporated by reference in its entirety, provide additional guidance regarding such assays for determining the presence and amount of protein expressed from genes associated with hot flash symptoms.

6.2.7. Primers and Probes Useful in Certain Methods for Quantifying the Expression of Genes Associated with Hot Flash Symptoms

[0139] The present invention further provides nucleic acid primers that are useful in certain methods for quantifying the expression of genes associated with hot flash symptoms. As one of skill in the art will readily recognize, certain of such methods described above rely on the use of oligonucleotide primers to amplify nucleic acids that comprise sequences of genes associated with hot flash symptoms. Methods of using such primers to reverse transcribe RNA and/or to amplify DNA of known sequence are well-known to the art and will not be presented in detail here. The primers, their sequences, and the genes from which sequences that the primers can amplify are derived are presented in TABLE 2, below.

TABLE 2

Gene	Primer 1 (Forward Primer)	Primer 2 (Reverse Primer)
НКІІ	M68971 211F: ATATGATCGCCTGCTTATTCA SEQ ID NO:28	M6897 1378E: AAAGGTAGGCAACATTTTCAC SEQ ID N0:29
HKII	M68971 577F: TTGACCACATCGCCGAATGC SEQ ID NO:30	M68971 893B: AGTGCCCACAATGAGACCAATC SEQ ID N0:31
Parvalbumin	AI175539 250F: CCCGTCCTTGTCTCCAG SEQ ID NO:32	AI175539 402B: AGAAAAAGAGTGCGGATGATG SEQ ID NO:33
Parvalbumin	AI175539 41F: AGCATTTTCCAGAAGAGTGGTGTC SEQ ID NO:34	AI175539 285B: ACAAAGACGCTGATGGCTGC SEQ ID NO:35
Activin beta E	AF089825 669F: GAGCACCAAACCACTTCCTC SEQ ID NO:36	AF089825 918B: CTACAACATAAGGGGGGTCTC SEQ ID NO:37
Activin beta E	AF089825 492F: AAATCCACTTCAACCTACCGCTC SEQ ID NO:38	AF089825 941B: TCGTCTACAACATAAGGGGGTCTC SEQ ID N0:39
Glutamate receptor	U08255 642F: TCTATGACAGCGAGTATGATA SEQ ID NO:40	U08525 945 B: CAAGGGCACTGTGGACCAGAT SEQ ID NO:41
Glutamate receptor	U08255 1030F: TAACCACCGCATCTCTTCCCTG SEQ ID NO:42	U08255 1336 B: TGTGCCAAGGATTTCAAACTGG SEQ ID N0:43
PKC epsilon	M18331 512F: CAGAATGGGAGCCGTCACTTC SEQ ID NO:44	M18331 836B: AGCGCACTTCGTAATAATGAG SEQ ID N0:45
PKC epsilon	M18331 1298F: TTTGACAACCGAGGAGAGGAGC SEQ ID NO:46	M18331 1631B: CCTTGGTCTGGAAGCAGCAATAG SEQ ID NO:47
EST 203549	AI009098 115F: GGGGAACTGTGTAGGACCTT SEQ ID NO:48	AI009098 395E: ATGTAAAAATGCCACCTCACT SEQ ID NO:49
EST 203549	AI009098 61F: TTCAAACCTGTCCAACCAGCC SEQ ID NO:50	AI009098 382B: TTGTGGGTAAAGAAGAGGGGTC SEQ ID NO:51
VAP1	AF034582 1239F: TCGCATCCGTGTCTACTCCATC SEQ ID N0:52	AF034582 1573B: GGAAGTCCTTTTCTGTCACCACC SEQ ID N0:53
VAP1	AF034582 313F: CAGAACCACCCCATTTACCTG SEQ ID N0:54	AF034582 655B: TGTTTACATCCAAGGCTCTCACTG SEQ ID NO:55
MDR	M81855 2147F: CGAAAGAGGATGTGGATGAAGATG SEQ ID NO:56	M81855 2468B: ATGTATCGGAGTCGCTTGGTGAGG SEQ ID NO:57
MDR	M81855 2153F: AGGATGTGGATGAAGATGTGCC SEQ ID NO:58	M81855 2468B: ATGTATCGGAGTCGCTTGGTGAGG SEQ ID NO:59
Arginino- succinate synthetase	X12459 448F: GGAGGATGCCCGAGTTTTACAAC SEQ ID NO:60	X12459 766B: AAGAGGTCCAAGGATGTGCTGTGG SEQ ID NO:61
Arginino- succinate synthetase	X12459 730F: AAGATGGCACTACCCACAGCAC SEQ ID NO:62	X12459 1057B: TTTCCTTCCACCCGTTCCTG SEQ ID NO:63

TABLE 2-continued

Gene	Primer 1 (Forward Primer)	Primer 2 (Reverse Primer)
BAD2	U02553 865F: ATCAAGGATGCTGGAGGAAGGG SEQ ID N0:64	U02553 1193B: TAGTTCAGGGCACTGTTCGTGG SEQ ID N0:65
BAD2	U02553 717F: CTTGGGTATCACTGCTTTGA SEQ ID N0:66	U02553 990B: ATAATACTCCGCCTCTGCTTC SEQ ID N0:67
Prolactin	AF022935 145F: TGTTCTGGTGGCGACTGCCAGACACCT SEQ ID NO:68	AF022935 528B: TATCTTTTCAATCCCTTCAAGAAGCCG SEQ ID N0:69
2-alpha-1 globin	X56325 299F AAGAACTGCTGGGGGAAGATTG SEQ ID NO:70	X56325 562B: TTGCCGTGAGCCTTGACCTG SEQ ID N0:71
RNR1	L08595 305F: ACAACTACAGCACAGGCTACGACG SEQ ID N0:72	640B: AGAAGAGTGAAAGGCGGGAGAC SEQ ID N0:73
RNR1	L08595 541F: GACGATCCGGGCTCCCTTCAC SEQ ID N0:74	L08595 780B: ATGGATGCCGGCTTGCGAATG SEQ ID N0:75
IL18	AY077842 334F: GACCACTTTGGCAGACTTCACTG SEQ ID N0:76	AY077842 546B: CCTTCCATCCTTCACAGATAGGG SEQ ID N0:77
IL18	AY077842 435F: GCCTGATATCGACCGAACAGC SEQ ID NO:78	AY077842 709B: ATCATCTTCCTTTTGGCAAGC SEQ ID N0:79
ARL gene 4	X77235 135F: ACTTCCATCCTATCCAGCCTGC SEQ ID NO:80	X77235 410B: CACCACAAACACAATGCCATCTG SEQ ID NO:81
ARL gene 4	X77235 301F: GCAATTCCAAAACAGTCAC SEQ ID N0:82	X77235 617B: TTTAGCCCATCTCCTATGATT SEQ ID NO:83
Calpain	Calpain 1424F: AGGCTACGCTGTCTACCAGATTCC SEQ ID NO:84	Calpain 1791B: AACACCCTCAAGCAGAAGTCACC SEQ ID NO:85
Calpain	Calpain 1224F: TGGACACGGGGTTCTACA SEQ ID NO:86	Calpain 1356B: CAACTCCTTGGGAATCTGGTA SEQ ID NO:87
EST 196325	EST196325 131F: GGAGCCATTGTTCACATTACCG SEQ ID N0:88	EST196325 356B: TACCCTGCCTTCTTCTCTCTGGAG SEQ ID NO:89
EST 196325	EST196325 150F: CCGACCAGCAACACAGAGC SEQ ID N0:90	EST196325 431B: TTCGCCGTAAAACATCAGCAT SEQ ID NO:91
CPP32	CPP32 362F: GGAGCAGTTTTGTGTGTGTGTGATTC SEQ ID N0:92	CPP32 630B: TGCGGTAGAGTAAGCATACAGGAAG SEQ ID N0:93
CPP32	CPP32 492F: GCCGAAACTCTTCATCATTCA SEQ ID NO:94	CPP32 796B: GATCTGTTTCTTTGCGTGGAA SEQ ID NO:95
Annexin1	NM_012904 822F: TGGAACTGAAGGGTGACATTGAG SEQ ID N0:96	NM_012904 1041B: ATGGCTTGGCAGAGAGGGATTC SEQ ID N0:97
Annexin1	NM_012904 824F: GAACTGAAGGGTGACATTGAG SEQ ID N0:98	NM_012904 1089B: GGGATGTTTAGTTTCCTCCAC SEQ ID N0:99

TABLE 2-continued

Gene	Primer 1 (Forward Primer)	Primer 2 (Reverse Primer)
EST AI014169	AI014169 212F: CTGACACAGGACACGGAACAAAG SEQ ID N0:100	AI014169 393B: GGTGACACTCTTACATTGAGATGCC SEQ ID NO:101
EST AI014169	AI014169 171F: CACAGTTCTCGGGTGGAGT SEQ ID NO:102	AI014169 360B: CATTGAGATGCCCTAACAGTG SEQ ID NO:103
HBP1	U09551 540F: GACCACTGGAAGGAAGAAACACC SEQ ID NO:104	U09551 864B: CAGACTCACCGAATGACACACTCTC SEQ ID NO:105
HBP1	U09551 840F: GAGAGTGTGTCATTCGGTGAGTCTG SEQ ID NO:106	U09551 1131B: CGGAAGAGTCCATAGGTGTGAAGTC SEQ ID NO:107
Amiloride Binding Protein	X73911 819F: TGGCTCGGAAATACGCAGTTG SEQ ID NO:108	X73911 1150B: AGGTGTGTGTGTCCTCCATACAGTGC SEQ ID NO:109
Amiloride Binding Protein	X73911 1367F: GGTGGCTTCAACTTCTATGCGG SEQ ID NO:110	X73911 1687B: CCAGGGATTGGTGAGGTTTTCC SEQ ID NO:111

[0140] Furthermore, the present invention provides probes that can also be used in certain methods for quantifying the expression of genes associated with hot flash symptoms. As one of skill in the art will readily recognize, certain of such methods described above rely on the use of nucleic acid probes to detect and quantify nucleic acids that comprise sequences of genes associated with hot flash symptoms. Methods of using such probes to detect and quantify nucleic acids of known sequence in, for example, RNAse protection assays, dot blots, and the like, are well-known to the art and will not be presented in detail here. The regions of genes associated with hot flash symptoms that can be used as probes to detect and quantify nucleic acids from such genes are presented in TABLE 3, below.

TABLE 3

Gene Name	Sequence	Length of cDNA
MDR	2147-2468	321 bp
Parvalbumin	41-285	244 bp
HKII	577-893	316 bp
BAD2	865-1193	294 bp
PKCe	1298-1631	333 bp
IL18	334-546	213 bp
Calpain	1224-1356	234 bp
EST196325	131-356	226 bp
Annexin1	822-1041	220 bp
EST207724(N27)	212-393	180 bp
HBP1	840-1131	292 bp
PRL	145-528	383 bp

6.3. Methods of Identifying Candidate Compounds that Decrease the Incidence of Hot Flash Symptoms

[0141] In another aspect, the invention provides methods of identifying candidate compounds that decrease the incidence of hot flash symptoms. These methods generally comprise performing a method of the invention for determining the effect of a candidate compound on hot flash

symptoms, and additionally determining that the candidate compound decreases the incidence of hot flash symptoms.

[0142] A candidate compound can be determined to decrease the incidence of hot flash symptoms based upon the effect of the candidate compound on regulation of genes associated with hot flash symptoms as extensively described above. In certain embodiments, the effect of the candidate compound on regulation of expression of genes associated with hot flash symptoms can be compared to a reference pattern of expression, as described above. In other embodiments, the effect of the candidate compound on regulation of expression of genes associated with hot flash symptoms can be compared to a reference on regulation of expression of genes associated with hot flash symptoms can be compared to the effect of a compound with a known effect on regulation of expression of genes associated with hot flash symptoms, as described above.

6.4. Kits for Determining the Effect of a Candidate Compound on Hot Flash Symptoms

[0143] In another aspect, the invention provides kits for determining the effect of a compound on hot flash symptoms. The kits generally comprise at least one primer or probe that can be used to detect the presence and amount of an expression product of a member of a panel of genes associated with hot flash symptoms. The primer or probe can be any primer or probe known by one of skill in the art to be useful for detecting the presence and amount of an expression product of a member of a panel of genes associated with hot flash symptoms without limitation. The members of the panel of genes can be any genes associated with hot flash symptoms known by one of skill in the art without limitation, especially those described above.

[0144] In certain embodiments, the primer or probe can be used to detect an mRNA expressed from a member of a panel of genes associated with hot flash symptoms. Primers and probes suitable for such kits are extensively described in Section 5.2.7., above. In other embodiments, the primer or

probe can be used to detect a protein expressed from a member of a panel of genes associated with hot flash symptoms.

[0145] In another aspect, the invention provides kits for determining the effect of one or more candidate compounds on hot flash symptoms. In certain embodiments, the kit comprises at least one gene-specific nuclease protection probe that is specific for a member of a panel of genes associated with hot flash symptoms; a surface having multiple spatially discrete regions, wherein at least two of the regions are substantially identical and wherein each region comprises at least two different oligonucleotide anchors; at least one bifunctional linker, wherein each bifunctional linker comprises a first region that can specifically bind to one of the oligonucleotide anchors and a second region that specifically binds to one of the gene-specific nuclease protection probe(s); and at least one detection probe, wherein the detection probe(s) specifically binds to the gene-specific nuclease protection probe(s).

[0146] In another embodiment, the kit for determining the effect of a compound on hot flash symptoms, comprises at least one gene-specific nuclease protection probe that is specific for a member of a panel of genes associated with hot flash symptoms and that can be directly or indirectly detectable; and a surface having multiple spatially discrete regions, at least two of which regions are substantially identical, and wherein the regions are adapted to specifically bind to the gene-specific protection probe(s).

[0147] The kits of the invention can comprise any components described as useful in the methods of the invention, above, without limitation. For example, gene-specific nuclease protection probes, detection probes, primers, and probes described as useful in the methods of the invention may also be included in a kit of the invention.

[0148] In certain embodiments, a kit of the invention can comprise instructions for determining the effect of a compound on hot flash symptoms. In certain embodiments, the kit can comprise instructions for identifying a compound that decreases the incidence of hot flash symptoms.

6.5. Compositions for Determining the Effect of a Candidate Compound on Hot Flash Symptoms

[0149] In yet another aspect, the invention provides compositions suitable for determining the effect of a compound on hot flash symptoms. The compositions may also be used in the methods and kits of the invention. In certain embodiments, the composition comprises a plurality of gene-specific nuclease protection probes, wherein each member of the plurality of gene-specific nuclease protection probes hybridizes under stringent conditions to an mRNA expressed from a member of a panel of genes associated with hot flash symptoms. The member of the panel of genes can be any member of a panel of genes associated with hot flash symptoms known by one of skill in the art without limitation.

[0150] In other embodiments, the composition comprises one or more primers that can be used to determine the presence and amount of an expression product of one or more genes associated with hot flash symptoms and a suitable buffer, diluent, or excipient. In certain embodiments, the primer or probe can be used to detect an mRNA expressed from a member of a panel of genes associated with hot flash symptoms. Primers and probes suitable for such kits are extensively described in Section 5.2.7., above. In other embodiments, the primer or probe can be used to detect a protein expressed from a member of a panel of genes associated with hot flash symptoms.

[0151] In certain embodiments, the member of the panel of genes associated with hot flash symptoms can be selected from the group consisting of Activin Beta E, Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Argininosuccinate Synthetase, Ribonucleoside Reductase 1, Interleukin-18, ARL gene 4, Calpain, EST196325, CPP32, EST208064, 2-alpha-1 globin, Amiloride Binding Protein, Annexin 1, N27, HBP1, D-binding protein, FE65, Protein Kinase C type I, Glutamate Receptor subunit d1, VAP1, Protein Kinase C subspecies epsilon, EST203549, and Heat Shock Transcription Factor 1. In a preferred embodiment, the member of the panel of genes is selected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon.

6.6. Arrays for Determining the Effect of a Candidate Compound on Hot Flash Symptoms

[0152] In yet another aspect, the invention provides arrays useful for the identification of the effect of a plurality of compounds on hot flash symptoms. In certain embodiments, the array can comprise a non-porous surface; and a plurality of different oligonucleotides connected with the surface, wherein at least one of the oligonucleotides hybridizes under stringent conditions to a member of a panel of genes associated with hot flash symptoms, and wherein each of the different oligonucleotides is connected with the surface in a different predetermined region of the surface. The member of the panel of genes can be any member of a panel of genes associated with hot flash symptoms known by one of skill in the art without limitation.

[0153] In certain embodiments, the member of the panel of genes can be selected from the group consisting of Activin Beta E, Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Argininosuccinate Synthetase, Ribonucleoside Reductase 1, Interleukin-18, ARL gene 4, Calpain, EST196325, CPP32, EST208064, 2-alpha-1 globin, Amiloride Binding Protein, Annexin 1, N27, HBP1, D-binding protein, FE65, Protein Kinase C type I, Glutamate Receptor subunit d1, VAP1, Protein Kinase C subspecies epsilon, EST203549, and Heat Shock Transcription Factor 1. In a preferred embodiment, the member of the panel of genes is selected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon.

7. EXAMPLES

[0154] The invention is described in reference to a number of examples presented below. The examples are intended to provide illustration of certain embodiments of the invention, and should not be construed to limit the invention in any way.

Generation of Reference Expression Profiles of a Panel of Genes Associated with Hot Flash Symptoms

[0155] The following example describes the generation of expression profiles of a panel of genes whose expression level is associated with the increase or decrease of hot flash symptoms using the compounds estradiol, raloxifene, tibolone, and 4-hydroxy tamoxifen. Estradiol and raloxifene are known to have a decreasing effect on hot flash symptoms, while tibolone and 4-hydroxy tamoxifen are known to have an increasing effect on hot flash symptoms.

[0156] Treatment of GH3 Cells and Preparation of Cell Lysates. In 96-well V-bottom dishes, 50,000 GH3 cells per well were plated in 200 μ l phenol red free Ham's F-12K media supplemented with 2.5% charcoal stripped FCS, 1% penicillin & streptomycin, 1% 200 mM glutamine. The plates was incubated at 37° C. for 24 hours in a humidified atmosphere containing 5% (v/v) CO₂.

[0157] The next day, compound dilutions were prepared according to a standard compound dilution protocol: Briefly, from a 5 mM stock, the compounds (estradiol, raloxifene, tibolone, and 4-hydroxy tamoxifen) were serially diluted in 100% DMSO from 5 mM to 0.00005 mM. Next, the compounds were diluted from 100% DMSO to into water by 1:25 to reduce the DMSO concentration to 4% by transferring 10 μ l of compound solution into 240 μ l of water. After mixing the compound solutions well, 10 μ l of diluted compounds were added to each well of the 96-well plates. As such, the cells were exposed to a final compound concentration of 10 μ M to 0.0001 μ M. The 96-well plates were then incubated at 37° C. for 24 hours.

[0158] The lysis buffer containing probe linker solution and the denaturation oil were warmed to 50° C. The plate heat block/oven was set to 95° C.

[0159] The plates were removed from the incubator and spun down at 1200 rpm for 5 minutes to ensure that the cells will not lift off. The media was aspirated from the wells using the 8-channel aspirator, and immediately thereafter, 30 μ l of lysis buffer/probe-linker solution per well were added, followed by 60 μ l of denaturation oil per well. The plates were covered with foil plate cover and sealed. Then the plates were heated at 95° C. for 15 minutes.

[0160] Analysis of Gene Expression. The panel of signature genes used in this example included protein tyrosine phosphatase BAD2, Type II Hexokinase, multiple drug resistance gene, parvalbumin, prolactin, IL-18, N27, calpain, annexin I, and PKC subunit epsilon. Expression of the listed genes along with four housekeeping genes, i.e., actin, GAPDH, cyclophilin and L32, were analyzed using a cell lysate nuclease protection assay kit from High Throughput Genomics, Tucson, Ariz., following the manufacturer's protocol. Custom-made detection probes and linkers required to perform the assay had been obtained from the manufacturer.

[0161] Data Analysis. First, gene expression data were normalized using the housekeeping gene expression. Then, the expression level of each gene in the cell samples treated with estradiol, raloxifene, tibolone, and 4-hydroxy tamoxifen was divided by the corresponding gene expression level

in DMSO treated control samples. The effect of the compounds estradiol, raloxifene, tibolone, and 4-hydroxy tamoxifen, respectively, on the expression of each signature gene is shown in **FIGS. 1A through 1E**. These expression profiles serve as reference expression profiles for the testing of candidate compounds.

7.2. Example 2

High Throughput Assay for Determining the Effect Candidate Compounds on Hot Flash Symptoms

[0162] The following example describes a high throughput assay for determining the effect of candidate compounds on the expression of a panel of genes whose expression level is associated with increase or decrease of hot flash symptoms. The rat pituitary cell line GH3 is used as the model system. Estradiol and Raloxifene at 100 nM are included in each experiment as reference compounds.

[0163] Treatment of GH3 Cells and Preparation of Cell Lysates. In 96-well V-bottom dishes, 50,000 GH3 cells per well are plated in 200 μ l phenol red free Ham's F-12K media supplemented with 2.5% charcoal stripped FCS, 1% penicillin & streptomycin, 1% 200 mM glutamine. The plates are incubated at 37° C. for 24 hours in a humidified atmosphere containing 5% (v/v) CO₂.

[0164] The next day, candidate compound dilutions are prepared according to the compound dilution protocol described in Example 1, such that the cells are exposed to a final compound concentration of $10 \,\mu$ M to $0.0001 \,\mu$ M. The 96-well plates are then incubated at 37° C. for 24 hours.

[0165] As described in Example 1, the lysis buffer containing probe linker solution and the denaturation oil is warmed to 50° C. The plates are removed from the incubator and spun down at 1200 rpm for 5 minutes to ensure that the cells will not lift off. The media is aspirated from the wells using the 8-channel aspirator, and immediately thereafter, 30 μ l of lysis buffer/probe-linker solution per well is added, followed by 60 μ l of denaturation oil per well. The plates are covered with foil plate cover and sealed, and the plates are heated at 95° C. for 15 minutes.

[0166] Analysis of Gene Expression. Expression levels of the signature genes listed in Example 1, along with the expression levels of the four housekeeping genes used in Example 1, are analyzed using the cell lysate nuclease protection assay kit from High Throughput Genomics, Tucson, Ariz., following the manufacturer's protocol, and detection probes that had been custom-ordered from the manufacturer.

[0167] Data Analysis. After normalizing the gene expression data using the housekeeping gene expression, the expression level of each gene in the cell samples treated with candidate compounds is divided by the corresponding gene expression level in DMSO treated control samples. The effect of each candidate compound on the expression level of the panel of signature genes is compared with the reference profiles shown in **FIGS. 1A through 1E**.

7.3. Example 3

Assay for Determining Hot Flash Side Effects of an Osteoporosis Candidate Compound

[0168] The assays of the present invention may be used to screen compounds identified as potential therapeutic agents for the treatment of osteoporosis (or other medical conditions) for hot flash side effects prior to costly clinical trials. The compound is assayed as described in Example 1. The effect of the compound on the expression of the panel of genes listed in Example 1 is compared with the expression profiles of estradiol, tibolone, raloxifene and 4-hydroxy tamoxifen. A compound whose effect on the expression profile of the panel of signature genes mirrors more closely that of raloxifene and 4-hydroxy tamoxifen than that of estradiol and tibolone is likely to increase the incidence of undesirable hot flash side effects.

7.4. Example 4

Validation of Candidate Compounds Using a Rat Model of Hot Flash Symptoms

[0169] The following animal model is used to validate the effects of a candidate compound on hot flash symptoms.

[0170] Ovariectomized rats are treated for 8 or 9 days with candidate compounds. Rats are made morphine-dependent by implanting a morphine pellet (75 mg each) subcutaneously (sc) on days 3 and 5 of treatment. On the last day of treatment, a thermistor, connected to a data acquisition system, is placed on the tail of each animal and morphine addiction is withdrawn by naloxone injection (1.0 mg/kg, sc). Temperature measurements are taken for 1 h under ketamine (80 mg/kg, im) anesthesia. The candidate compounds that decrease the incidence of hot flash symptoms decrease the temperature of the rat tail in this model.

SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 111 <210> SEQ ID NO 1 <211> LENGTH: 2600 <212> TYPE: DNA <213> ORGANISM: Rattus norvegicus <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1714)..(1714) <223> OTHER INFORMATION: n is a, c, g, or t <400> SEQUENCE: 1 gcgatctact ctcagtcttc ctgagtcaca ggctaccaag gacaagtagc tctgtctgcc 60 120 ctttqttqaq qqqaqctqtq acactqqttt qctqctqctq ctqctqctqc tqctqcatct tctttgggaa atcagactca ataaactgcc atccatctga ggttctcaac tcagagccat 180 ctacctggag catgggactt tcaaatgtcc agctctggac aatactgctg tgggcattgg 240 catgggtgca gagtacaaga tctgcgtgcc cgtcctgtgg ggccccaact ctgacacccc 300 aaggagaacg cgctctggtc ctagagctag ccaagcagca aatcctggag ggactgcacc 360 taaccagccg tcccagaata actcgtcctc tgccccaggc agcactgacc agagccctcc 420 ggagactgca gcccaggagc atggtccctg gcaaccgaga gaaagtcatc agctttgcta 480 ccagcataga caaatccact tcaacctacc gctccgtgct caccttccaa ctgtcccctc 540 tttggtccca ccacctgtac catgcccgcc tctggctgca cgtgcctccc tcttttccgg 600 ccactctgta tctgaggatc ttcggttgcg gtaccacgag gtgcagagga tcccgcacgt 660 tcctagctga gcaccaaacc acttcctccg gctggcacgc cctgactctg ccctctagcg 720 gcttgcggag tgaggaatct ggagtcacaa aactccaact ggaattcaga cctctggacc 780 ttaacagcac tactgccaga ctgccacggc tgctgttgga cacagcggga cagcagcgtc 840 ccttcttgga acttaagatc cgagctaatg aacccggagc aggccgggcc aggaggagga 900 ctcccacctg tgagtctgag acccccttat gttgtagacg agaccactat gtcgatttcc 960 aggagctggg gtggagagac tggatcctgc agccggaggg ataccagctg aattactgca 1020 1080 gtgggcagtg cccgccccac ctggctggca gccctggcat tgctgcttcc ttccattctg ctgtctttag cctcctcaaa gccaacaacc cttggcctgc gggttcttcc tgctgtgtcc 1140

23

ccaccgcgcg aaggeetete teeeteet acettgacea taatggeaa	t gtggtcaaga 1200
ccgatgtgcc agacatggtt gtagaggcct gtggctgcag ctagcaaga	g gacctgaagg 1260
ttttgagtga agttcaaggt tcaagttggg ggttcccaag caaaagggt	c ctgtgtctgg 1320
aagcacaagt tooggatoca tactgacaco caacaagotg tgtagcagt	a tgcctgagtt 1380
tgacccctgt ggaactcaaa tgggcatttt tcttgtccca gattctggc	c tatttcaggc 1440
tgtttcaaat gtggacagat gggtaaaacg tttcctttcg agaaactgc	c tggccagcac 1500
cattteetac atcaageeet gtteeaggae ageaggggat geegtggga	g ggaaggaaga 1560
atgcagggaa aactacttag tctctcccga aaaagaattc ctcaagtaa	t aaaggaggaa 1620
ttagaaggtt aggcagattg gggaaaggta tacaggctaa gaacaggga	c tgttgcctgc 1680
tttgagcaag gtcaagagga atatgagcag gcantgaggt gggagagca	g ttaggaggcc 1740
ctggaattga cagtcagtaa aaaggggtgc tgaacccata agttctcta	g cttccccttg 1800
gggagaggac ccatgtaaat gacatacgtt tatattttct taataaaaa	g gagaaagaaa 1860
agcaacagtg tgtaaggggt tgttaaaatg agccagaaac aaagtgtgg	t ctggggacct 1920
ctgtgcttcg gggccttttc aaggggtttt caaactattt gcataatca	c atagagaagt 1980
tatttgtcat ttactatcat tattttttca ttgttctgtg ggaacaggg	t ttacacttat 2040
aactacagcc ctcaggaggc tgagacagga ggatcgccgt gagttcaag	a ccagcettea 2100
tagtgaatgc tgggctagcc tgagctatgg agtgagatcc tgtctcaaa	g caaaagaaac 2160
aaacaaaaca acaaagacta agtagtgagt ctttccagag tgtattata	t gatacageeg 2220
atgacattgt ggcttatata ttctcctttc tctcctttaa acaatttta	t ttatttttat 2280
tgtatgtgta tgatgagtct taggcctgca ccggcttgca gtgcccata	g aggtcagaag 2340
aggacgctgg atccttggaa ctaaagttag agcagtgtga gctgcctgt	g tctgttaaca 2400
gaactcaggt ccacagtaag agaaacaaac aattaaaggc tgagctacc	t ctccacctga 2460
gacatgtgca cacacagtca cacattgttt tgttttgttt	c cacgctatct 2520
tggaactete aateeteetg ceteagaeee teetgeeetg gaattaaag	g cataaaccac 2580
caaaaaaaa aaaaaaaaa	2600
<210> SEQ ID NO 2 <211> LENGTH: 1731 <212> TYPE: DNA <213> ORGANISM: Rattus norvegicus	
<400> SEQUENCE: 2	
gtcgacagtc tgggaggaat cgcccatcga gggaatagat gaaccacac	
gtagaagcgg cccagcagag caacgtgggc tggggtgtac ttcagtcgg	
gatetecagt agtggeecat geeatecaga ggtgggggaga gagettggg	
ttggaaatgg atggccctgt cttctttcca tgtaactttc caactccca	
caccagcaac aacctcatgc catttgaggt gctacttcaa tatcgctgg	
ctatgtgaac ttaagagtct ggtgtcaggc gtgagctgag gtagaggtg	
gcctctataa accaattaca ccacttgagc caagcagtac acatgcact	
ctatcagcct agctcctgac aaggtttctc tccagccttt tactttcct	
aggcggatat ataccagggt ggggagttgc atttcagagt gagacggtt	c tgtcttcacc 540

taccacttgt	tggcgatgtg	accttgggca	aagctcatta	acagcacagt	gcctagttcc	600
ctaatttgta	aaacatatgc	tataggtgtg	acgattacga	agggctgact	tttgtaatgg	660
ctttgcttca	gggatctgca	gactcgttga	gccacaatta	ggatgagaat	caaggtgctt	720
cagacttgtg	acaggcactg	gcggcccctc	acatgatcct	cagataccag	attgtggcgt	780
gtgctgctag	gatcacttgt	ctttccagtc	tcccaacatc	tcttgggtcc	gtgatacgcg	840
ccccccaccc	caagcccagc	ctgacgcggc	ggtggctcat	gcgccctgga	gtcccgggct	900
ctagccacgg	aacacgtccc	aactctggcg	cccggctccg	cccctagcct	cgggcgcgtc	960
tctcccgccg	cctgcttggg	tgctggagca	gccgcgcccg	cggctctggg	agctgattgg	1020
ctgtggactg	cgggacgggc	agccggagag	cgcacacacc	ctcttcccgc	agccaatgag	1080
cgcgcccacg	tcactgtctt	gggcggccca	aagagccggc	agcccctcaa	taagccacat	1140
tgttgcacca	actccagtgc	tagagtctca	ggacaccaca	ggctacacgg	agttatcccg	1200
cttaggagac	ccgaaggcag	gagcatcact	ccagtgactc	tgataaggtg	cgatcgcccg	1260
agaggaacag	aactgtcatt	tttgcgaagt	tgagccttac	ggatcccgtg	ggcgaagtta	1320
gcgacgggac	gctgagcaac	tagaccggtc	ggcaggagtg	agacttaggt	gccttctagt	1380
agttgtgact	taaaaaaaaa	aaaaaaagg	aaaagaaaaa	aggaggaaaa	cctgtttctg	1440
gaaacgcgag	gccctcagct	ggtgagccat	cgtggttaag	cttctttgtg	tggctcctgg	1500
agtctccgat	cccagccgga	cacccgggcc	tggtttcaaa	gcggtcgaac	tgctctgccc	1560
gctccaccgg	tagcgctcga	acctcggttt	ctctactcga	ccccgactcg	ccgcagcagg	1620
atgatcgcct	cgcatatgat	cgcctgctta	ttcacggagc	tcaaccaaaa	ccaagtgcag	1680
aaggtaagtc	ggcacgggcg	ggagctgctg	gctcgcttcg	accaagttgc	a	1731
<210> SEQ I <211> LENGT <212> TYPE:	D NO 3 H: 4254 DNA	ggagctgctg s norvegicus		accaagttgc	g	1731
<210> SEQ I <211> LENGT <212> TYPE:	D NO 3 H: 4254 DNA ISM: Rattus			accaagttgc	a	1731
<210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN <400> SEQUE	D NO 3 TH: 4254 DNA HISM: Rattus	s norvegicus			-	60
<210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN <400> SEQUE gctcccatct	D NO 3 H: 4254 DNA HISM: Rattus NCE: 3 tcgaggctca	s norvegicus gctcaactca	5	ttccaaattc	tacatcttgg	
<pre><210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN <400> SEQUE gctcccatct cggacttcgc</pre>	D NO 3 "H: 4254 DNA HISM: Rattus NCE: 3 tcgaggctca gaaggaaacc	s norvegicus gctcaactca cggagtgtta	gagctacttc	ttccaaattc tgatggagtt	tacatcttgg tgaagagggc	60
<pre><210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN <400> SEQUE gctcccatct cggacttcgc cttaacggaa</pre>	D NO 3 H: 4254 DNA HISM: Rattus NCE: 3 tcgaggctca gaaggaaacc gagcagacaa	s norvegicus gctcaactca cggagtgtta gaacttctca	gagctacttc cgtgaggtcc	ttccaaattc tgatggagtt aaaagagtaa	tacatcttgg tgaagagggc aaaggagaag	60 120
<pre><210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN <400> SEQUE gctcccatct cggacttcgc cttaacggaa gagaagaaac</pre>	D NO 3 "H: 4254 DNA IISM: Rattus NCE: 3 tcgaggctca gaaggaaacc gagcagacaa ctgctgttgg	s norvegicus gctcaactca cggagtgtta gaacttctca catattcggg	gagctacttc cgtgaggtcc aagatgggca	ttccaaattc tgatggagtt aaaagagtaa atgcagattg	tacatcttgg tgaagagggc aaaggagaag gcttgacaag	60 120 180
<pre><210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN <400> SEQUE geteceatet cggaettege cttaacggaa gagaagaaac ctgtgcatgg</pre>	D NO 3 H: 4254 DNA IISM: Rattus NCE: 3 tcgaggctca gaaggaaacc gagcagacaa ctgctgttgg ctctgggaac	getcaactca cggagtgtta gaacttetca catatteggg tetegetget	gagctacttc cgtgaggtcc aagatgggca atgtttcgct	ttccaaattc tgatggagtt aaaagagtaa atgcagattg gaaccctgct	tacatcttgg tgaagagggc aaaggagaag gcttgacaag tcccctcctg	60 120 180 240
<pre><210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN <400> SEQUE gctcccatct cggacttcgc cttaacggaa gagaagaaac ctgtgcatgg atgctggtgt</pre>	D NO 3 H: 4254 DNA HISM: Rattus NCE: 3 tcgaggctca gaaggagacaa ctgctgttgg ctctgggaac tcggatacat	gctcaactca cggagtgtta gaacttctca catattcggg tctcgctgct gacagatagt	gagctacttc cgtgaggtcc aagatgggca atgtttcgct atcatccacg	ttccaaattc tgatggagtt aaaagagtaa atgcagattg gaaccctgct gcagagaccc	tacatcttgg tgaagagggc aaaggagaag gcttgacaag tcccctcctg gcattctgac	60 120 180 240 300
<pre><210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN <400> SEQUE gctcccatct cggacttcgc cttaacggaa gagaagaaac ctgtgcatgg atgctggtgt cgagcgatta</pre>	D NO 3 H: 4254 DNA IISM: Rattus NCE: 3 tcgaggctca gaaggaaacc gagcagacaa ctgctgttgg ctctgggaac tcggatacat ctaatcaaag	gctcaactca cggagtgtta gaacttctca catattcggg tctcgctgct gacagatagt tgaaatcaac	gagctacttc cgtgaggtcc aagatgggca atgtttcgct atcatccacg tttaccccaa	ttccaaattc tgatggagtt aaaagagtaa atgcagattg gaaccctgct gcagagaccc ccgtcagcga	tacatcttgg tgaagagggc aaaggagaag gcttgacaag tcccctcctg gcattctgac cacgagtctg	60 120 180 240 300 360
<pre><210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN <400> SEQUE gctcccatct cggacttcgc cttaacggaa gagaagaaac ctgtgcatgg atgctggtgt cgagcgatta gaggaggaca</pre>	D NO 3 H: 4254 DNA HISM: Rattus NCE: 3 tcgaggctca gagcaggaaacc gagcaggaaac ctgctgttgg ctctgggaac tcggatacat ctaatcaaag tggccatgta	s norvegicus gctcaactca cggagtgtta gaacttctca catattcggg tctcgctgct gacagatagt tgaaatcaac tgcctactat	gagctacttc cgtgaggtcc aagatgggca atgtttcgct atcatccacg tttaccccaa agtacacata	ttccaaattc tgatggagtt aaaagagtaa atgcagattg gaaccctgct gcagagaccc ccgtcagcga ttggtgccgg	tacatcttgg tgaagagggc aaaggagaag gcttgacaag tcccctcctg gcattctgac cacgagtctg tgtgctcatc	60 120 180 240 300 360 420
<pre><210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN <400> SEQUE gctcccatct cggacttcgc cttaacggaa gagaagaaaac ctgtgcatgg atgctggtgt cgagcgatta gaggaggaca gttgcctaca</pre>	D NO 3 H: 4254 DNA IISM: Rattus NCE: 3 tcgaggctca gaaggaaaacc gagcagacaa ctgctgttgg ctctgggaaca tcggatacat ctaatcaaag tggccatgta tccaggtttc	gctcaactca cggagtgtta gaacttctca catattcggg tctcgctgct gacagatagt tgaaatcaac tgcctactat actttggtgc	gagctacttc cgtgaggtcc aagatgggca atgtttcgct atcatccacg tttaccccaa agtacacata tacacgggca	ttccaaattc tgatggagtt aaaagagtaa atgcagattg gaaccctgct gcagagaccc ccgtcagcga ttggtgccgg ggagacaaat	tacatcttgg tgaagagggc aaaggagaag gcttgacaag tcccctcctg gcattctgac cacgagtctg tgtgctcatc acacaagatt	60 120 180 240 300 360 420 480
<pre><210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN <400> SEQUE gctcccatct cggacttcgc cttaacggaa gagaagaaac ctgtgcatgg atgctggtgt cgagcgatta gaggaggaca gttgcctaca aggcagaagt</pre>	D NO 3 H: 4254 DNA IISM: Rattus NCE: 3 tcgaggctca gagcaggacaa ctgctgttgg ctctgggaac tcggatacat ctaatcaaag tggccatgta tccaggtttc ttttccatgc	s norvegicus gctcaactca cggagtgtta gaacttctca catattcggg tctcgctgct gacagatagt tgaaatcaac tgcctactat actttggtgc catcatgaat	gagctacttc cgtgaggtcc aagatgggca atgtttcgct atcatccacg tttaccccaa agtacacata tacacgggca ctggcagctg	ttccaaattc tgatggagtt aaaagagtaa atgcagattg gaaccctgct gcagagaccc ccgtcagcga ttggtgccgg ggagacaaat gctggtttga	tacatcttgg tgaagagggc aaaggagaag gcttgacaag tcccctcctg gcattctgac cacgagtctg tgtgctcatc acacaagatt cgtgaatgac	60 120 180 240 300 360 420 480 540
<pre><210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN <400> SEQUE gctcccatct cggacttcgc cttaacggaa gagaagaaaac ctgtgcatgg atgctggtgt cgagcgatta gaggaggaca gttgcctaca aggcagaagt gctggggagc</pre>	D NO 3 H: 4254 DNA IISM: Rattus NCE: 3 tcgaggctca gaaggaaaacc gagcagacaa ctgctgttgg ctctgggaaca tcggatacat ctaatcaaag tggccatgta tccaggtttc ttttccatgc tcaacacccg	gctcaactca cggagtgtta gaacttctca catattcggg tctcgctgct gacagatagt tgaaatcaac tgcctactat actttggtgc catcatgaat tctcacagat	gagctacttc cgtgaggtcc aagatgggca atgtttcgct atcatccacg tttaccccaa agtacacata tacacgggca ctggcagctg caggagatag	ttccaaattc tgatggagtt aaaagagtaa atgcagattg gaaccctgct gcagagaccc ccgtcagcga ttggtgccgg ggagacaaat gctggtttga aaattaatga	tacatcttgg tgaagagggc aaaggagaag gcttgacaag tcccctcctg gcattctgac cacgagtctg tgtgctcatc acacaagatt cgtgaatgac cggaattggt	60 120 180 240 300 360 420 480 540 600
<pre><210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN <400> SEQUE gctcccatct cggacttcgc cttaacggaa gagaagaaac ctgtgcatgg atgctggtgt cgagcgatta gaggaggaca gttgcctaca aggcagaagt gctggggagc gacaaacttg</pre>	D NO 3 H: 4254 DNA IISM: Rattus NCE: 3 tcgaggctca gaaggagaaacc gagcagacaa ctgctgttgg ctctgggaac tcggatacat ctaatcaaag tggccatgta tccaggtttc ttttccatgc tcaacacccg gaatgttctt	getcaactca cggagtgtta gaacttctca catattcggg tctcgctgct gacagatagt tgaaatcaac tgcctactat actttggtgc catcatgaat tctcacagat tctcacagat	gagctacttc cgtgaggtcc aagatgggca atgtttcgct atcatccacg tttaccccaa agtacacata tacacgggca ctggcagctg caggagatag gacgtctcca	ttccaaattc tgatggagtt aaaagagtaa atgcagattg gaaccctgct gcagagaccc ccgtcagcga ttggtgccgg ggagacaaat gctggtttga aaattaatga cagccggttt	tacatcttgg tgaagagggc aaaggagaag gcttgacaag tcccctcctg gcattctgac cacgagtctg tgtgctcatc acacaagatt cgtgaatgac cggaattggt tataatagga	60 120 180 240 300 360 420 480 540 600 660
<pre><210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN <400> SEQUE gctcccatct cggacttcgc cttaacggaa gagaagaaaac ctgtgcatgg atgctggtgt cgagcgatta gaggaggaca gttgcctaca aggcagaagt gctggggagc gacaaacttg tttataagtg</pre>	D NO 3 H: 4254 DNA IISM: Rattue NCE: 3 tcgaggctca gaaggaaacc gagcagacaa ctgctgttgg ctctgggaac tcggatacat ctaatcaaag tggccatgta tccaggtttc ttttccatgc tcaacacccg gaatgttctt gttggaagct	s norvegicus gctcaactca cggagtgtta gaacttctca catattcggg tctcgctgct gacagatagt tgaaatcaac tgcctactat actttggtgc catcatgaat tctcacagat tccagtccata aacccttgta	gagctacttc cgtgaggtcc aagatgggca atgtttcgct atcatccacg tttaccccaa agtacacata tacacgggca ctggcagctg caggagatag gacgtctcca acgacattt	ttccaaattc tgatggagtt aaaagagtaa atgcagattg gaaccctgct gcagagaccc ccgtcagcgg ggagacaaat gctggtttga aaattaatga cagccggttt tcagccctct	tacatcttgg tgaagagggc aaaggagaag gcttgacaag tcccctcctg gcattctgac cacgagtctg tgtgctcatc acacaagatt cgtgaatgac cggaattggt tataatagga tattgggttg	60 120 180 240 300 360 420 480 540 600 660 720

gagcagttgc	cgaagaagtc	ttagcagcca	tcagaactgt	gattgcgttt	900	
agaaggaact	tgaaaggtac	aataaaaatt	tagaagaagc	taaaagagtt	960	
aagccatcac	ggccaacatt	tccataggta	ttgcctacct	gttggtctat	1020	
cactggcatt	ctggtatggg	acctccttgg	tcctctcaaa	tgaatattct	1080	
tgcttaccgt	cttcttctct	attttattgg	ggactttcag	tattggacat	1140	
acatagaagc	ctttgcaaat	gcaagagggg	cagcctatga	aatcttcaag	1200	
atgagccaag	catcgacagc	ttctcaacca	agggacacaa	accagacagt	1260	
atttggaatt	taaaaatgtt	tacttcaact	acccatcacg	aagtgaagtt	1320	
agggcctcaa	cctgaaggtg	aagagcgggc	agacggtagc	cctggttggc	1380	
gtgggaaaag	cacaactgtc	cagctgctgc	agaggctcta	cgaccccata	1440	
tcagtattga	cggacaggac	atcaggacca	tcaatgtgag	gtatctgcgg	1500	
gggtggtgag	tcaggaaccc	gtgctgtttg	ccaccacgat	tgccgaaaac	1560	
gccgagaaaa	cgtcaccatg	gatgagatag	agaaagctgt	caaggaagcc	1620	
acttcatcat	gaaactgccc	cacaaatttg	acaccctggt	tggtgagaga	1680	
tgagtggggg	acagaaacag	aggatcgcca	ttgcccgggc	cctggtccgc	1740	
tccttttgtt	ggatgaggcc	acgtcagcct	tggacacaga	aagcgaagcc	1800	
ccgctctgga	taaggctaga	gaaggccgga	ccaccattgt	gatagctcac	1860	
cagtgcgcaa	tgctgacgtc	attgctggtt	ttgatggtgg	tgtcattgtg	1920	
atcatgaaga	gctcatgaaa	gagaagggca	tttacttcaa	acttgtcatg	1980	
gaggaaatga	aattgaacca	ggaaataatg	cttatgaatc	ccaaagtgac	2040	
ctgagttgac	ttcagaagaa	tcaaaatctc	ctttaataag	gagatcaatt	2100	
tccacagaag	acaagaccag	gagagaagac	ttagttcgaa	agaggatgtg	2160	
tgcctatggt	ttccttttgg	cagatcctaa	agctaaatat	tagtgaatgg	2220	
ttgtgggtgt	actttgtgct	gttataaatg	ggtgcataca	accagtgttt	2280	
tttcaaagat	tgtaggggtt	ttttcaagag	acgacgacca	tgaaaccaaa	2340	
gtaacttgtt	ttcccttctc	tttctggtca	tgggaatgat	ttcttttgtt	2400	
ttcaaggctt	cacatttggc	aaagctggag	agatecteae	caagcgactc	2460	
tcttcaaatc	catgctgcga	caggatataa	gctggtttga	tgaccataaa	2520	
gctcgctgac	taccaggctc	gctagtgacg	cttctaatgt	taaagggggct	2580	
ggcttgctgt	agttacccag	and the set of a second second			2640	
	agecaeeeag	aatgtagcaa	accttggcac	aggaattatc	2040	
	tggctggcag				2700	
tcttagtcta		cttacacttt	tacttgtagt	aattatacca		
tcttagtcta tgggtggaat	tggctggcag	cttacacttt aaactgttgt	tacttgtagt ctggtcaagc	aattatacca cttgaaggac	2700	
tcttagtcta tgggtggaat tagagatctc	tggctggcag tattgaaatg	cttacacttt aaactgttgt gctacagaag	tacttgtagt ctggtcaagc caattgaaaa	aattatacca cttgaaggac cttccgcact	2700 2760	
tcttagtcta tgggtggaat tagagatctc tgactcggga	tggctggcag tattgaaatg tgggaagatc	cttacacttt aaactgttgt gctacagaag gaaactatgt	tacttgtagt ctggtcaagc caattgaaaa atgcccagag	aattatacca cttgaaggac cttccgcact cttgcagata	2700 2760 2820	
tcttagtcta tgggtggaat tagagatctc tgactcggga atgctttgaa	tggctggcag tattgaaatg tgggaagatc gcagaagttt	cttacacttt aaactgttgt gctacagaag gaaactatgt gtctttggga	tacttgtagt ctggtcaagc caattgaaaa atgcccagag tcaccttcgc	aattatacca cttgaaggac cttccgcact cttgcagata cttcacccag	2700 2760 2820 2880	
tcttagtcta tgggtggaat tagagatctc tgactcggga atgctttgaa atttttccta	tggctggcag tattgaaatg tgggaagatc gcagaagttt gaaagcacac	cttacacttt aaactgttgt gctacagaag gaaactatgt gtctttggga ttccggttcg	tacttgtagt ctggtcaagc caattgaaaa atgcccagag tcaccttcgc gtgcctactt	aattatacca cttgaaggac cttccgcact cttgcagata cttcacccag ggtggcacga	2700 2760 2820 2880 2940	
	agaaggaact aagccatcac cactggcatt tgcttaccgt acatagaagc atgagccaag attgggctaa ggggggaaaag tcagtattga gggtggtgag gccgagaaaa acttcatcat tgagtggggg tccttttgtt ccgctctgga cagtgcgcaa atcatgaaga gaggaatga ttgagttgac tccacagaag tgcctatggt tttcaaggt tttcaagat	agaaggaact tgaaaggtac aagccatcac ggccaacatt cactggcatt ctggtatggg tgcttaccgt cttcttctct acatagaagc cttgcaaat atgagccaag catcgacagc attggaatt taaaaatgtt agggcctcaa cctgaaggtg gtgggaaaag cacacactgtc tcagtattga cggacaggac gggtggggg acagaaccc gggtggggg acagaaccag cccgagaaaa cgtcacagag tccttttgtt ggatgaggc cagtgcgcaa tgctgacaga cagtggggaaaag gcatgaagcc cagtggggaaaag cagtagagc cagtgtggga acagaacag cagtgcgcaa tgctagagaa gadtgaggaatga gctagaaaa gaggaaatga acttgaagaa ctcacaagaag acaagaccag ttcacaagaat acttgaagaa ttcacaagaat ttccatttgg ttcaaaggtt ttccttttgg ttcaaaggtt ttccttttgc ttcaaaggctt cacatttggc	agaaggaacttgaaaggtacaataaaattaagccatcacggccaacatttccataggtacactggcattctggtatgggacctccttggtgcttaccgtcttcttctatttattggacatagaagccatcgacagctcctcaaccaagggcccaagcacaagagggaagagcggggattggaatttaaaaatgtttactcaactaagggcggaaagcacacactgtccagcaggatggggtgggaaagcagaactgccgatgagatagggtgggggacagaacaggatgagataacttcatcatgaaactgccgatgagatatccttttgtggatgagacaaaggccggatccttttgtggatgagacagatgagcctcagtatggtacagaacaaggatcggaacttcatcatgaactgccacgtcagcatccttttgtggatgaggaaaggacggaacatagaaggctcatgaagaaaggccgaagggaaatgaacttgaacagaaagaggcagagtggggacaagaccagaaagaggcagagtggggaaagacaagaccagaaagagggaacatagaagagctcatgaagaaagagggaacatagaaggctcatgaagaaagagggaacatagaagagctcatgaagaaagagggaacatagaagagctcatgaagaaagaggagaagaaggaacaagaccagaaagaaggaacatagaagagctcatgaagaaagaggaacatagaaggacaagaccagaaagaggaacatagaaggacaagaccagaaagagagaacatagaaggacatgaagagaaagaggaacataggaggaagaacaagaccagaaagagagaacataggaggaagaacaagaccagaaagagagaacataggaggaaga<	agaaggaacttgaaaggtacataaagttagaagaaggagccatcacggccaacatttccataggtattgctacctcactggcattctggtatgggacctccttggtcctctcaatgcttaccgtcttctcctatttattggggacttcagacatagaagccttgcaaatgcaagggggagggcacaaaatttggaatttaaaaatgtttacttcaacaagagggctcagggggggaaagcacaactgtccagcaggggagaagggtggggggggggcaggaacaaggaaggctcatcaatgtaggggggggggcaggaacaaggaaggctgaacacacggagggggggggcaggaacaaggaaggctgaacacacggagggggggggcaggaacaaggaaggctgaacacacggagggggggggacagaacagggatgagaaagaaggcgggggggggacagaacagaggatcgcattgcccgggggggggggacagaacagaggatcgcattgcccgggggggggggacagaacagaggatcgcattgcccgggggggggggacagaacagaggatcgcattgcccggggaggggggacaggaacagaggatcgcattgcccgggtgagggggacaggaacagaggatcgcattgacgggccgctctggtaaggctaggaaggccggttactcaagaggaaatgaacttgaacaggaagaaggttatgaacaggggggggacaagaccaggaagagaggattatgaacaggggaaatgaacatggacagaagaccaaitagtcgaaggggagggacaagaccagggaagaagaitagtcgaaggggagggacaagaccagggaagaaggaitagtagaaacaatgagaacacatgaagaagagcgaaacatgg	<pre>gagcagttgc cgaagaagtc ttagcagcca tcagaactgt gattgcgttt agaaggaact tgaaaggtac aataaaatt tagaagaagc taaaagagtt aagccatcac ggccaacatt tccataggta ttgcctacc gttggtctat cactggcatt ctggtatggg acctccttgg tcctctcaaa tgaatttct tgcttaccgt cttcttct atttattgg ggacttcag tattggacat acatagaagc ctttgcaaat gcaagagggg cagcctatga aatcttcaag atgagccaag catcgacagc ttctcaacca agggacacaa accagacagt attggaatt taaaaatgtt tacttcaact acccatcag aagtgaagtt aggggctcaa cctgaaggtg aagagcgga agacggtag cggctagg gtgggaaaag cacaactgtc cagctgctgc agaggctca cgacccata tcagtattga cggacaggac atcaggacca tcaatgtgag gtatctgcgg gggtggtgag tcaggaacca gtgctgttg ccaccacgt tgccgaaac acttcatcat gaaactgcc cacaaattg accaccgg tggtgaga tgagtgggg acagaacag aggatcgac ttgccggc cctggtcgc ccgctctgga taaggccga agaggcgga caccactgt ggtggaga tgagtgggg acagaacag aggatcgac ttgccggg ccggagaac ccggtcggaaa ggtagacca ggagagac ttgccggg ccaggaagc ccggtctgga taaggccga agaggcgga caccattgt ggtggagag tgagtgggg acagaacag aggatcgac ttgccggg ccaggaagc ccggtctgga taaggctaga gagaggcgg ccaccattgt gatagctcac cagtgcgcaa tgctgacg attgctggt ttgatggtgg tgtcattgtg gaggaaatga actgaacca ggaaatadg cttaatga gagatcaat tccacagaag accagaccag gagaagac ttagttcga agaggacgg ccgagtagaa aattgaacca ggaaatadg cttatgaat ccaaagtgac ctgagttgac ttcagaagaa tcaaaatcc ctttaataag gagatcaat tccacagaag acaagaccag gagaagagc ttagttcgaa agaggatgat tgtgggtg tccttggc gttattaaatg ggtgcataca accagtgtt ttccaaaga tcattgtc gttataaatg ggtgcataca accagtgtt ttccaaaga ttgagggt tttcttcaa agtagaac tgaaccaaa gtaacttgt ttcctttc tttctggtca tgggaatga ttctttgt ttcaaagat tgtagggt acaggataga agacgaga ccaaacacaa gtaacttgt ttccttcc tttctggtca tgggaatga ttctttgt ttcaaagct cacattgc aaagctgaa agacgag agaccac caagcgacc tcttcaaat catgctgcg acaggataa gctggatga ttctttgt ttcaaagct taccaggcc gcaggataa gctggttga tgaccaaaa gctcgctgac taccaggcc gctaggaca acctacacaa gctggatcaa caagcgacca tcttaaat caattggc aaagccga agacgaga cacaacacacaa gcacattgt ttccttcc tttctggtca tgagacaacaacaa gctcgctgac taccaggcc gcagataaa gctggataaa accaacaacaa gctggttgac taccaacaca</pre>	agaaggaact tgaaaggtac aataaaaatt tagaagaagc taaaagagtt 960 aagccatcac ggccaacatt tccataggta ttgcctacct gttggtctat 1020 cactggcatt ctggtatggg acctcctgg tcctctcaaa tgaatattct 1080 tgcttaccgt cttcttct atttattgg ggacttcag tattggacat 1140 acatagaagc cttgcaaat gcaagagggg cagcctatga aatcttcaag 1200 attgggcaa catcgacagc ttctcaacca agggacacaa accagacagt 1260 attgggaatag catcgacagc ttctcaacca agggacacaa accagacagt 1320 aggggcctcaa cctgaaggtg agaggggg agacggtagc cctggttggc 1380 gtgggaaaag cacaactgtc cagctgctgc agagggtag cctggttgg 1500 gggtggtga tcaggacaggac atcaggacca tcaatgtgag gtatctgcgg 1500 gggtggtgag tcaggaccg ggctgtttg ccaccacgat tgccgaaaac 1620 acttcatcat gaactgcc cacaaattg acaaatgt agaagcgg ctggtggg tggggagaa agggaggg caggacggt caggaagcg 1620 acttcatcat gaactgcc cacaaattg acaccotggt tggtgagag 1680 tgagtggggg acagaaacag aggatcgcca ttgcccggc cctggtccgc 1740 tccttttgtt ggatgaggcc acgtcagct tggacacaga aagcgaagcc 1800 ccgctctgga taaggctaga gaaggcgga ccaccattgt gatagctcac 1860 cagtgcgcaa tgctgacgt attgctggtt ttgatggtgg tgcattgg 1920 atcatgaaga gctcatgaa gagagaggc tttacttcaa acttgtcatg 1980 gaggaaatga aattgaacca ggaaataatg cttatgaatc ccaaagtgac 2040 ctgagttgac ttcagaagaa tcaaaatct ctttaataag gagatcaatt 2100 tccacagaag acaagaccag gagaagag ttagtcgaa agcggatgg 2220 ttgtgggtg tcctttgg cagatcctaa agctaaatt tagtgaatgg 2220 ttgtgggtg acttatgatg ttttccattgg agaggagg 2220 ttgtgggtg acttgggt ttttcctttg cagaagaa accaggtg 2220 ttgtgggtg acttgggt ttttccttct tttctggtca tggaacaa accagtgtt 2280 tttcaaagat tgtagggtt ttttcaagag acgacgacca tgaaccaaa 2340 gtaacttgt ttcctttct tttctggtca tgggaatga ttctttgt 2400 ttcaaagat tgtagggt ttttccaga agagtgag acgacaa 2340 gtaacttgt ttccttct ttctggtca tgggaatgat ttcttttgt 2400

26

cacatcattg	ggatcattga	gaaaatcccc	gagattgaca	gctacagcac	ggagggcttg	3180
aagcctaatt	ggttagaagg	aaatgtgaaa	tttaatggag	tcaagttcaa	ctatcccacc	3240
cgacccaaca	tcccagtgct	tcagggactg	agcttcgagg	tgaagaaggg	gcagacgctc	3300
cgcctggtgg	gcagcagtgg	ctgcgggaag	agcacggtgg	tccagctgct	cgagcgcttc	3360
tacaacccca	tggctggaac	agtgtttcta	gatggcaaag	aaataaagca	actcaatgtc	3420
cagtgcgtcc	gcgcactggg	cattgtgtcc	caggagccca	tcctgtttga	ctgcagcatc	3480
gccgagaaca	tcgcctacgg	agacaacagc	cgtgtcgtgt	ctcatgagga	gatcgtgagg	3540
gccgccaggg	aggccaacat	ccaccagttc	atcgactcac	tgcctgagaa	atacaacacc	3600
agagtgggag	acaaagggac	tcagctgtcg	ggcgggcaga	agcagcgcat	cgccatcgcg	3660
cgcgccctcg	tcagacagcc	tcacatctta	cttctggatg	aagcgacatc	agctctggat	3720
acggagagtg	aaaaggtcgt	ccaggaagcg	ctggacaaag	ccagggaagg	ccgcacctgc	3780
gttgtgatcg	cgcaccgcct	gtccaccatc	cagaacgcag	acttgatcgt	ggtgattcag	3840
aacggccagg	tcaaggagca	cggcacccac	cagcagctgc	tggcccagaa	aggcatctat	3900
ttctcgatgg	ttcaggctgg	agcaaagcgc	tcatgagctg	ggagtatttg	aggtgctaag	3960
tatttctaat	attggtgttc	aaacatggca	cgtaaccaaa	gttaaaaggt	taaaagcact	4020
gttaaaggta	atttcatcaa	gacgagaagc	cttcagagac	ttcataatta	aatgaaccga	4080
aattgaaaaa	aaaatcatta	aacagggcca	catttttaa	ttgtattatg	tgattcaaga	4140
gaacatatag	ttttttaaa	aagaaatgtg	tagttttgtt	tcagtttttt	taatttctac	4200
cctattccct	taaatgatca	taaaggctgt	aaaaagcact	attttttgc	ggcc	4254
	TH: 1016 : DNA NISM: Rattus	s norvegicus	5			
<400> SEQUE						
		-	tgacggaaat			60
			gtgtcgaagg			120
			tcttggggaa			180
			gcagggacac			240
			ctgccagtct			300
			gtcatgcttt		_	360
-	5 5	2	cagtatgtcc	5 5 5		420
			ctagctactc			480
		-	ctgatcctca			540
			ggtggaatcc			600
			aacaagcggc			660
ataattagcc	aggcctatcc	tgaagccaaa	ggaaatgaga	tctacttggt	ttggtcacaa	720
			tccaaagact			780
cggtgcctgc	gcagggattc	ccacaaggtt	tccaaagact gacaattatc attcattcca	tcaagttcct	gaggtgccaa	780 840 900

27

aaaagtctat ttcttcaaag gttctatttg cattacaact ttcagcacat gcttaagtat	960
aattggtctc ttcttaaata ataaaaacaa acttttaaaa aaaaaaaa	1016
<210> SEQ ID NO 5 <211> LENGTH: 1908 <212> TYPE: DNA <213> ORGANISM: Rattus norvegicus	
<400> SEQUENCE: 5	
gcgcggtgaa gccagattag gatcagcgag cacttgagga tttagggcca caaaaaaccg	60
cacaagatcg acagactatt tctggagagc tgcagaacgg gcacgctggg gtcgctggtg	120
ctggccatgg tgatggaggt gggcatcctg gacgccgggg ggctgcgcgc gctgctgcga	180
gagegegeeg cteagtgeet gettetggat tgtegeteet tettegeett caaegeegge	240
cacatcgtgg gctcagtgaa cgtgcgcttc agcaccatcg tgcggcgccg cgccaagggc	300
gccatgggcc tggagcatat cgtgccgaac accgaactgc gcggccgcct gctggccgga	360
gcctatacgc ccgtagtgct gctggacgaa cgcagcgccg ccctggacgg ccgcaagcgc	420
gacggcaccc tggccctggc cgcgggcgcg ctctgccgag aagcgcgctc cactcaagtc	480
ttetteetee aaggaggata tgaagegttt teggetteet geeetgaget gtgeageaaa	540
cagtccaccc ccatggggct cagcctcccg ctgagtacta gtgtgcctga cagtgcagaa	600
teeggatgea geteetgtag caeceetete taegaceagg ggggeeeagt ggagateetg	660
tccttcctgt acctgggcag tgcttaccat gcttcccgga aagatatgct cgacgccttg	720
ggtatcactg ctttgatcaa cgtctcggcc aattgtccta accactttga gggtcactac	780
cagtacaaga gcatccctgt ggaggacaac cacaaggcag acattagctc ctggttcaac	840
gaggcgattg actttataga ctccatcaag gatgctggag gaagggtgtt tgtgcactgc	900
caggccggca tctccaggtc agccaccatc tgccttgctt acctcatgag gactaaccga	960
gtgaagctgg acgaggcctt tgagttcgtg aagcagaggc ggagtattat ctcccccaac	1020
ttcagettca tgggccaget getgeaattt gagteeeaag taetggeeee teaetgttet	1080
gcagaagctg ggagcccggc catggctgtc cttgaccggg gcacctctac tacaacggtc	1140
ttcaacttcc ctgtctccat ccctgttcac cccacgaaca gtgccctgaa ctaccttcaa	1200
agccccatca caacctctcc gagctgctga agggccaggg gaggtgtgga gtttcacgtg	1260
ccaccgggac gacacteete ceatgggagg ageaatgeaa taaetetggg agaggeteat	1320
gtgagctggt ccttatttat ttaacacccc ccccccaaa cacctcccga gttccactga	1380
gttcccaagc agtcataaca atgacttgac cgcaagacat ttgctgaact cagcccgttc	1440
gggaccaata tattgtgggt acatcgagcc cctctgacaa aacagggcag aagggaaagg	1500
actctgtttg agccagtttc ttcccttgcc tgttttttct agaaacttcg tgcttgacat	1560
acctaccagt attaaccatt cccgatgaca tacacgtttg agagttttac cttatttatt	1620
tttgtgtggg tgggtggtct gccctcacaa atgtcattgt ctactcatag aagaacgaaa	1680
tacctcactt tttgtgtttg cgtactgtac tatcttgtaa atagacccag agcaggcttt	1740
cagcactgat ggacgaagcc agtgttggtt tgtttgtagc ttttagctat caacagttgt	1800
agtttgttta tttatgatct gaagtaatat atttcttctt ctgtgaagac attttgttac	1860
tgggatgact ttttttatac aacagaataa attatgacgt ttctattg	1908

cc 602 <210> SEQ ID NO 7 <211> LENGTH: 1495 <212> TYPE: DNA <213> ORGANISM: Rattus norvegicus <400> SEQUENCE: 7 caatccaaga caagatgtcc agcaagggct ctgtggttct ggcctacagt ggtggtctgg 60 acacctcctq catcctcqtq tqqctqaaqq aacaaqqcta tqatqtcatc qcctacctqq 120 180 ccaacattgg ccagaaggaa gactttgagg aagccaggaa gaaggcactg aagcttgggg ccaaaaaggt gttcattgag gatgtaagca aggagtttgt ggaagagttc atctggcctg 240 ctgtccagtc cagtgcactc tatgaggacc gctatctcct aggcacctct ctcgccaggc 300 360 cttgcatagc tcgcaaacaa gtggaaattg cccagcgcga aggggccaag tatgtgtctc acggcgccac ggggaagggc aatgaccagg tccgctttga gctcacctgc tactcgttag 420 caccccagat taaggtcatc gccccctgga ggatgcccga gttttacaac cggttcaagg 480 gccgaaatga tttgatggaa tacgcaaagc aacatggaat ccccatccct gtcaccccca 540 agagcccctg gagcatggat gagaacctta tgcacatcag ctacgaggct ggaatcctgg 600 aaaaccccaa gaaccaagca cctccaggtc tctacacaaa aactcaggac cctgccaaag 660 cacccaacac cccagatgtc cttgagatag aattcaaaaa aggggtccct gtgaaggtga 720 ccaacgtcaa agatggcact acccacagca catccttgga cctcttcatg tacctgaatg 780 840 aagttgcggg caagcatgga gtagggcgca ttgacatcgt ggagaaccgc ttcattggaa tgaagtcccg gggtatctac gagaccccag cagggaccat cctttaccac gctcatttag 900 acatagaggc cttcaccatg gatcgggaag tacgcaaaat caagcagggc ctgggcctca 960 aattcgcaga gctcgtatac accggtttct ggcacagccc tgaatgtgaa tttgttcgcc 1020 actgcatcga caagtcccag gaacgggtgg aaggaaaggt gcaggtatct gtcttcaagg 1080 gccaggtgta catcettgge egggagtete caettteact atacaatgaa gagetggtga 1140

<210> SEQ ID NO 6 <211> LENGTH: 602 <212> TYPE: DNA <213> ORGANISM: Rattus sp. <400> SEQUENCE: 6 acaggtggtg tccgatgggt acagcettta ttgtttctcc agcattttcc agaagagtgg 60 tgtcattcga gggccataaa ggatggggga gtaaaaaata acataaacaa actgaacaga 120 aacccaggag ggccgcgaga agggctgaga tggggcatgg ggggtggaga ggtgggagac 180 ccaagcagtc agcgccactt agctttcggc caccagagtg gagaattctt caaccccaat 240 cttgccgtcc ccgtccttgt ctccagcagc catcagcgtc tttgtttcct tagcagacaa 300 gtctctggca tctgaggaga agcccttcag aatggacccc agctcatcct cctcaatgaa 360 gccacttttg tctttgtcca gaatgtggaa caccttcttc acatcatccg cactctttt 420 cttcaggccc accatctgga agaacttttt gtggtcgaag gagtctgcag cagtaaaggc 480 tcctatcgcc ttcttgatgt cctcagcgct gagcaagtct gtcatcgaca tcctgcaact 540 tggatgacca gaagtcagag cctatataga aaagctgggc tggtggggaga tcccctcgtg 600

29

gcatgaacgt acagggtgac tatgaaccca ttgatgccac cgg	gcttcatc aatatcaact 1200
cgctcaggct gaaggagtac catcgccttc agagcaaggt ca	ccgccaaa tagaccgtga 1260
caaagaggee gggeeteeee getetgeage teteceagge tee	cagcatta attgttgtga 1320
taaatttgta attgtagctt gttctcctac cacctgactg gg	getgetgt gececeete 1380
acctcccccc cacccacagg ctttgttccc tggtccccta tag	gcctacaa aagtggtcat 1440
cgaagggaag gggggggggg aggcagctgc agaaagcgcg taa	aaatgaca attaa 1495
<210> SEQ ID NO 8 <211> LENGTH: 2559 <212> TYPE: DNA <213> ORGANISM: Rattus norvegicus	
<400> SEQUENCE: 8	
tggatcccca aattgctttt taaaaaatat cttggaaact ttg	gtcctttg ctgaattacg 60
acactgtcca cctttaattt cctcgaaaac tccaatcact cg	gctgaagc catgccttgt 120
gttcaggcgc agtatgggtc ctcgcctcaa ggagccagcc cc	gcttctca gagctacagt 180
taccactctt cgggagaata cagctccgat ttcttaactc cag	gagtttgt caagtttagc 240
atggacetea ceaacaetga aattaetgee aceaettete tee	cccagctt cagtaccttt 300
atggacaact acagcacagg ctacgacgtc aagccacctt gc	ttgtacca aatgcccctg 360
tccggacagc agtcctccat taaggtagaa gacattcaga tg	cacaacta ccagcaacac 420
agccacctgc cccctcagtc cgaggagatg atgccacaca gc	gggtcggt ttactacaag 480
ccctcttcgc ccccgacacc cagcaccccg ggcttccagg tg	cagcatag cccgatgtgg 540
gacgatccgg gctcccttca caacttccac cagaactacg tg	gccactac gcatatgatc 600
gagcagagga agacacctgt ctcccgcctt tcactcttct cc	tttaagca gtccgccccg 660
ggcactcctg tgtctagctg ccagatgcgc tttgacgggc cto	ctgcacgt ccccatgaac 720
ccggagcccg cgggcagcca ccacgtagtg gatgggcaga cc	ttcgccgt gcccaatccc 780
attogcaago oggcatocat gggottocog ggootgoaga tog	ggccacgc gtcgcagttg 840
cttgacacgc aggtgccccc gtcgccgtcc cggggctctc cc	tccaatga gggtctgtgc 900
gctgtttgcg gtgacaacgc ggcctgtcag cattacggtg tto	cgcacttg tgagggctgc 960
aaaggtttct ttaagcgcac ggtgcaaaaa aacgcgaaat at	gtgtgttt agcaaataaa 1020
aattgcccag tggataagcg ccgccgaaat cgttgtcagt act	tgtcggtt tcagaagtgc 1080
ctggctgttg ggatggttaa agaagtggtt cgcacggaca gt	ttaaaagg ccggagaggt 1140
cgtctaccct caaaaccgaa gagcccacag gatccctctc ccc	ccctcacc tccgggatct 1200
gatcagtgcc ctcgtcagac ccacgtcgac tccaatccgg ca	atgaccag cctggactat 1260
tccaggttcc aggcaaaccc tgactatcag atgagtggag at	gatactca acatatccag 1320
cagttctacg atctcctgac tggctctatg gagatcatca gag	gggtgggc agagaagatt 1380
cctggctttg ctgacctgcc caaagccagt caggacctgc tt	tttgaatc agctttctta 1440
gaattatttg ttctacgctt agcatacagg tccaacccag tg	gagggtaa actcatcttt 1500
tgcaatgggg tggtcctgca caggttgcaa tgcgtgcgtg gc1	tttgggga atggattgat 1560
tccattgttg aattctcctc caacttgcag aatatgaaca tcg	gacatttc tgccttctcc 1620
tgcattgctg ccctggctat ggtcacagag agacacgggc tca	aaggaacc caagagagtg 1680

gaagagctac aaaacaaaat tgtaaattgt cttaaagacc atgtgacttt caataatggg 1740 ggattgaacc gacccaacta cctgtccaaa ctgttgggga agctcccaga acttcgcacc 1800 ctttgcacac aggggctcca gcgcattttc tacctgaaat tggaagactt ggtaccacca 1860 1920 acgtcaaaga actggaaaga aaaaaaaaat ccagaggggg ctggtcaaga tgggtagaga 1980 gctggctgaa gtgtccggtt catgtctccc ttctgtagac ccctagccct cacccctaaa 2040 gtaaacaaac aaacaagcaa acaaacaaac acaaattaaa aactgttgct atttcctaac 2100 ctgcaggcag aacgtgaaag ggcattttgg ctccggggca tcctggattt agaaaacgga 2160 caacatacac agtacagtgg tataaacttt tttattatca gttcaaaatc agtttattgt 2220 tcagaaggaa gattgcaaat gtatgatggg aaatgtttgg ccatgcttgc ttgttgcagt 2280 taagacaaat gtaaggcaaa tgtaacacac acacacaca acacacaca acacacacac 2340 acctcttaat gggaccctca tattttgccc tttaacaaga cttcaaagtt ttctgctgta 2400 aagaaagctg taatatatag taaaactaaa tgttgcgtgg gtggcatgaa ttgaaggcag 2460 aggettgtaa attttatcca atgeagtttg getttttaaa ttattttgtg eetatttatg 2520 2559 aataaatatt acaaattcta aaaagtaagt gtgtttgca <210> SEQ ID NO 9 <211> LENGTH: 628 <212> TYPE: DNA <213> ORGANISM: Rattus norvegicus <400> SEQUENCE: 9 atggctgcaa taccagaaga aggctcttgt gtcaacttca aagaaatgat gtttattgac 60 aacacacttt accttatacc tgaagataat ggagacttgg aatcagacca ctttggcaga 120 cttcactgta caaccgcagt aatgcggagc ataaatgacc aagttctctt cgttgacaaa 180 agaaacccgc ctgtgttcga ggacatgcct gatatcgacc gaacagccaa cgaatcccag 240 accagactga taatatatat gtacaaagat agtgaagtaa gaggactggc tgtgacccta 300 tctgtgaagg atggaaggat gtctaccctc tcctgtaaaa acaaaatcat ttcctttgag 360 gaaatgaatc cacctgaaaa tattgatgat ataaaaagtg atctcatatt ctttcaaaaa 420 cgtgtgccag gacacaacaa aatggaattt gaatcttccc tgtatgaagg acactttcta 480 gcttgccaaa aggaagatga tgctttcaaa ctcgttttga agaggaagga tgaaaatggg 540 gataaatctg taatgttcac tcttactaac ttacatcaaa gttaggtatt aaggtttctg 600 tattccagaa agatgattag cacacatg 628 <210> SEQ ID NO 10 <211> LENGTH: 1067 <212> TYPE: DNA <213> ORGANISM: Rattus norvegicus <400> SEQUENCE: 10 acggaggacc gtcagccagc aatcgcgtag ctcgatcgat cacccaggaa gagaaattgt 60 aagcagataa gaagaacgcg ttcggtttgg gacaccattt gcagctggaa atggggaatg 120 gactgtcaga ccagacttcc atcctatcca gcctgccgtc ctttcagtcc tttcacattg 180 ttattctggg tttggactgt gctggaaaga caacagtttt atacaggctg cagttcaacg 240

30

aatttqtaaa tactqtacct accaaaqqat ttaacactga qaaaattaaq qtaaccttqq 300 gcaattccaa aacagtcact tttcacttct gggatgtagg tggtcaagag aaattaagac 360 cactgtggaa gtcatatacc cgatgcacag atggcattgt gtttgtggtg gactctgttg 420 atgttgagag aatggaagaa gccaaaactg aacttcataa aataactagg atatcagaaa 480 atcagggagt ccctgtgctt attgttgcta acaaacaaga cctgaggaac tcactctctc 540 tctcagagat cgagaagttg ttagcaatgg gtgaactgag ctcatcgact ccttggcatt 600 tacagcccac ctgtgcaatc ataggagatg ggctaaagga aggacttgag aaactacatg 660 atatgataat taaaagaaga aaaatgttgc ggcaacagaa aaagaagaga tgaatggcag 720 tacttttata tcggtgtgga ataggtttta cttggtctga tttctgacaa gctgaagagt 780 gtctacagcc tggtttgcct gtctgccctc acggatgcta ttaaagcttt gttttgttga 840 acagtcagat acccaactct gttgccttgt ggaagatgag taaatgcaat gcttcttaaa 900 ggggtctctt ctccgtgacc cacaaatctt ttggtactac cattttggga agccaaaaaa 960 ggctagtaat tgaccagaaa acaattttgt ggaaatttga cctgaagtta gtgaaataaa 1020 1067 actttgaaga gtgtaaaaaa aaaaaaaaa aaaaaaaaa aaaaaaa <210> SEQ ID NO 11 <211> LENGTH: 2641 <212> TYPE: DNA <213> ORGANISM: Rattus norvegicus <400> SEQUENCE: 11 gccctggaag ccctgctttc ctgacaccct acaggactca caggcaggcc atggcagctc 60 tggcagcggg agtatccaag caacgtgcag ttgctgaggg gcttggctct aaccagaatg 120 ctgtgaagta tctgggccag gacttcgaga ccctgaggaa gcagtgcttg aactcggggg 180 tectatttaa ggaeceagaa ttteeageat gteeateage tttgggetae aaggatetag 240 gaccaggete eccagaeaet caaggeateg tatggaageg acceaeggaa ttgtgteeea 300 accctcagtt tattgttggt ggagccacac gcacagacat ccgccaaggg ggtcttgtgt 360 gggcacatgc gtctttgtga ttctctgctg gagaaacctg aacatgggct gaactgtagg 420 actcccttga tggtccaaga gactgctggc ttctagcagc cattgcctcc ctcaccttga 480 atgaaaagct gctttaccgg gtgcttccca gggaccagag cttccagaag gactacgcgg 540 gcatatttca tttccagttc tggcagtatg gagagtgggt ggaggtggtc attgatgacc 600 ggctccccac caagaacggg cagctgcttt ttctacactc cgaagaaggc aatgagtttt 660 ggagcgctct gctggagaaa gcctatgcca agctaaatgg ttcatatgag gctcttgttg 720 gaggeteeac aategagggg tttgaggatt teacaggtgg catetetgag ttttatgaet 780 tgaagaagcc tccggaaaat ctgtactaca tcatccagaa ggccctccgc aaaggctctc 840 tgctgggctg ctccattgat gtctcaactg cagctgaagc agaagccacc accaggcaaa 900 agctggttaa gggtcatgca tactctgtta ctggagtcga agaggtgaat ttccatggcc 960 1020 ggagtgataa tgcacctgag tggaattaca tagatccaag gaggaaggag gagctggaca 1080 agaaagcaga agatggcgag ttctggatgt ccttttcgga tttcttgaag cagtactccc 1140 gactggagat ctgcaacctg tccccagact ctctgagcag tgaagagata cacaaatgga 1200

acctagtact	cttcaacggc	cgctggacac	ggggttctac	agccggggggc	tgcctgaact	1260
acccaggcac	gtactggacc	aacccccagt	ttaaaatcca	tttggatgag	gtggatgagg	1320
accaggagga	gggcaccagt	gaaccctgct	gtaccgtgct	gctgggtctg	atgcagaaga	1380
atcgaagacg	tcaaaagagg	atcggccagg	gcatgctcag	cataggctac	gctgtctacc	1440
agattcccaa	ggaggttctc	agcacgatca	ggagtgtaaa	tagaccagca	gggtccagat	1500
tcatagactt	gggcccaggc	tatgttccca	gattgcagac	tactggtctg	tcctgccctt	1560
ggatcacaga	tgcacgccac	ttatcatgga	ggggacggcc	cagttggaga	gtcacacgga	1620
tgcacacctt	ggccgggact	tcttcctggg	acgccagccc	tctacctgct	ccagcactta	1680
catgaacctt	cgggaggtgt	ccagcagggt	ccgactcccc	ccgggacagt	acctggtggt	1740
gccatccacc	ttcgagccct	tcaaggatgg	tgacttctgc	ttgagggtgt	tctcagagaa	1800
gaaggccaag	gctctggaaa	ttggggatac	tgtatctgga	caccctcatg	agccacatcc	1860
ccgtgacatg	gatgaagaag	atgaacatgt	ccggagcctg	tttgaggagt	ttgtgggcaa	1920
ggattctgag	atcagtgcta	atcagctcaa	gagggtcctg	aatgaagtac	tttctaaacg	1980
aacagacatg	aaatttgatg	gattcaacat	caacacttgc	agagaaatga	tcagcctgct	2040
ggatagtgat	gggacaggaa	gcctgggacc	tatggagttc	aagactctct	ggctgaagat	2100
ccgcacatat	ctggagatct	tccaagaaat	ggaccataac	catgtaggga	ccattgaagc	2160
ccatgagatg	aggacagctc	tcaagaaagc	aggtttcacc	ctcaacaacc	aggtgcagca	2220
gaccattgcc	atgaggtatg	cgtgcagtaa	gcttggtgtt	gacttcaacg	gttttgtggc	2280
gtgtatgatc	cgcctggaga	ccctgttcaa	actgttcagg	cttttggata	aggaccagaa	2340
tggcattgtc	cageteteec	tggctgagtg	gctgtgctgt	gtgctggtct	gacccgctgt	2400
ttggacatca	acaacttccc	tgtctcccac	ttgtcccttt	cagtcttatg	aacatgtgac	2460
ctcaggtggc	atttactgac	tgttgtattg	ttccagccaa	ctgttgttcc	tgagacactg	2520
cctttcccaa	cagagcagtc	tagggagccc	cagatctctc	agcagcaccg	agctatgagc	2580
taactgggca	gatcccaggg	ttcagcagaa	ggaaaagaat	caattaaagt	tgtgggccag	2640
a						2641
	EH: 560 : DNA NISM: Rattus	s sp.				
<400> SEQUE						
-		cacacagtcc	-			60
	-	ctttacatgg	-	-		120
		ttcacattac			-	180
	2	ctcagccaca	2	55	5 5	240
5 5		tgttacagcc		2 2	5 5	300
555	-	caaccgtatt	5 5	5 5 55	555 5	360
-		ataaattgac	-		-	420
		tttacggcga				480
atagacataa	tttgaataaa	ttgataatac	tgtctgatgg	ccactcttta	caccagcttc	540

```
-continued
```

		-concineed		
aaaatggacc catttaaact			560	
<210> SEQ ID NO 13 <211> LENGTH: 1081 <212> TYPE: DNA <213> ORGANISM: Rattus	norvegicus			
<400> SEQUENCE: 13				
gcttggaacg gtacgcgaag a	aaaagtgacc atggacaad	a acgaaacctc cgtggattca	60	
aaatccatta ataattttga a	aacaaagact atccatgga	aa gcaagtcgat ggactctgga	120	
atatatctgg acagcagtta c	caaaatggat taccctgaa	aa tgggcttgtg tataataatt	180	
aataataaga acttccataa a	aagcactgga atgtcagct	c gcaatggtac cgatgtcgat	240	
gcagctaacc tcagagagac a	attcatggcc ctgaaatad	g aagtcaggaa taaaaatgac	300	
cttactcgtg aagaaattat g	ggaattgatg gatagtgti	t ctaaggaaga tcacagcaaa	360	
aggagcagtt ttgtgtgtgt	gattctaagt catggagat	g aaggagtaat ttttggaacg	420	
aacggacctg tggacctgaa a	aaaactaact agtttcttc	a gaggcgacta ctgccggagt	480	
ctgactggaa agccgaaact c	cttcatcatt caggcctgo	cc gaggtacaga gctggactgc	540	
ggtattgaga cagacagtgg a	aactgacgat gatatggca	at gccagaagat accagtgggg	600	
gccgacttcc tgtatgctta c	ctctaccgca cccggttac	t attcctggag aaattcaagg	660	
gacgggtcat ggttcatcca g	gtcactttgc gccatgct	ja aactgtacgc gcacaagctg	720	
gaattcatgc acatcctcac t	tcgtgttaac cggaaggto	gg ccatggaatt tgagtccttc	780	
teeetggaeg ceaettteea e	cgcaaagaaa cagatcccc	jt gtattgtgtc aatgctcaca	840	
aaagaactgt acttttatca c	ctaaaggaat gactgggag	ıt ggggtagggg catgtttctg	900	
ttttggtttt tttttggttt t	ttggtttgtt tttttttt	t ttatttgaat gccaaatgag	960	
aaaactgtca gggagacttt t	ttttttcccc tctcattta	aa atcaaatccg atgttccagg	1020	
tcgtcattga acaataccac t	tgcctgcaat gcagccaca	aa tacaatacct cagctttgat	1080	
a			1081	
<210> SEQ ID NO 14 <211> LENGTH: 387 <212> TYPE: DNA <213> ORGANISM: Rattus	sp.			
<400> SEQUENCE: 14				
gacatgtctc agaatttgct t	ttattaacag tatcttgct	c tcacagctag atctttggga	60	
ttggatagga ttcaatcagt a	aggtggtgtc ggagctcct	t cttctggctt cattgtgata	120	
actttttgaa gaaaacttcg a	aattetteat agetaaett	c tccatcaccg ttcttatcca	180	
gctctttaaa gagattgtct a	agagtacttg aagccttca	ag gaggctgggg aactctgact	240	
gaatcagcag cttcagctcc t	teettggaca getggttte	gg atcgccttct ttggctgcat	300	
atttttgaaa aatgctcttc a	atttcttcgg gagatttct	t agegeteatt tttetgtget	360	
gcttgctgtc agtgagtgct g	gccagag		387	
<210> SEQ ID NO 15 <211> LENGTH: 2668 <212> TYPE: DNA <213> ORGANISM: Rattus	norvegicus			

<400> SEQUENCE: 15	
gagtggccag gagcaaagtc tggaagccgg cgagccad	gg agcagagcac acagagctat 60
gaggettgea caaatgtgte tggeettegg etgggeag	ct gtcatattgg ttctacagac 120
ggtagacacg gcatctgctg tgaggactcc ttatgaca	aa gcgagggtat ttgcagacct 180
gageceecag gagataaagg etgtteacag etteetga	tg aacagggagg agctggggct 240
gcagcogtoc aaggaacoga otttggocaa aaactoto	tg tttctcattg agatgctact 300
gcccaagaag aagcatgtgt tgaaatttct ggatgaag	ga agaaaaggtc ctaaccggga 360
agctagggct gtcatcttct tcggtgccca ggactacc	cc aatgtcactg agtttgctgt 420
ggggcccctg ccacggccct actatattcg agcacta	cc cccaggccag ggcaccatct 480
gtcctggtca tccaggccca tctccacagc agagtac	ac ctcctctacc acacgctgaa 540
gagagccacc atgcctctgc accagttttt ccttgaca	acc actggcttct cattcctagg 600
ctgtgacgac cgatgcttga cttttactga cgtagcto	ca cgtggtgtgg cgtctggtca 660
gcgtagaagc tggtttattg tgcagcgcta tgtggaag	gc tatttcctgc atcctacagg 720
gctggagatc ctattggatc atgggagcac agatgtco	ag gactggagag tggagcagct 780
ctggtataac ggcaagttct acaacaaccc agaggaac	tg gctcggaaat acgcagttgg 840
agaagtggac acggtggtcc tcgaggaccc actgccca	at ggcacagaga agcccccact 900
cttttcttcc tacaaacccc gggggggaatt ccatacac	ca gtcaatgttg ctggccccca 960
cgttgtccag cccagcggcc cccgatataa actagagg	gc aacactgtgc tctatggagg 1020
ttggagette tettategge taagateete ttetggge	tg cagatettea atgtgetett 1080
tggaggtgag cgtgttgcct acgaggtcag tgtgcag	ag gctgtggcac tgtatggagg 1140
acacacacct gcaggcatgc agactaagta cattgat	ytt ggctggggcc tgggcagtgt 1200
cactcacgag ttggcccctg gcattgactg tccagaga	ect gctactttcc tggatgcctt 1260
ccactattac gacagegatg geeetgteea ttateead	at getetgtgee tetttgagat 1320
gcccacaggg gtgcccctga ggcgccactt taactcaa	ac tttaaaggtg gcttcaactt 1380
ctatgcgggt ttgaagggat atgtgctggt gctacgga	ncg acatcaactg tctataatta 1440
tgattacatc tgggatttca tcttctactc taacggg	tg atggaggcca agatgcacgc 1500
cactggctat gtccatgcga ccttctacac tcctgag	ga ctgcgccatg gcactcgctt 1560
acaaacccac ctgcttggta acatccacac ccacctg	tg cactaccgtg ttgacatgga 1620
cgtggcaggc accaagaaca gcttccagac actgacga	tg aagctggaaa acctcaccaa 1680
teeetggage ceaagteact ceetggteea geceaead	tc gagcagaccc agtactccca 1740
ggagcaccag gctgcattcc gcttcggaca gactctgo	cc aagtacctgc tctttagcag 1800
cccccaaaag aactgctggg gtcacaggcg cagctaco	gc ctgcagatcc attctatggc 1860
tgagcaggtg ctgccaccag gctggcagga ggagcgg	ct gtcacttggg ccaggtatcc 1920
tttggctgta acaaagtatc gggaatctga gcgctaca	ugc agcagcetet acaaccagaa 1980
tgacccctgg gatccccccg tggtctttga ggagttco	tt cggaacaacg agaacattga 2040
agatgaggat ttggtggcct gggtgacagt gggcttco	tg cacatecete acteagaaga 2100
tgtccccaac acagccacac ctggaaactc tgtgggct	tc ttgctccggc ccttcaactt 2160
ctteccagag gacceatece tggettetag agaeaete	tg atagtgtggc cccaggacaa 2220

gggcctcaac cgtgtccagc gctggatccc tgaggacagg cgctgcttgg tgtctcctcc 2280 tttcagctat aatgggacct acaagcctgt gtgatgggtc agccccagcc tctgcagcac 2340 acccagagee teacaaagae agggaaaaca aacaaaegaa aettetgtet etaeeetgta 2400 tgctaccttt tagctctact cgtgtttcat taccatacct gccacagact tccaagacca 2460 ttgcaaagga aggaccacaa ttttctgccg gtggttcggt ggtttggagg gtggtgtttt 2520 ttaaatattt gaggtgttta tcttcctatc aggagacttt agagaaattg tctcacctca 2580 gtgatgggag ggagtaagga aactgtcata tgaaaatcta ataaaatgac acctttgctc 2640 tttagacatc aaaaaaaaa aaaaaaaa 2668 <210> SEQ ID NO 16 <211> LENGTH: 1140 <212> TYPE: DNA <213> ORGANISM: Rattus norvegicus <400> SEQUENCE: 16 60 ggatcctaac ttcttcccaa gcaccagtca ctggagacat aggagaggca agaagcctct gggcaactga taaggattcc ccgcacccag gggaggcgat ccccaagccc agcctctcag 120 ggtcctgaca agccatgctg cggagagcaa tcacaggcca gccaatgaca gctgctccaa 180 gggcgtgtcc ttacctcctg cacatataaa tgaaacttgc tgcggggcca atacattctc 240 attetgatag acteaggaag caateatggt getetetgea getgacaaaa eeaacateaa 300 360 gaactgctgg gggaagattg gtggccatgg tggtgaatat ggcgaggagg ccctacagag gtaacatcag gaccctgttc tttaaggaca gcaggatcca aaccggacca gggactcagt 420 480 gggtagctcc taagtgtgct ttcccgtggc ctcaacttat ctctccttct cacaggatgt togetgeett ceceaceace aagaectaet teteteacat tgatgtaage eccggetetg 540 cccaggtcaa ggctcacggc aagaaggttg ctgatgccct ggccaaagct gcagaccacg 600 tcgaagacct gcctggtgcc ctgtccactc tgagcgacct gcatgcccac aaactgcgtg 660 tggatcctgt caacttcaag gtgtgagctc agacctggca ggggggcacct gggaccttca 720 780 aggatecett ggggcagtgg tgaggggcae aggggggggg ggaaggggtt ecteatgeee agggcaggga acacagtgtt ccaggaaggg gagcttaccc agcagggtgt ctactactag 840 ggactgaccc ttcctgtctc tgcagttcct gagccactgc ctgctggtga ccttggcttg 900 ccaccacct ggggatttca cacctgccat gcacgcctct ctggacaaat tccttgcctc 960 tgtgagcacc gtgctgacct ccaagtaccg ttaagccacc tcctgtcggg cttgccttct 1020 gaccaggccc ttcttccgtc ccttgcacct gtctttgaat aaagcaaaag taggaagaat 1080 cccgtgtgcc tgtttctcac atgtgcaaag gtgacaatgt ttggtatggg aaaatcctcc 1140 <210> SEQ ID NO 17 <211> LENGTH: 626 <212> TYPE: DNA <213> ORGANISM: Rattus sp. <400> SEQUENCE: 17 gtottataaa attgttttat tttattotat gtaaacttot ttotcaggaa tggtaccaaa 60 gtgacttgct tacagggatt tataatttgg gataaacata attaacaaaa caagtatttc 120 tctattgtac agatgaatga tctaaaacat atttataggc tacattattc aaagaaggta 180

attagactta ctgacaaagc aactttccta cttaagcctt gcaataggaa gaaaacaacg	240
gctaagagat gttctcctcg gaatcttaca gagcagttgg gatgtttagt ttcctccaca	300
cagagccacc aggatttttt catagtctcc tttggtttca tccaggatgg cttggcagag	360
agggattccg tacttcttct ggtaaaatac tttgatttca ttcatgtcaa tttccgaacg	420
ggagaccata atcctgatca atgtcttatg gcgagttcca gcacccttca tggcttcata	480
cagtttctca gcaaagaaag ctggagtgct ggtggcacac ttcacaatgg ttgtgaggca	540
cttctcaatg tcacccttca gttccagatc caaggctttg ttcatgtcat gttgactgta	600
ctttctataa ttctgaaaca ctttcc	626
<210> SEQ ID NO 18 <211> LENGTH: 508 <212> TYPE: DNA <213> ORGANISM: Rattus sp.	
<400> SEQUENCE: 18	
gccattaaaa aactttattt tgatttttt ttttttacaa aggatagccc cactttgggg	60
tgaaaatata tttggttaag tacaaaatat agtttttaat catacaaaaa gatacacaaa	120
atacaaaaac aacaaagacg acacctccat cagctcacac tttctggctg cacagttctc	180
gggtggagtg cttagagtgg agcttggagc tctgacacag gacacggaac aaagtgctaa	240
ggcggagtaa gttttggagt gctagaggcc acggcgagag cagaactttc tcctaacact	300
ggacaggaaa tgggtctggg agcttccatg gaaacctgca gttctcactg tgcctccatc	360
actgttaggg catctcaatg taagagtgtc accagggtcc agctgtcagc agcaaccctt	420
catatgagta gtgtcagaat cacagaagtc tgtgtgttgg gggaaagcct ccaaaagtaa	480
taaccaagct gggcctttaa cctcagca	508
<210> SEQ ID NO 19 <211> LENGTH: 2642 <212> TYPE: DNA <213> ORGANISM: Rattus norvegicus	
<400> SEQUENCE: 19	
agtgtgctct aaaggcgacg ggtttgtcgg agcaccataa tatggtgtgg gaagtgaaga	60
cgaaccagag gcctcatgca gtacagagac tcctgctggt gatggacgag agagctacag	120
gagtgagtga ctcattggag ttgctgcagt gtaatgagaa tgtgccgtcc tctccaggat	180
acaactcctg tgatgagcac atggagcttg atgaccttcc tgaacttcag gctgttcaaa	240
gtgaccctac ccaatctgcc atataccagc tcagttcaga tgtatctcat caagaatatc	300
caagaccatc ttggagccag aatacctcag acataccgga aaatactcac cgtgaagatg	360
aggtggactg gctaacagag ttagcaaata ttgccactag tccacaaagt ccactaatgc	420
agtgeteatt ttataacaga teateteetg tacacateat agetaetage aacagtttae	480
attectatge acgeceacea ceagtgteet etgeaaagag eggaceagee tteeeteatg	540
accactggaa ggaagaaaca ccagtaagac atgaaagggc aaacagtgag tcagagtcag	600
gaattttctg catgtcctcc ctgtcagatg atgatgatct gggctggtgc aattcctggc	660
catcaaccgt ttggcattgc tttctcaaag gcacacgact gtgcttccat aaggaaagca	720
aaaaggagtg gcaagatgtt gaagactttg ctagagccgc cacctgtgat gaggaggaga	780

tccaaatggg cactcacaag ggctatgggt ctgatggtct aaagttgtta tcccatgaag	840
agagtgtgtc attcggtgag tctgtactga agttgacatt tgatcctggt acagtagaag	900
atggcttgct tactgtggag tgcaagctgg accacccttt ctatgttaaa aataaaggct	960
ggtcatcatt ttatccaagc ttgactgtgg tacagcacgg cattccatgc tgtgagattc	1020
atattggtga cgtatgtcta cctcctggac accctgatgc cattaatttc gatgattcag	1080
gtgtttttga tacatttaaa agctatgact tcacacctat ggactcttcc gcagtctacg	1140
ttttgagtag tatggctcgc cagcgccgcg catctttgtc ttgtggagga cctggtactg	1200
gtcaagagtt tgcaggatct gaattcagta aaagctgtgg ttcaccagga tcatcacagc	1260
tctcctctag ttctttatac actaaagctg tcaaaagcca cagctcaggg actgtgagtg	1320
ccacttctcc taataagtgc aaaagaccaa tgaatgcctt catgcttttt gccaaaaaat	1380
acagagttga atatactcag atgtatccag ggaaagataa cagagccata agtgtgatcc	1440
ttggtgacag gtggaaaaaa atgaagaacg aggaaaggag gatgtataca ttagaagcaa	1500
aggetttgge tgaagaacaa aagegtttaa ateeegaetg etggaaaagg aaaagaacea	1560
attcaggete teaacageae taaacetgat gettetgtet gtaagtetgt acettgeate	1620
agtactgact ctgtacctgc ataaggactg actctggacg gaaaagcttg gaagaccttg	1680
gtctcaccat ttgtcctaca tttgtgtgac cataaaatgc tgggagcatt gagttttgta	1740
atgatttaat gggtgaggag gatctgcttt ctccattaga gcattaagta agctaaaact	1800
atcaacattg taaaccaaat tgccttattt tccttccaaa cttcatatat gtctatcagg	1860
taatataggc ttgaaaattg atatcctgtg gtgctaaagt acagtagaaa gagagatgtg	1920
tatacatgtc ttattttaaa ttgtacgaag gggaatttaa aaatatgtaa ctgctgttta	1980
tacatcagct ccttactgct tattaatctg tattgtaccc acgatatcag gaatgaagta	2040
gaagctggcc tttccatgaa tagccaccac atggcccagt gtctctgcca aacacagttg	2100
cttctagtct ggccagtgcc aagagacaac ataacatggc aggtggatgg tgtcattgtc	2160
tcagctgaga gccacctgct tcagatacca tgggcgtgtg ctgagtggat gcaccagggg	2220
gcagcacagc tccatgattc ccagtggggg ccaagccagg ctaaggtgca gtcagttagc	2280
attgggacag tcattgtaat ggtgctgtta tcagttgaaa ccatgctccc tgtctcctca	2340
gccacatccc ctccgtctct gctgtcatct tctctgtggt ggggcagact ttgcacttac	2400
tgcagtgcaa cacttgcact ttacccctcc ggcttctaca gtagagcaag tccttcggca	2460
gccctgctgc tttcgctctg cgctacaatc atggcttctc atgttactta ccaagtggta	2520
tttttggtta ggaatcacag ctgtaaagtt gatttcagtt cattacactt cttaaacata	2580
ttgcccctca attttgcaca ctatattctt gtatattatt tcaaataaaa tgaaaaaagt	2640
ct	2642
<210> SEQ ID NO 20 <211> LENGTH: 1671 <212> TYPE: DNA <213> ORGANISM: Rattus norvegicus <400> SEQUENCE: 20	
cetttetttg egagaagtge aaaattgget agagecagag tetegeceae etggtacaga	60
aggagegege geetgtgtee ettgggggaee eacagttgea aagagaeage tgettgattt	120
ayyayuyuyu yoolyuyuu oolyyyyaaa cacayiiyta aayayacayo iyotiyatti	12.0

180

ggtcacccac tcgcccagac tataggagcc tcccgggaca ctcttgagtt gcacctttct

					J	
gcagagcaga	ctgtttgagc	ccccgcagtg	ctcgtaggat	ttgaagcgtt	ctgatactgg	240
aggettgete	gccgcgctcg	cccgactctg	ggacacattt	gtccgagcca	caggagtgtg	300
cgggtgactg	acatatcatc	tcttcgactc	tccatgagct	catgaacctg	ggagcaggtg	360
cccggaaatg	gcgcggcctc	tgagcgacag	gaccccgggc	cccctgctgc	tgggtggccc	420
ggctggggcc	ccccctggcg	ggggagcgct	gcttgggctg	aggagccttc	tgcagggaaa	480
cagcaagccc	aaagaaccgg	ccagctgtct	cctgaaggaa	aaggagcgca	aggcaactct	540
gccctcagcc	cccgtcccgg	gacccgtcct	ggaaacggcg	ggcccagcgg	atgccccaac	600
tggggcggtt	agtggcggtg	ggtcccctcg	ggggcgctca	gggcctgtgg	ctggcccgag	660
tcttttgcg	ccgctgctgt	gggaacgcac	tttgcctttc	ggggacgtgg	aatacgtgga	720
cctggacgcc	ttcttgctgg	agcacgggct	accgccgagc	ccgccgcccc	ccgggggcct	780
gtcgccggca	ccctctccag	cgcgcactcc	cgcgccctcc	cccgggcccg	gctcttgcag	840
ctcctcttcc	ccccgctcct	cgcccgggca	cdccccdcd	cgggccactc	tgggagccgc	900
cggcggccac	cgcgcaggct	tgacctctag	ggacacaccc	agtcctgtgg	acccagacac	960
cgtggaggtg	ctaatgacct	ttgaacctga	tccggctgat	cttgccctgt	caagcattcc	1020
aggccatgag	acttttgacc	ctcggaggca	ccgcttctca	gaggaggaat	tgaagcctca	1080
gccaatcatg	aagaaggcaa	ggaaagtcca	ggtgcccgag	gaacagaagg	atgagaagta	1140
ctggagccgg	aggtacaaga	acaatgaagc	agccaagagg	tcgagagacg	caagaagact	1200
caaggagaac	cagatatctg	tgcgggcagc	cttcctggag	aaggaaaacg	ccctattgcg	1260
gcaggaggtg	gtggctgtgc	ggcaggagct	gtcccactac	cgtgctgtgc	tttcacgcta	1320
ccaggcccaa	cacgggacac	tgtgaggcca	cttccaccct	gccagggcag	agtcctgttc	1380
cttgttcaga	cttacacctg	acacccccct	tcctccttgt	cccatggcca	atggtctggc	1440
cagctaggtg	cccaggaacg	tcatgatgca	gacaaataca	tttatatttt	taagaaaaag	1500
ctagccttcc	cccacctccc	ttgtgggggt	ggggagggtc	ctgtgtgcac	ttttagcatg	1560
tcgaggaacc	catccatcca	accgcctcca	tcaacacaat	cctgaataaa	tcttgagaac	1620
ccaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaagaatt	с	1671
<210> SEQ I <211> LENGT <212> TYPE: <213> ORGAN	H: 2249	s rattus				
<400> SEQUE	NCE: 21					
aaaggtccaa	gcttaatgga	tgtatactcg	tgactgagct	ctcggcccac	aatcagccaa	60
ccgagggctt	catggateeg	ccaagatcat	caacacccag	ggactgggac	cagatgaagg	120
agggagaagg	cagcgaggag	aagttgagga	ggaggatgaa	gatgaggagg	aagaggatga	180
ggaggaggag	gaagaggatg	aggaggagga	ggacttgtct	tctcctcaag	ggctacctga	240
gcctctggag	aatgtggaag	tcccctctgg	accccaggtc	ctcacagatg	gcccccggga	300
acatagcaag	agtgctagcc	tcctatttgg	catgcgaaac	agtgcagcca	gtgacgagga	360
ctcaagctgg	gccaccttat	cgcagggcag	cccctcctat	ggctctccgg	aggacacaga	420
tteettetgg	aaccccaacg	ctttcgagac	ggattccgat	ctaccggctg	gatggatgag	480

<213> ORGANISM: Rattus norvegicus								
<400> SEQUENCE: 22								
cctagatgcc ccagtettet actgetetga ecceaceege titeteeegg eteggtacag	60							
ctggtgccgg ggggtgctgc tttctgccct gcgctgcgca ccgttagtgc cctgcccctg	120							
teetteegat etcagagtet geggagtgee cetategeeg teeacetgtt teeteagaaa	180							
aaaggccagc tcgtgatccc tgctgcgttc ctgggggccat ggcgggtctg ggtcctggcg	240							

<210> SEQ ID NO 22 <211> LENGTH: 3113 <212> TYPE: DNA <213> ORGANISM: Rattus norvegicus

US 2005/0064462 A1

,,,						
acccccaggc	cgggcctccc	catcacaggg	gaacagtccc	caagaagagt	cccagctcac	600
ctggactggc	tttgctcacc	aagaaggctt	tgaggaagga	gagttttgga	aggatgaacc	660
tagtgaagag	gccccaatgg	agttgggact	gaaggaccct	gaggagggga	cattgccctt	720
ctcagctcag	agcctcagcc	cagagccagt	gccccaggag	gaggagaatc	tgccccaacg	780
gaacgccaat	ccagggatca	agtgtttcgc	tgtgcgctcc	ctaggctggg	tagagatgac	840
tgaggaggag	ctggccccag	gacgcagcag	tgtggcagtc	aacaattgta	tccgccagct	900
ctcctaccac	aaaaacaatc	tacatgatcc	gatgtctgga	ggctggggag	agggaaagga	960
tctgctgctc	cagctggagg	atgagacgct	aaagttggtg	gagccacaga	accagacact	1020
gctgcatgcc	cagcccatcg	tcagcattcg	cgtgtggggc	gttgggcggg	acagtggaag	1080
agagagggac	tttgcctacg	tagctcgaga	taagctgacc	cagatgctca	agtgccacgt	1140
gtttcgctgt	gaggcacctg	ccaagaacat	cgccaccagc	ctgcatgaga	tctgctccaa	1200
gatcatgtct	gaacggcgca	atgctcgctg	cttggtaaat	ggactctccc	tggaccactc	1260
taaacttgtg	gatgtccctt	tccaagtgga	attcccagca	ccaaagaatg	aactggtgca	1320
gaagtttcaa	gtctattacc	tagggaacgt	gcctgtggct	aaacccgttg	gggtagatgt	1380
gattaatgga	gccctggagt	cagtcctgtc	ttccagtagt	cgtgagcagt	ggaccccaag	1440
tcacgtcagc	gtggcccctg	ccaccctcac	catcttgcac	cagcagacag	aagcagtgct	1500
ggggggagtgt	cgagtgcggt	tcctctcctt	cctggctgtg	ggcagagatg	tgcacacgtt	1560
cgcattcatc	atggctgccg	gcccagcctc	cttctgctgt	cacatgtttt	ggtgcgagcc	1620
caatgctgcc	agtctctcgg	aggctgtgca	ggctgcatgc	atgctccgct	accagaagtg	1680
tctggatgct	cgttcccaga	cctccacctc	ctgcctccca	gcaccccctg	cggagtcagt	1740
tgcgagacgt	gtagggtgga	ctgtccgcag	gggtgttcag	tctctgtggg	gttccctcaa	1800
gcccaaacgt	ctaggatccc	agaccccatg	aagagctccc	atcctccctc	tacctgcttg	1860
ttttgggccc	cagggaactc	aagggtttgg	ggcaggtagg	ggctgtggat	gttcttccta	1920
caccccatgt	cccccgggct	gcccctcctc	agtagctggg	gttccctacc	taggggctgg	1980
gagagagaaa	ttgaatteet	tcacagaagt	cattacactg	gactgatgac	atcggggccg	2040
agaagcaaag	ccagccttgg	gctctccatc	cccagtgttt	gaggtggagc	aggaggaact	2100
ggtccaagcc	aggccccatc	ctcaaaggcc	caataagggc	aggaggggac	tggtctcggc	2160
atggatcccc	tgtcccctgt	tctgcggaca	cctccactgt	actgatatca	ctaataaagt	2220
ctgtctgtcg	ctgaaaaaaa	aaaaaaaa				2249

ggtccaagac acctcaggga cctactactg gcacatccca acagggacca cccagtggga

39

-continued

ggggcgactc agaaggggga	ccccgacccc	tgttttgcag	aaagggggggg	ctgaggcaga	300
aggtggtcca cgaggtgaag	agccacaagt	tcaccgctcg	tttcttcaag	cagccaacct	360
tctgcagtca ctgtaccgac	ttcatctggg	gcattggaaa	gcagggcctg	caatgtcaag	420
tctgcagctt tgtggttcac	cgccgatgcc	acgaatttgt	gaccttcgag	tgtccaggag	480
ctggaaaggg cccccagacg	gacgaccctc	gcaacaagca	caagttccgt	ctgcacagct	540
acagcagtcc caccttctgc	gaccactgtg	gttccctcct	ctacgggctg	gtgcaccagg	600
gcatgaaatg ttcctgttgc	gaaatgaatg	tgcaccgacg	ctgtgtgcgc	agcgtgccct	660
ccctttgcgg cgtggaccat	acagagcgcc	gtggacgtct	gcaactggaa	atccgggctc	720
ccacatcaga tgagatccat	attactgtgg	gtgaggeeeg	gaacctcatt	cctatggacc	780
ccaatggcct gtctgatccc	tatgtgaaac	tgaagctcat	cccggaccct	cggaacctga	840
caaaacagaa gacaaagacc	gtgaaagcca	cactgaatcc	cgtgtggaac	gagaccttcg	900
tgttcaacct gaagccgggg	gatgtggagc	gccggctcag	tgtggaggtg	tgggattggg	960
ataggacatc ccgaaatgac	ttcatgggtg	ccatgtcctt	tggtgtctca	gagctactca	1020
aggctcctgt ggatggatgg	tacaagttac	tgaaccagga	ggagggcgag	tattacaatg	1080
taccggtggc cgatgctgac	aactgcagcc	tcctccagaa	gtttgaggcc	tgtaattacc	1140
ccttggaatt gtatgagaga	gtgcggatgg	gcccctcttc	ctctcccatt	ccttctccat	1200
cccccagtcc cacggactcc	aagagatgct	tcttcggtgc	cagcccagga	cgcctgcata	1260
tctctgactt cagcttcctc	atggttctag	ggaaaggcag	ttttgggaag	gtgatgctgg	1320
cagagcgcag aggatccgat	gaactctatg	ccatcaagat	actgaaaaaa	gacgtcattg	1380
tccaggatga tgatgtagac	tgcacccttg	tggagaagcg	tgtgctggca	ttgggaggcc	1440
gaggtcctgg aggccggcca	cactttctca	cacaacttca	ttccaccttt	cagactccgg	1500
accgcctgta ttttgtgatg	gagtacgtca	ctggggggcga	tttaatgtac	cacattcagc	1560
aactgggcaa gtttaaggag	ccccacgcag	cattctatgc	cgcggaaatc	gccataggcc	1620
tcttcttcct tcacaaccag	ggcatcatct	acagggacct	caagttggat	aatgtgatgc	1680
tggatgctga aggacacatc	aagatcacag	acttcggcat	gtgtaaagag	aatgtcttcc	1740
ctgggtccac aacccgcacc	ttctgtggga	ccccagacta	catagcacct	gagatcattg	1800
cctatcagcc ctatgggaag	tctgtcgact	ggtggtcctt	tggagtcctg	ctgtatgaga	1860
tgttggcagg acagccacco	tttgatgggg	aagatgagga	ggagctgttt	caagccatca	1920
tggaacaaac tgtcacctat	cccaagtcac	tttcccggga	agctgtggcc	atctgcaagg	1980
ggttcctgac caagcaccca	ggaaagcgcc	tgggctcagg	gccagatggg	gaacccacca	2040
tccgggctca tggctttttc	cgttggatcg	attgggagag	gttggagaga	ctggaaattg	2100
cgcctccttt tagaccacgt	ccgtgtggcc	gcagcggcga	aaactttgac	aagttcttca	2160
cgcgggcagc gccagccttg	accccgccag	accgcttggt	cctagccagc	atcgaccaag	2220
ctgatttcca gggctttact	tatgtgaacc	cggacttcgt	gcacccagat	gcccgcagcc	2280
ccacaagccc tgtgcctgtg	cccgtcatgt	aatctcatct	gctgccgcta	ggtgttccca	2340
gtgctccctc cgccaagttg	gctgtaactc	ccatccaccc	ccatccccgc	ctctagtccg	2400
aattttaggt ctcttaaacc	acccaacctt	ctggcctctt	tcacgcgccc	caagtgggtt	2460
ctagacgctg ttccccagca	ttgctggcat	tttaaacttc	aaacagtctc	tagggccttt	2520

ctgtgttcta ggttcgttgt gctgagccct ggtttttccc cacccccaac atctggatgc 2580 tgttccaact cttcccagaa accccactcc gtgtggggtt ctagactcta tcttggtagt 2640 tttatgcctt ctctctccct agaccacgtt gggagaaata gtctcatgag attgcctgct 2700 ccagactaag attccagatc agctctctgc atccttcaag gcccctccta cctccacttc 2760 agttgtagaa ttaagtggga ggctgggctc cgtgttccag gccacctccc ttccatgttc 2820 tggggattcc tggcatgcac ggaggattct ctccccgact tttctcagtc agcttttgtt 2880 ctagatttgt tccagaaccc ttcactgctc acctgccccg tgcatggctc cagccttggt 2940 3000 ccttgtcctc cgcagtgcct gccactttct gggactttct catcccccac gcccttcctt 3060 tatectetee cacecagaca cagetgetgg agaataaatt tggagetete gag 3113 <210> SEQ ID NO 23 <211> LENGTH: 3611 <212> TYPE: DNA <213> ORGANISM: Rattus norvegicus <400> SEQUENCE: 23 cccgcggggg aagacgcacg ggcgggctcg gctctcccgg ggagcggccc gggactgcac 60 cgggaccggc gcctccccgc tccggctgcc ctcggcctcg ccccgggccc gggcggatga 120 gccgggggcc cgggggggaca tggaagcgct gacgctgtgg cttcttccct ggatatgcca 180 240 gtgcgttacg gtgcgggccg actccatcat ccacatcggt gccatcttcg aggagaacgc 300 agccaaggac gacagggtgt tccagttggc tgtatcagac ttgagcctca atgatgacat cctgcagagt gagaagatca cctactccat caaggtcatc gaggccaata atccgttcca 360 ggcggtgcag gaagcotgtg acotcatgac coaggggatt ttggcottgg toacgtocac 420 480 gggctgtgca tctgccaacg ccctgcagtc cctcacagac gccatgcaca tcccacacct ctttgtccag cgcaaccccg ggggttcacc acgtactgcc tgccacctga accctagccc 540 cgacggcgag gcctacacac tggcttcgag accgcccgtc cgtctcaatg atgtcatgct 600 caggctggtg acagaactgc gctggcagaa gttcgtcatg ttctatgaca gcgagtatga 660 tatccgtggg ctccaaagct ttctggatca ggcctcacgg ctgggtcttg acgtctcttt 720 acaaaaggtg gacaagaaca tcagtcacgt gttcaccagc ctcttcacca ccatgaagac 780 ggaggagctg aatcgctacc gggacacact gcgccgggcc atcctcctgc ttagcccaca 840 ggggggggcac tcgttcatca acgaggctgt ggagaccaac ttggcttcca aggacagcca 900 ctgggtcttc gtgaatgagg aaatcagtga ccccgagatc ctggatctgg tccacagtgc 960 ccttggcagg atgaccgtgg tccggcaaat cttcccatct gcaaaggaca accagaaatg 1020 catgaggaat aaccaccgca tctcttccct gctctgtgat ccacaggaag gctacctcca 1080 aatgetgeag atetecaate tetatetgta egacagtgtt etgatgetgg ceaaegeett 1140 1200 ccacaggaag ctggaagacc ggaagtggca tagtatggca agccttaact gcatacggaa atctaccaag ccatggaatg gagggagatc catgctagac accattaaaa agggacacat 1260 caccggcctc acaggagtta tggagtttcg ggaagacagc tcaaatccct atgtccagtt 1320 tgaaatcctt ggcacaacct atagtgagac ttttggcaaa gacatgcgca agctggcgac 1380 ctgggactca gagaagggcc tgaatggcag tctgcaggag agacccatgg gcagccgcct 1440

ccaaggactg	actctcaaag	tggtgactgt	cttggaagag	ccttttgtga	tggtagctga	1500
gaatatcctt	ggacagccca	agcgttacaa	agggttctcc	atagatgtgc	tggatgcatt	1560
ggctaaagct	ctcggattca	aatacgagat	ataccaggcc	cctgatggca	ggtatggcca	1620
ccaactccat	aacacttcct	ggaacgggat	gatcggggag	ctcattagca	agagagcaga	1680
cttggccatc	tctgctatta	ccatcacccc	ggagagagag	agcgttgtgg	acttcagcaa	1740
gcgatacatg	gactactcag	tggggatcct	catcaagaag	ccggaggaga	aaatcagcat	1800
cttctccctt	ttcgccccct	ttgactttgc	ggtgtgggcc	tgcattgctg	cagccattcc	1860
cgtggtgggt	gtgctcatat	tcgtgttgaa	tcggatacag	gctgtaaggt	ctcagagtgc	1920
cacccagcct	cggccctcag	cttctgcgac	tttgcacagt	gccatctgga	tcgtctatgg	1980
agcctttgtc	cagcaaggtg	gtgagtcttc	ggtgaactct	gtggccatgc	gcatcgtgat	2040
gggcagctgg	tggctcttca	cgctcattgt	atgttcctcc	tacacagcca	accttgctgc	2100
tttcctcaca	gtgtccagga	tggacagccc	cgtaagaaca	tttcaggacc	tgtccaagca	2160
actggagatg	tcttatggca	ctgtccggga	ctctgctgtc	tatgagtact	tcagagccaa	2220
ggggaccaat	cccctggagc	aggatagcac	ttttgctgag	ctctggcgga	ccataagcaa	2280
gaatggaggg	gctgacaact	gtgtgtccaa	tccttcagaa	ggtatcagga	aggcaaagaa	2340
ggggaactac	gcctttctgt	gggatgtggc	cgtggttgag	tatgcagccc	tgacagatga	2400
cgactgctca	gtgactgtca	tcggcaacag	catcagcagc	aagggctatg	ggattgccct	2460
gcaacatggc	agcccctaca	gggacctctt	ctcccagagg	atcctggagc	tgcaagacac	2520
aggggacctg	gatgtgctca	agcagaagtg	gtggccacac	acaggccgct	gcgacctcac	2580
cagccattcc	agtgcacaga	ctgatggtaa	atcccttaag	ctgcacagct	tcgctggggt	2640
cttctgcatt	ttggccattg	gcctccttct	cgcctgcctc	gtggctgctc	tagagttgtg	2700
gtggaacagc	aaccggtgcc	accaggagac	ccccaaagag	gacaaagaag	tgaatctgga	2760
acaggtgcac	cggcgcatca	acagcctcat	ggatgaagac	attgctcaca	agcaaatttc	2820
cccagcatcc	attgagcttt	ctgccctgga	gatggggggc	ctggctccaa	gccaagcttt	2880
ggagcccacg	agggagtacc	agaacaccca	gctctcagtc	agcacctttc	tgcctgagca	2940
gagcagccat	ggcaccagcc	ggacactgtc	gtcagggccc	agcagcaacc	tgccactgcc	3000
gctgagcagc	tcagccacca	tgccctcaat	tcagtgcaaa	cacaggtcgc	ccaatggggg	3060
actgtttcga	cagagtccgg	tgaagacccc	catccctatg	tctttccagc	ccgtgcctgg	3120
aggcgtcctt	ccagaggccc	tggacacctc	tcatggcacc	tccatctgac	tgtgtcgcct	3180
gccctcctgc	ccgccaccca	gcccacccga	ccagcagagc	ttttaatac	aagaaaatga	3240
caacacagac	cacacacaca	cacacacaca	cacacacaca	cacacacaga	ctctttcatt	3300
tttcttgtac	atacgtgtaa	ataatgacag	aatggagtgg	ggtaaaagtg	tattttgaat	3360
attcccaatt	ttcgaagtca	gtaaaaaaaa	acaaaacaaa	acaaaaactg	tatgaatgac	3420
tttgtaaatt	ttgttctata	tgaataaaaa	ggcaaattac	ttgtgatcta	ttttatttct	3480
gtgagtgggg	taggcaggcc	agtacagagg	ggattgatct	gcaggtgctg	gtcctgcagg	3540
gtccaagtgg	ctccccttc	ctggttgcat	gaccctgtgc	caggatgccg	ggacatcggt	3600
ttgcaggtcc	a					3611

 210. SEC ID NO 24 210. TUPE: NAA 211. SECURATION: Actual provegicus 212. SECURATION: Actual provegicus 213. ORGANISM: Ratue norvegicus 213. ORGANISM: Concerning and the provegicus 214. SECURATION: Actual provegicus 215. ORGANISM: Concerning and provide a sequence of the provided and provided and		
gatectaggagateccagetteogeogetacqeaggaeagytecqtagf0gitgitgeogecitgittecitgeoceteceaggittegtytecqtecitgittecitgeocetetytecqtecitgittecitgittecitgeocetecitgittecitgeocetecitgittecitgeocetecitgittecitgeocetecitgittecitgeocete <t< td=""><td><211> LENGTH: 4422 <212> TYPE: DNA</td><td></td></t<>	<211> LENGTH: 4422 <212> TYPE: DNA	
gtytgtoge eyttytte etgeeree tyteegy tyteegy tyteegy egyseeree 120 ggeerttet eegetytg egeseeree tyteegyte egeseree 130 etgygyteg agesgyg tyteegyte egeseree tyteegyte egeseree 130 etgygyteg agesgyg tyteegyte egeseree tyteegyte egeseree 240 eetgygyteg egeseree etgeeree egeseree 130 tyggeeret egeseree egeseree egeseree 140 eggseret egeseree egeseree egeseree egeseree 140 tyggeeret egeseree egeseree egeseree egeseree egeseree egeseree egeseree egeseree egeseree tygggeere aleanaetge teeraagg gatatte eggeeree egeseree	<400> SEQUENCE: 24	
ggocottet cegetgtegg egegeecee tigtetegtt eggeecee ggacaaege ggocottet cegetgtegg egegeecee tigtetegtt eggeecee ggacaaege 180 ettgagtege ageageegg tigtegegee egteetegt eaceaegtt teeaggetge 240 cetegeagteege ageageegg tigtegegee egteetegt eaceaegt teeaggetge 300 tiggageetet teegtagaeae ecceattae etggeeaeag ggacaetegt eoegeagtg 360 ggaegegaeat teegtaeae egetteete teegtagaeateg agetegaeet teegagetge 420 teettagaa tigaagteet teetaeagga gatgtteet gagatateg agetegaeet teegagetge 420 teettagaa tigaagteet teetaeagga gatgtteet gagatateg agetegaeet teegagetge 540 ggaaatggaa acattate teetaeagga gatgtteet gagattega eaeggaagtt 600 gtgattgee aaaaggeea geeageegg eoegeegge eaeeagae ateagetge 720 aatttegea eteegae eeegaget eaaaeaege eaeeagae ateagetge 780 attgeetgg ateegaege ggeeaeet agatteegaeee eaegaeaga taeeagetge 900 atgeetgg aaeegaege eageaeet ggeeaeet ggeegaeet gatgeeaeet agateegaeae 900 atgeeatge gateegage ggtegeaeet ggetgeaeet ggeegaeet teegageae 1080 ggagtateg aaaataeg eagageag agattete gattegea eeegaeae eagaagete 1080 ggagtateg aaaataeg eagagegat teggaattee gattegeaeet tegageaeet 1200 ceggttetgg aaaatee eagaaged eagaagea eeegaeage eeegaeage tegeageae 1200 ceggattetg taageetge egeeegae eeegaeage eeegaeage eeegaeageaeageaeaeageae 1200 ceggattetg aaaateeg eeegaega eeegaegaeaeeeegaeaeaeageaeaeaea	gateetggga gagteegaeg ttegeegget aaegeaggae aggteaetga ggteegeeag	r 60
ctggagtog agogogg tyatogogo cyteatoot tacacatgt tocaggotg 240 cotgotogg agtgggiga atgaagot aaggagatag accgoacag gatgoagog 300 tggagoot cocgatoo coccatta ctggocacag ggacatog tocagoagtg 360 gaogogaat toagtacca coccatta ctggocacag ggacatog tocagaagtg 460 tootiggat tgagtootg tgotactt tocoogto acagtigat 480 tggggacot ataaaatgg ttocaaggg agtgttotg gatttigat tgoaggigg 640 ggaaatggaa acattato ctacgatoc totaaaata tagotggag caaggaggt 600 ggatagogaa ttoggacoa goatacog cocagaa gatogaag catggaggt 640 ggaaatggaa acattato ctacgatoc totaaaata tagotggag caaggaggt 600 ggatogo aaaggaca goatacog cocagaag tataacato 660 cagacaat tggtgoot tggtgtaa gaactgaa totaaatig ggatotaac 720 aatttigoa ctocaatga gocaggag aaacaag caccgaga tatcagotg 780 atagootgg atcoagga aaacaggo catgaagt caagaaga tatcagotg 900 atgoatgga tacagaag tocagaat attacaag cacgaaga tatcagotg 900 atgoatgg atcoagga aaacaggo gatgtoca ctaagatg cottgatg goagatoot 1020 cgggtatgg aaatagg gtocagaag tigggatot gattig citggaca ggagatot 1080 gaatgigt agaatocag ggocagagg tigggatot gattigat goagatgg 1140 gaggtatta tagactgo aaagaag cacgaag aaacaagt gocacag tggogga 1140 gaggatata tagactg cogocag aaacaag caccagaag tocacaca 1260 atggaggag goatagacg ctaaggag aaacaagt gocacaca cagtagat fice 1220 cggatatat atgactot cocacaaca cagtggtg citgatoca fice fice 1220 cggatata tagactg cogocaga aaacaag cococo catacaag fice fice fice 1220 cggatata tagactg cagtaga aaacagag coctoo catacaag fice fice fice 1220 cggatata tagactg cogocaga aaacaagt gocacagt fice fice fice fice fice fice fice fice	gtgtgtccgc cgtttgtttc ctgcccctcg ccaggttcgg tgtccgctgc cgaggcccga	120
cctgctcggg agtggggga aatgaagcta aaggaagatag accgcacagc gatgcaggog 300 tggagcoctg cccagaacca occcattac ctggccacag ggacatctg tcagcagttg 360 gacggacat tcagtaccaa ogottoott gagatattog agotgcacot ttoogaocog 420 toottggat tgaagtootg tgotacttt tootootga aggagattgga gatgttgga 480 tggggacoto ataaaatgga ttooaaagg gatgttotg gagtttgat tgoaggtgga 540 gaaaatggaa acattatto toogatoot totaaaata tagotggaga caaggaagtt 600 gtgattgooc aaaaggacaa goatactggg ccagtgaga cottggatgt aaacatotto 660 cagaacaatt tggtggoot tggtgtaat gaatotgaa totaaattg ggatctaaca 720 aattttgoaa otocaatgac gocaggagot aaaacaago caccagaaga tatcagotgo 780 atagootgga accagacagg ocagoagaot ataccaag coagtcacag tggcoggoa 840 acggtotgga accagacagg ocagoatato ttagoatcag coagtaactg 900 atgoattgo ctgggotgg atggcaacg gatgtgogt atatcaagt ogotacot otococot 1020 cgggtattg ogatacog gggggat ttggoatot gattgogat togagact 1080 gaagtattat atgaactoc caccaacaa cagtggtgot tggatgat ggagatot 1080 gaggattgt taagotgg aaaaagtgo aaacaagt accaggtg totaacagga 1140 gaggaattgt gataccag gottaagga aaacagtg ocatcggtg cagtgogg 1140 gaggaattgt gatagacg ottaaggag aaacaagtg acaagttg totagtota 1220 cggaatctg accgtoot tgotgoca aaacaagt gocaccg atgotggt tagaatca 1220 attggagga goatagacg ottaaggag aaacaagtg acaagttt gtogtott 1220 cggaatctg cogtootgt tgocgotto ttogatggt gocaccg atgotggt tagaagtot 1220 cggaatctg accgtacg gotcagaag cegococc cattacaaa tocacacagga 1140 gaggaattga cogttag cgacagaag cegococc cattacaaa tocacacaga 1380 acttoacag acagacag gotggagag ttggtgaat toggaagot cogagaact 1440 gtgggggac cottotaat oggaggaag ttggtgaat toggaagat tacaggocg 1500 cctaagcag gactgaga gocaggag taggagag tacagacg tacaggagat tacagggag 1500 cctaagcag gagetgaga gocaggag tacagagag tacagcag tacaggagat tacagggga 1560 cctaagcag gagetgaga gocagagag tacagagag tacagcag tacaggagat 1620	ggcccttctt ccgctgtcgg cgcgcccccc tgtctcgttt cggccccgcc gggacaacgc	: 180
tgyagcortg occagaacca occattae otgooraag gyacatotgo taagaagtg 360 gaagagacat taaaatga tacaagaag agstattog agotagacat tacagacag 420 toottggat tgaagtootg tgotactte tootogtoo acaggtaca caagtgatt 480 tggggacoto ataaaatga tacaagag gatgttootg gagtttgat tgoaggtgga 540 gaaaatggaa acattatto otacgatoo totaaaatta tagotggaag caaggaagtt 600 gtgattgoo aaaaggaca goatactgg ocagtgaga octuggatga aaacatotto 660 cagaacaatt tggtggooto tggtgotaat gaatotgaa otacaattg ggatotaaco 720 aattttgoaa otocaatgac gocaggagot aaaacacago caccagaaga tatcagoogo 780 atagootgga acagacagt ocagotatoo tagaacaag caccagaaga tatcagoogo 780 atagootgga acagacag ocagaagat otagaacaa otagaagat otagaacga 900 atgoatgga acagacag gocagagot ataacacago cacagtagg octugotgot 960 gaggatgato otgggotga agaacacog gatgoot gattgoot otagaaga ottogaacoo office 960 gaggatgato gataccag gocagaga tatgagoot ottogatgo ottogotto 960 gaggatgato gataccag ggooggaat tuggaacto gattgoot ottoocoo 1020 ogggttotgg aaaacacag cacagaagat ottogaacga ggoagatoo 1080 gaggatgta ogatacoo cacaacaa cagtggoot tugatacoo taacaggaa 1140 gaggaatgtg cagtacoo tacaacaa cagtggoot tugatacca taacacagga 1140 gaggaatoo ogotootgo tagoocoo aagaagtg cacagoaga taccagoga 1140 gaggaattgt taagootgo ottaagaga aaacagtg ocaccoo aagaagt cacacagaga 1380 acttoacago acagacag gotcoocoo aagaagtg cacagaagt cogagacoo 1440 gtgggagoo octootoo octoo 1020 cogaatoo octootaa ogotoo ocaacaa cagtggto tugaacoo gagagat cacagaga 1380 acttoacago acagacag goocoocoo aagaagtg cacagaagt cogaacoo ocaagaag 1380 acttoacago acagacag goocoocoo aagaagoo cacagoag 1380 acttoacago acagacag goocoocoo aagaagoo cacagaagoo cacagoaga 1500 cocaacaga gagoo occaacago cacoocoo caastaga googgaco 1440 gtgggooco cottoo octoo ocaacago caccoocoo caastaga googgaco 1560	ctggagtege ageageeggg tgategegee egteateete taeeaaegtt teeaggetge	: 240
<pre>gacggacat tcagtaccaa cgcttocctt gagatattog agotogacot tcogacoog 420 tcottggata tgaagtootg tgotacttto toologicto acaggtacca caagtgatt 480 tggggacoto ataaaatgga ttocaagga gatgttootg gagtttiga tgocagtggag 540 gaaaatggaa acattatto ctaogatoo totaaaatta tagotggaga caaggaagtt 600 gtgattgooc aaaaggacaa goatactggg coagtgagag oottggatgt aaacatotto 660 cagaccaatt tggtggooto tggtgotaat gaatotgaa totacattig ggatotaaco 720 aatttigoaa ctocaatgac gocaggagot aaaacacago cacoagaaga tatcagotgo 780 atagootgga acagacagt coagcatato ttagoatog gocagtagag catgagaga tatcagotgo 780 atggactgg atotcaggaa aacagagot attacaag tcagoacca cagtaactgg 900 atgoactgot ctgggotggo atggcacot gatgtogata ctacagtgg cottgotot 960 gaggatate gattaccagt ggtocagat gtgggatott gattgoto ctotococto 1020 cgggttotgg aaaacacag cacgaggat ttggcaatt gtuggacat ggocagatot 1080 gagtattat atgaactto caccaacac cagtggtgot ttgatacco gagggatot 1080 gagtattat atgaactto caccaacac cagtggtgot ttgatacca gtggtgotot 1200 cggattotg cggototg tgcocgto ttggggac tcagatgt caccogatg totaccact 1260 atggagagga gocagacg cttaaggaga aacaagtg cacagtggt ctactocato 1260 atggagagga gocagacg cttaaggaa aacaagtg coccoc cattacaag tocagaga 1380 acttacacgo acagcatg coccoc gaaggaga ttgggactt togagacgt tacaggoga 1500 coccagagg gagtgaga gocaggog ctagagog caccogtg toatcagta ggtggtgaca 1560 gaagaaggact toctcago ctoagacg cacagcag togtogagt tacaggogot tacaggoga 1500</pre>	cctgctcggg agtgggtgag aatgaagcta aaggagatag accgcacagc gatgcaggcg	i 300
toottggata tgaagtootg tgotactte tootogtoot acaggtacca caagtgatt 480 tggggacote ataaaatgga ttooaaagga gatgtttog gagtttgat tgotaggtgga 540 gaaaatggaa acattatto otacgatoot totaaaata tagotggaga caaggaagt 600 gtgattgooc aaaaggacaa goatactggg ocagtggag ocotggatgt aaacatotto 660 cagaccaatt tggtggoote tggtgotaat gaatotgaaa totacattg ggatotaaac 720 aatttgoaa otocaatgae gocaggaget aaaacacage caccagaaga tatcagotge 780 atagootgga acagacagg ocagotato ttagoatcaa coagtacgt ggooggac 840 acggtotggg atotcaggaa aaacgagoot attatcaaag toagcaacca cagtaactgg 900 atgoactget otgggotge atggcaccet gatgoota coagatggt cottgottot 960 gaggatgate gattaccag ggtocagat tuggagatte gatttoot 1020 cgggttotgg aaaatcatge cagggggat tuggagatte gattgoot 1020 cgggttotg aaaatcatge cagggggat tuggagatte gottaccae taccacegga 1140 gaggtatta atgaactee caccaacaa cagtggtge tugatacca gtggtgtoot 1200 cggaatcotg cogtootge tycocott togatgge goaccect attacaaat cocacagoga 1140 gaggaatgat gattacgg gottaggga aaacagatg ocacagatgt gootaccet ataccaetgga 1140 gaggaatcotg cogtootge tycocotte ttogatgge goatcotg ottogottot 1220 cggaatcotg cogtootge tgocgotte ttogatgge goatcotg totaccatca 1260 attggaggag gcatagacgg cttaaggcag aaacaagtg acaagatgt acaagtte gtogtottt 1320 gggaatctg atcogttgg cacaggaga gootocot cattacaat cocacagoag 1380 acttcacage acagacag gotococtg aagaagceg coagtggat coggagact 1440 gtgggcoot cottocatt cggaggaag ttggtgactt togagacgt tacaggocag 1500 coccagcagg gagetgaga gcacagoeg cacceggeg cagecegtg toactogate 1620	tggagccctg cccagaacca ccccatttac ctggccacag ggacatctgc tcagcagttg	; 360
tggggacctc ataaatgga ttccaaggga gatgtttctg gagtttgat tgcaggtgga 540 gaaatggaa acattattet etaegateet tetaaatta tagetggaga caaggaagtt 600 gtgattgee aaaggacaa geataetggg eeagtgagag eettggatgt aaacatette 660 cagaceatt tggtggeete tggtgetaat gaateegaa tetaeattg ggatetaace 720 aattttgeaa eteeaatgae geeaggaget aaaacaege eaceagaaga tateageege 780 atageetgga acagaeaggt eeageataet ttageetagaa eeagaaga tateageege 780 atageetgga acagaeaggt eeageataet ttageetagaa eeagaaga tateageege 780 atageetgga acagaeaggt eeageataet etageateg eaceagaaga tateageetge 780 atageetgga acagaeaggt eeageataet etageetage eeageaga tateageetge 900 atgeeetgg ateeeagaa aaacgageet attateeaag teageacee eagtaeetg 900 atgeeetge etggeegge atggeeeet gatgeeget attateeaag teageacee eagtaeetg 900 atgeeetge gattaceagt ggteeagatg tgggatette gattgette ettegeegget 1020 egggtateg aaaateage eaggggatt ttggeaattg ettggageat ggeagateet 1020 egggatetg aaaateage eagggggat ttggeaattg ettggageat ggeagateet 1020 eggaateetg eegeetge tegeegetee teegatggte etaeteeagega 1140 gaggatatta atgaeettee eaceaceae eagtggtget ttgatateea gtggtgeett 1200 eggaateetg eegeetge tgeegettee ttegatggte geateegtge teateeage 1380 aetteeage acageatgg eetaaggeag eeegeege eeaagtegg teegagaeet 1440 gtgggegeet eetteeatt eggaggaag ttgggaeet tegagaeet teeaggeega 1500 eetaageag gaeetagae geeegegge eeeegeegeegeegeegeegeegeegee	gacgcgacat tcagtaccaa cgcttccctt gagatattcg agctcgacct ttccgacccg	i 420
gaaaatggaa acattattet etacgateet tetaaatta tagetggag caaggagatt 600 gtattgeee aaaaggacaa geataetggg eeagtgagg eettggagt aaacatette 660 cagaacatt tggtggeete tggtgetaat gaatetgaaa tetaeatttg ggatetaace 720 aattttgeaa eteeagae geeaggaget aaaacaeage eaceagaaga tateagetge 780 atageetgga acagaeaggt eeageatet ttageteeg eagteegge eagteggge 840 acggtetgg ateeaggaa aaaegageet attateaaag teageacea eagtagetg 900 atgeeetge etggeetgge atgeeeetg gatgeegta eteegaget eetgeetge 900 atgeeetge etggeetgge atgeeeetg gatgeegta eteegaget eetgeetge 900 atgeeetge etggeetgge atgeeeetg gatgeegta eteegagetge eetgeetge 900 atgeeetge etggeetgge atgeeeetg gatgeegta eteegagetge eetgeetge 900 atgeeetge etggeetgge atgeeeetg gatgeegta eteegagetge eetgeetge 900 atgeeetge etggeetgge atgeeeetg gatgeegta eteegaget eetgeetge 900 atgeeetge etggeetgge atgeeeetg gatgeegta eteegaget eetgeetge 900 atgeeetge etggeetgg etgeeegge teggeegge etggegate etgegaget eetgeetge 900 atgeeetge etggeetgg aaaacaegg eggeeggetgeetgeetgeetgeetgeetgeetgee	teettggata tgaagteetg tgetaettte teetegtete acaggtaeea caagttgatt	480
gtgattgood aaaaggadaa gdatactggg ddagtdoga dda	tggggacctc ataaaatgga ttccaaagga gatgtttctg gagttttgat tgcaggtgga	540
cagaccaatt tggtggcete tggtgetaat gaatetgaaa tetacatttg ggatetaac 720 aattttgeaa eteecaatgae geeaggaget aaaacagage caecaggaga tateagetge 780 atageetgga acagacaggt eeageaget attateeaag eeageegggea 840 aeggtetggg ateeaggaa aaaegageet attateaaag teageaacea eagtaaetgg 900 atgeaetget etgggetgge atggeaeeet gatgtegeta eteagatggt eettgette 960 gaggatgate gattaceagt ggteeagatg tgggatette gatttgette eteeceet 1020 egggttetgg aaaateatge eagggggatt ttggeaattg ettggageat ggeagateet 1080 gaattgttgt taageetgg aaaagatget aagatteet gettgatee taaeaeggga 1140 gaggatatta atgaaettee eacaeaeae eagtggtget ttgatateea gtggtgteet 1200 eggaateetg eegeeetge tegeegete teegatggt eedeetget 1220 eggaateetg aceagaeag ettaaggaa aaaeaagtg aeaagette gtette gtetteet 1220 gggaateetg ateegettgg eacaggaeag eegeeetee eeagtget etaeteetee 1260 atgggaagga geatagaegg ettaaggeag aaaeaagttg aeaagette gtegtettt 1320 gggaateetg ateegttgg eacaggaeag eegeeetee eeaagtgget eeaageete 1440 gtgggegeet eetteeteet eegagggeg etgegeeete 1440 gtgggegeet eetteeteet eegaggegg eageeegtg teateeagte ggtggtgea 1500 eeteageagg gagetgagea geeaeggeg eageeegtg teateeagtea ggtggtgea 1560 gaaaaggaet teeteageeg eteagageag etacageeg tegtegget teagggett 1620	gaaaatggaa acattattct ctacgatcct tctaaaatta tagctggaga caaggaagtt	. 600
aattttgcaa ctccaatgac gccaggagct aaaacacagc caccagaaga tatcagctgc 780 atagcctgga acagacaggt ccagcatatc ttagcatcag ccagtcccag tggccgggca 840 acggtctggg atctcaggaa aaacgagcct attatcaaag tcagcaacca cagtaactgg 900 atgcactgct ctgggctggc atggcaccct gatgtcgcta ctcagatggt ccttgcttct 960 gaggatgatc gattaccagt ggtccagatg tgggatcttc gattgctc ctctcccctc 1020 cgggttctgg aaaatcatgc cagggggat ttggcaattg cttggagcat ggcagatcct 1080 gaattgttgt taagctgtgg aaaagatgct aagattctc gctctaaccc taacacggga 1140 gaggtatta atgaacttcc caccaacaa cagtggtgct ttgatacca gtggtgctct 1200 cggaatcctg ccgtcctgt tgccgcttc ttcgatggt gcatccg gt gtcgtctt 1200 cggaatctg acagacag cttaaggcag aaacaagttg acaagcttc gtcgtcttt 1320 gggaatcttg atccgttgg cacaggacag ccgctccct cattacaaat cccacagcag 1380 acttcacaga cagcatcgt gctgcccctg aagaacgc ccaagtggat ccggagacct 1440 gtgggcgcct ccttctcatt cggaggaag ttggtgactt tcgagaacg tacaggcag 1500 cctcaqcagg gagctgagca gccacggcg ctaaggcag ctacagcag tcgtcgagt tcaggggctt 1620	gtgattgccc aaaaggacaa gcatactggg ccagtgagag ccttggatgt aaacatctto	660
atagootgga acagacaggt ocagoatato ttagoatoag ocagtoocag tggooggga 840 acggtotggg atotoaggaa aaacgagoot attatoaaag toagoaacoa cagtaactgg 900 atgoactgot otggootggo atggoocoot gatgtogota otoagatggt octtgottot 960 gaggatgato gattaccagt ggtocagatg tgggatotto gattgooto otoocoot 1020 ogggttotgg aaaatcatgo cagggggatt ttggoaattg ottggagoat ggoogatoot 1080 gaattgttgt taagootgg aaaagatgot aagattoot gootoacoo taacacggga 1140 gaggattata atgaactoo caccaacaa cagtggtgot ttgatatoca gtggtgtoot 1200 oggaatcoot gootootgg ottaaggoog ottogatggo goatoott 1200 atggagagga goatagacgg ottaaggoog aaacaagtg acaagotto gtogtottt 1320 gggaatottg atcogttgg cacaggacag cogotooto cattacaaat occacagog 1380 acttoacago acagoateg gotgoocootg aagaagoog cacagtggt toatooggagoot 1440 gtgggogoot octtotoat oggaggag ttggtgatt toggagacg tacaggoog 1500 cotcagoogg gagotgaga gocaggoog cacaggoog toatcagoog tootggt toagggoot 1500	cagaccaatt tggtggcctc tggtgctaat gaatctgaaa tctacatttg ggatctaaac	: 720
acggtetggg ateteaggaa aaaegageet attateeaag teageaacea eagtaaetgg 900 atgeaetget etgggetgge atggeaecet gatgtegeta eteagatggt eettgettet 960 gaggatgate gattaceagt ggteeagatg tgggatette gattgette etteeceete 1020 egggttetgg aaaateatge eagggggatt ttggeaattg ettggageat ggeagateet 1080 gaattgttgt taagetgtgg aaaagatget aagattetet getetaaecee taaeaeggga 1140 gaggtattat atgaaettee eacaeae eagtggtget ttgatatee gtggtgteet 1200 eeggaateetg eegteetge tgeegetee ttegatggte geateegtg etteetet 1260 atggggaggg geatagaegg ettaaggeag aaaeaagttg aeaagette gtegtettt 1320 gggaatettg ateegtttgg eacaggaeag eegeteete eatteete gtegtgat eegagaeet 1440 gtgggegeet eetteete egagggaag ttggtgaett tegagaegt taeaggeag 1500 eetteageagg gagetgagea geeeggeg eageeegtg teateagte ggtggtgeet 1620	aattttgcaa ctccaatgac gccaggagct aaaacacagc caccagaaga tatcagctgc	: 780
atgcactgct ctgggctggc atggcaccct gatgtcgcta ctcagatggt ccttgcttct 960 gaggatgatc gattaccagt ggtccagatg tgggatctc gattgctc ctctcccctc 1020 cgggttctgg aaaatcatgc cagggggatt ttggcaattg cttggagcat ggcagatcct 1080 gaattgttg taagctgtgg aaaagatgct aagattcct gctctaaccc taacacggga 1140 gaggtattat atgaacttcc caccaacaca cagtggtgct ttgatatcca gtggtgtcct 1200 cggaatcctg ccgtcctgtc tgccgcttcc ttcgatggte gcatccgtgt ctactccatc 1260 atgggagga gcatagacgg cttaaggcag aaacaagttg acaagcttc gtcgtcttt 1320 gggaatcttg atccgttgg cacaggacag ccgctccct cattacaaat cccacagcag 1380 acttcacagc acagcatcgt gctgcccctg aagaagcgc ccaagtggat ctagggcag 1500 cctcagcagg gagctgagca gccacggcgg cagcccgtg tcatcagtca ggtggtgcaa 1560 gaaaaggact tcctcagccg ctcagagcag ctacagcacg tcgtcgagtc tcagggctt 1620	atagcctgga acagacaggt ccagcatatc ttagcatcag ccagtcccag tggccgggca	. 840
<pre>gaggatgatc gattaccagt ggtccagatg tgggatcttc gatttgcttc ctctcccctc 1020 cgggttctgg aaaatcatgc cagggggatt ttggcaattg cttggagcat ggcagatcct 1080 gaattgttgt taagctgtgg aaaagatgct aagattctct gctctaaccc taacacggga 1140 gaggtattat atgaacttcc caccaacaca cagtggtgct ttgatatcca gtggtgtcct 1200 cggaatcctg ccgtcctgtc tgccgcttcc ttcgatggtc gcatccgtgt ctactccatc 1260 atgggagga gcatagacgg cttaaggcag aaacaagttg acaagcttc gtcgtcttt 1320 gggaatcttg atccgttgg cacaggacag ccgctccct cattacaaat cccacagcag 1380 acttcacage acagcatcgt gctgcccctg aagaagccge ccaagtggat ctacgggacct 1440 gtgggcgcct ccttctcatt cggaggaag ttggtgactt tcgagaacgt tacaggcag 1500 cctcagcag gagctgagca gccacggcgg cagcccgtgt tcatcagtca ggtggtgca 1620</pre>	acggtctggg atctcaggaa aaacgagcct attatcaaag tcagcaacca cagtaactgg	; 900
cgggttctgg aaaatcatgc cagggggatt ttggcaattg cttggagcat ggcagatcot 1080 gaattgttgt taagctgtgg aaaagatgot aagattotot gototaacco taacacggga 1140 gaggtattat atgaacttoc caccaacaca cagtggtgot ttgatatoca gtggtgtoot 1200 cggaatcotg cogtootgto tgoogottoo ttogatggto goatcogtgt otactocato 1260 atgggaggga goatagaogg ottaaggoag aaacaagttg acaagottto gtogtottt 1320 gggaatottg atcogttgg cacaggacag cogotocot cattacaaat cocacagoag 1380 acttoacago acagoatogt gotgoccotg aagaagoogo ccaagtggat coggagacot 1440 gtggggogoot oottocatt oggagggaag ttggtgactt togagaacgt tacaggoag 1500 cotcagoagg gagotgagca gocacggogg cagccogtgt toatcagtca ggtggtgaca 1560	atgcactgct ctgggctggc atggcaccct gatgtcgcta ctcagatggt ccttgcttct	. 960
<pre>gaattgttgt taagctgtgg aaaagatgct aagattctct gctctaaccc taacacggga 1140 gaggtattat atgaacttcc caccaacaca cagtggtgct ttgatatcca gtggtgtcct 1200 cggaatcctg ccgtcctgtc tgccgcttcc ttcgatggtc gcatccgtgt ctactccatc 1260 atgggaggga gcatagacgg cttaaggcag aaacaagttg acaagcttc gtcgtcttt 1320 gggaatcttg atccgttgg cacaggacag ccgctccct cattacaaat cccacagcag 1380 acttcacagc acagcatcgt gctgcccctg aagaagccgc ccaagtggat ccggagacct 1440 gtgggcgcct ccttctcatt cggagggaag ttggtgactt tcgagaacgt tacagggcag 1500 cctcagcagg gagctgagca gccacggcgg cagcccgtgt tcatcagtca ggtggtgaca 1560 gaaaaggact tcctcagccg ctcagagcag ctacagcacg tcgtcgagtc tcagggctt 1620</pre>	gaggatgatc gattaccagt ggtccagatg tgggatcttc gatttgcttc ctctcccctc	1020
<pre>gaggtattat atgaacttcc caccaacaca cagtggtgct ttgatatcca gtggtgtcct 1200 cggaatcctg ccgtcctgtc tgccgcttcc ttcgatggtc gcatccgtgt ctactccatc 1260 atgggaggga gcatagacgg cttaaggcag aaacaagttg acaagcttc gtcgtcttt 1320 gggaatcttg atccgtttgg cacaggacag ccgctccct cattacaaat cccacagcag 1380 acttcacagc acagcatcgt gctgcccctg aagaagccgc ccaagtggat ccggagacct 1440 gtggggcgcct ccttccatt cggagggaag ttggtgactt tcgaggacag tacaggcag 1500 cctcagcagg gagctgagca gccacggcgg cagcccgtgt tcatcagtca ggtggtgaca 1560 gaaaaggact tcctcagccg ctcagagcag ctacagcacg tcgtcgagtc tcagggctt 1620</pre>	cgggttctgg aaaatcatgc cagggggatt ttggcaattg cttggagcat ggcagatcct	. 1080
cggaateetg eegteetge tgeegettee ttegatggte geateegggt etaeteete 1260 atgggaggga geatagaegg ettaaggeag aaacaagttg acaagette gtegtetttt 1320 gggaatettg ateegtttgg eacaggaeag eegeteete eataeaaat eegaagaeet 1380 aetteaeage acageategt getgeeetg aagaageege eeaagtggat eeggagaeet 1440 gtgggegeet eetteete eggagggaag ttggtgaett tegagaaegt taeagggeag 1500 eeteageagg gagetgagea geeaeggegg eageeegtg teateagtea ggtggtgaea 1560 gaaaaggaet teeteageeg eteagageag etaeageaeg tegtegagte teagggettt 1620	gaattgttgt taagctgtgg aaaagatgct aagattctct gctctaaccc taacacggga	1140
atgggaggga gcatagacgg cttaaggcag aaacaagttg acaagcttc gtcgtcttt 1320 gggaatettg atecgtttgg cacaggacag ecgeteete cattacaaat eccacageag 1380 actteacage acageategt getgeeetg aagaageege ecaagtggat eeggagaeet 1440 gtgggegeet eetteete eggagggaag ttggtgaett tegagaaegt taeagggeag 1500 eeteageagg gagetgagea geeaeggegg eageeegtg teateagtea ggtggtgaea 1560 gaaaaggaet teeteageeg eteagageag etacageaeg tegtegagte teagggettt 1620	gaggtattat atgaacttcc caccaacaca cagtggtgct ttgatatcca gtggtgtcct	. 1200
gggaatettg ateegttgg eacagggaeag eegeecete eataeaaat eegagaeeg 1380 aetteaeage acageategt getgeeeetg aagaageege eeaagtggat eeggagaeet 1440 gtgggegeet eetteeteatt eggagggaag ttggtgaett tegagaaegt taeagggeag 1500 eeteageagg gagetgagea geeaeggeegg eageeegtgt teateagtea ggtggtgaea 1560 gaaaaggaet teeteageeg eteagageag etaeageaeg tegtegagte teagggettt 1620	cggaateetg cegteetgte tgeegettee ttegatggte geateegtgt etacteeate	1260
acttcacagc acagcatcgt gctgcccctg aagaagccgc ccaagtggat ccggagacct 1440 gtgggcgcct ccttctcatt cggagggaag ttggtgactt tcgagaacgt tacagggcag 1500 cctcagcagg gagctgagca gccacggcgg cagcccgtgt tcatcagtca ggtggtgaca 1560 gaaaaggact tcctcagccg ctcagagcag ctacagcacg tcgtcgagtc tcagggcttt 1620	atgggaggga gcatagacgg cttaaggcag aaacaagttg acaagctttc gtcgtctttt	. 1320
gtggggggct ccttctcatt cggagggaag ttggtgactt tcgagaacgt tacagggcag 1500 cctcagcagg gagctgagca gccacggcgg cagcccgtgt tcatcagtca ggtggtgaca 1560 gaaaaggact tcctcagccg ctcagagcag ctacagcacg tcgtcgagtc tcagggcttt 1620	gggaatettg atcegtttgg cacaggacag cegeteeete cattacaaat eecacageag	; 1380
cctcagcagg gagctgagca gccacggcgg cagcccgtgt tcatcagtca ggtggtgaca 1560 gaaaaggact tcctcagccg ctcagagcag ctacagcacg tcgtcgagtc tcagggcttt 1620	acttcacage acageategt getgeceetg aagaageege ceaagtggat eeggagaeet	. 1440
gaaaaggact teetcageeg etcagageag etacageaeg tegtegagte teagggettt 1620	gtgggcgcct ccttctcatt cggagggaag ttggtgactt tcgagaacgt tacagggcag	; 1500
	ceteageagg gagetgagea geeaeggegg eageeegtgt teateagtea ggtggtgaea	1560
atcagttact gccagaaaaa gatcgatgcg tcccagactg acttcgagaa gaatgtgtgg 1680	gaaaaggact teeteageeg eteagageag etaeageaeg tegtegagte teagggettt	. 1620
	atcagttact gccagaaaaa gatcgatgcg tcccagactg acttcgagaa gaatgtgtgg	1680
tccttcttga aggtaaagtt tgaggaggat tctcgtggga aataccttga gcttcttgga 1740	tccttcttga aggtaaagtt tgaggaggat tctcgtggga aataccttga gcttcttgga	1740
tatagaagag aagatctggg agagaagatt gctttggcct tgaacagagt ggacggatcc 1800	tatagaagag aagatctggg agagaagatt gctttggcct tgaacagagt ggacggatcc	1800
gatgtggete ttaaggaete tgaeegegta gegeagagtg atgggggggg gageeetgee 1860	gatgtggctc ttaaggactc tgaccgcgta gcgcagagtg atgggggagga gagccctgcc	1860
gaggaagggc agctcctggg agagcgcatt aaagaggaaa aacaggagtg tgactttctg 1920	gaggaagggc agctcctggg agagcgcatt aaagaggaaa aacaggagtg tgactttctg	1920
ccctcggctg gcggtgggac ctttaacatc tccgtcagtg gggatattga tggtttaatt 1980	ccctcggctg gcggtgggac ctttaacatc tccgtcagtg gggatattga tggtttaatt	. 1980
accogggott tgotgacogg caattttgag agogcagttg acotttgttt acaogataac 2040	acccgggott tgctgaccgg caattttgag agcgcagttg acctttgttt acacgataac	2040
	cgaatggctg atgccatcat attagccatc gcaggtgggc aggagctctt ggctcaaacg	g 2100

cagaagaaat acttigcaa atcocaage aagattacca ggettateae tgeggtggt 214 atgaagaact ggaaggagat tgttgaatee tgtgatetta aaaattggag agagetta 222 getgeggtee teaettatge taagecagat gagtteteeg eeetggate aggeetgeet etgetatate 223 tgtgeeggga atgtagagg attagttget tgttggaeca aageteaaga tggtageaae 244 eaegeaageee tggaeegaa eaetgteggg getettetgg eeggaagat gagteagta 255 geeaaettgt tgeeggeee ggeeggeet tgeeggaeet aggeeggee aggeaggeeg tgeegggge aggagteet taggaegeat geegeggeet tgeeggaeae aggeaggeeg gtgeegggge aggagteet taggaegee teegaggee aggeegtee eaaggeegge tgeeggge aggateet taggaegee teegagge ageegetgee caaggeegg 270 eeeggeegg ttgetggtea eeegeagge geegetgee eaaggeegge 270 eeeggeegg ttgetggtea eeegeagge teeagagge ageegetgee caaggeegg 270 eeeggeegg ttgetggtea eeegeagge teeagagge ageegetgee eaaggeegge 270 eeeggeeg ttgetggtea eeegeagge teeagagge ageegetgee eaaggeegg 270 eeeggeeg ttgetggtea eeegeagge teeagagge ageegetgee eaaggeegg 270 eeeggeeg ttgetggtea eeegeagg teeagagte aagteagea atattacee 270 eaggetagaa ttgeeeeta tgeaetae tggagggae gaeeetee acteeetee 270 eaegtagaa tgeeeeta tgteaetae tggaggae gaeeetee acteeetee 270 eaeatgeae aggeageet tgteeeaaa ageeetgee aceeteeetae ageeeagg 270 eaeatgeae geageeeg tgteeeaa ageeetgee eaeetee ageeege 270 eaeatgeae geageeeg tgteeeaa ageeetgee aaeageege 270 eaeatgeae geageeet gteeetae tggaggae gaeeetee ageeege 270 eaeatgeae ageeageet gteeeaa ageeetgee aaeageege 270 eaeatgeae ageeageet gteeeaa ageeetgee aaeageege 270 eaeatgeae ageeageet gteeeaaa ageeetgee aeedeeae 370 tatteettgg gaacaggeg tegteeaa ageeetgee aeeetee 370 gegteeaag gaacagegg gteageagt tateeaagee ageeegeege 370 eeteeaage ageeageet eegeageet tageeedee 370 eeteeaag gaacaggeg gteeageagt tateeaee ageeettee 370 eeteeaeet eetetggae gteetteeag eatgeeggee eageettee 372 eaeagaaga agaagetgee tggaacate ageeege etgeegeag aeegeegeege 370 eegagaaga agaagetgee tggaacate ageeege acegeege acegeege 370 gagagagaa agaagetgee tgagaacte ageeegeege acegeegee acedeeae 374 gaacaacate gegeettee eaacaage ageeetee ageegeege acegeegee acedeeae 374 gaaggage ageegeege ettee	
getgeggtee teacttatge taagecagat gagtteteeg eerstytya tetettygga 228 gecaggetty aaagtgaagg agacageete etgeggaete aggeetgeet etgetaatee 240 eerstytee teerstyggae attagttget tyttggaeea aageteaaga tygtaegaee 240 eerstytee teerstyggae gaetgeggg getettetge eegaagaet gagteagtat 252 gecaagtett tyggaeeeag eerstytegg getettetge eegaagaet gagteagtat 252 gecaacttyt tygeageeea gggeegeatt geeggeget tygegttee geetgaeaae 276 eerstytee teggaeegae eerstytegg getettetge eerstytegeggge aggagtee taggagetee taggaggee eaggeggee eaggeggee eaggeggee eaggeggee eaggeggee eaggeggee eaggeggee eaggeggee tageegeete taggaggee geesgeetee eaggeggge geesgeetee eagegggge geesgeetee eagegggge geesgeetee eagegggge geesgeetee eagegggge geesgeetee eagegggge eageestee eagegggge geesgeetee eagegggge eageestee eagegggge geesgeetee eageesgee easettatee eageesgees easettatee eageesgees easettatee eageesgees easettatee easettee easett	0
gecaggettg aagtgaagg agacageete etgeggaete aggeetgeet etgetaate 234 tgtgeeggga atgtagagg agacageete etgeggaete aggeetgeet etgetaate 234 eester etgegegge etgegegeet etgegggeet etgegegete etgegggeet 246 acgeeaagee etggaeagaa eaetgteggg getettetgg eegagaag eggetgeet 246 acgeeaagee etggaeacgaa eaetgteggg getettetgg eegagaag eggetgeet goetgaeaae 256 accaaceage eagatategt geagetget geeggeet etgeggettet goetgaeaae 256 accaaceage eagatategt geagetget gaeagaetet geeggegtee aggeggeg 270 eeegggeeg etgegegeet etaegaggege ageegetgee eaaggeegg 270 eeegggeeg etgetgege eeeste etgegaggee ageegetgee eaaggeegg 270 eeegggeeg etgetgee eeeste etgegaggee ageegetgee eaaggeegg 270 eeegggeegt ttgetggee eeeste etgegaggee ageegetgee eaaggeegg 270 eeegggeegt ttgetggee eeeste etgegaggee ageegetgee eaaggeegg 270 eeegggeegt ttgetggee eeeste etgegaggee ageegetgee eaaggeegg 270 eeegggeegt etgetgee eeeste etgegaggee ageegetgee eaaggeegg 270 eeegggeegt etgetgee eeeste etgegaggee ageegetgee eaaggeegg 270 eeeggeege etgeeede etgeegggge ageegetgee eaaggeegge 270 eeeggeege etgeeede etgeegggge gaegegetge eaeggegge eaeggeegge eaegeegge 270 eeeggeege etgeeede etgeeggege ageegetge eaegeegge 270 eeeggeege etgeeede etgeeggegge geeegeege eaegeeggeeggeege eaegeeggeeg	0
tytyceggga atgtagagag attagttyet tyttggacca aageteaaga tygtageaac 240 ceettytete teeggadeet gattgagaaa yttgteatee teegaaage tytacagete 246 aegeaageee tygacaegaa eaetgteggg getettetg eegagagat gagteagtat 252 geeaaettyt tygeageeega eaetgeegg getettetg eegagagete aggeagyte 264 gtgeegggge aggagteete taggagetee taegaggge ageeggetee aggeagyte 270 eeegggeegt tygetggtea eeegaggt teeagagge ageeggetgee eaaggeggg 270 eeegggeegt tygetggtea eeegaggt teeagagge ageeggetgee eaaggeggg 270 eeegggeegt tygetggtea eeegaggt teeagagge ageegetgee eaaggeggg 270 eeegggeegt tygetggtea eeegaggt teeagagge ageegetgee eaaggeggg 270 eeegggeegt tygetggtea eeegaggt teeagagge ageegetgee eaaggeggg 270 eaeggeegt tygetggtea tyteetaate tygaagtae gaacteeea tyeeeteee 282 ageeateeae etgeegetg teeetega acaeaggag ggaateetee aceeteagge 286 tteataatge atggeaaegt gteeeteaa ageeetgee eaetgeegae gteeeagge 294 eaeatgeeae geeageeeae acettateeg eageegae etaeeagee ageeeagea 300 tatteettyg gaacaggggg gteageagt tategaeete aceagee ageeeagea 300 tatteettyg gaacaggggg gteageagt tategaeete aceagee ageeeagea 300 eetteaage gttaceetaa egeeecatae gtaeteetg tegetteeta 300 getteeaag gtaeeegag geeetteeag eatggeggee eaggagetee acegteate 300 gegteeaag gaacaggege teagaagte taegaeegae eaeggeetge caeggeegae 302 teagettag eaetgeetee tygaacaaea ggtaeeegae eaeggeetee acegteate 302 teagettag eaetgeetee tygaacaaea ggtaeeege eaeggeetee acegteate 302 eegaagaaga agaagetgee tagaagtg tggaatgae eaeggeetee acegteate 302 eegaagaaga agaagetgee tagaaete atgeeege eaeageete ageetaagg 304 eeaaggtaa geeaeggeet etaeaaagg aggeetgae aaeageette agetteagg 346 eeaeggteaa geeedgeete etaeaaagge ageeteega aceageette agetteagg 346 eeaeggteaa geeettege teaaaeage atgeeeege aceageete ageetaagg 346 gaaaaaata eeaagaagee tatteeagae gageeteage aceageete ageetaaga 346 gaaggeggeee eeggeetee eatgegaa aceateeage atgeeagee afgee gaaaaaata eeaagaagee tatteeagae gageeege aceageete acegttegaa 347 gaeettatee ageetgeet eteeteaga agaeetege aceaceat 360 gaaggeegae aaegeetge teeteeage aceaceae aaecaagag gaagetgae 377 gaeettatee	0
cocttytete tecaggatet gattyagaaa gtigteatee tecagaaage tytacagete 246 aegeaageee tygacaegaa eaetytegyg getettetyg eegagatet geegagetea aggeagyte 255 geeaactigt tygeageeea gggeageatt geegeggeet tygegyttet geetgaeaee 256 aecaaceage eagatategt geagetgegt gaeagaetet geegagetea aggeagyte 266 gtgeegggge aggagteete taggagetee taegaggge ageegetyde eaaggeeggg 270 eeegggeegt tigetggtea eeegeagyt tecagagte aaagteagea atattateee 276 eaggitagaa tigeeeetae tyteeetaee taegaggge ageedeetee eaeggeegg 286 titeataatge atggeeaegt teeetaga gaeateeee aeeetage ggaateetee aeeetaegge 296 eacatgeeae etgeeaeet tyteeeaaa ageeetgee eaeeggeeg geeteeage 296 titeataatge atggeeaegt tyteeeaaa ageeetgee eaeeggeeg geeteeage 296 eacatgeeae geeageeae acettateeg eageegee eaeeggeeg geeteeage 296 eacatgeeae geeageeaee acettateeg eageegee eaeeggeeg geeteeage 296 tatteetaatge atggeeaegt tyteeeaaa ageeetgee eaeeggeeg geteeeagge 296 eacatgeea geeageeae acettateeg eageeggee eaeegeegge geeteeag 296 eacatgeea geeageeae acettateeg eageegee eaeegeeggeeggee ageeetgeeg 300 tatteetigg gaacaggggg gteageagt tategaeete aeeageegge 300 tatteetigg gaeaeggggg gteageagt tategaeete aeeageegg 300 ceteaatgt aeeageaeg geeetteeg eatgeee eaegeetee aeegteet 300 gettetaage gitaecetaa egeeeaaa gitaeceege eaggeetee aeegteet 300 gegteeaag gaacaggee teggaaeaaca geaeaceege eaggeetee aeegteet 300 gegteeaag gaacaggtee tagaaeaaa gitaeceege etgeeeaag 300 ceeaggaaaga agaagetgee tiggaaeaaea gitaecaege etgeeeaag 300 gegteeaag agaacaggee teggaaeate atgeeeage aeegeetee aeegteet 326 dagaaaagaa agaagetgee tiggaaeaaea gitaecaege etgeeeaag 300 ceeaggaaaga agaagetgee tiggaaeaaea gitaecaege etgeeeaag 300 ceaaggaaaga agaagetgee tiggaaeaaea gitaecaege etgeeeaag 300 ceaaggaaaga agaagetgee tiggaaeaaea aggeeegee aeegeeeaa aeegeetag 300 gaaaaaata eeagaagee tatteeaga giggetgeage aaeageette ageetgeaeaa 360 gaaaaaata eeagaagee tatteeaga aggeeeeae aeegeegg ageetgeea 377 gaeettatee ageegtgeet eteetaage aeegeeeae aaeecaegag gaagetggee 377 gaeettatee ageegeeee eatgeegga aeectee aeegeegg aeetteea 377 gaeettatee	0
acgeaageee tggacacgaa cactgteggg getettetg eegagaagat gagteagtat 252 geeaacttgt tggeageeea gggeageatt geegeggeet tgeegttet geetgacaac 256 accaaceage cagatategt geagetgegt gacagaetet geegagetea aggeaggte 264 gtgeegggge aggagteete taggagetee taegaggge ageegetgee eaagggegg 270 eeegggeegt ttgetggtea eeegaggtg teeagagtte aaagteagea atattateee 276 caeggttagaa ttgeeeeta tgteaetaee tggaagtaea gaacteeea tgeeeteee 282 ageeateeae etgeageetg teeetega acaeagggag ggaateetee aceteeagge 294 eacatgeae atggeaaegt tgtteeaaat ageeetgee eaetgeegae gteeeagge 300 tatteettgg gaacaggggg gteageagtt tategaeete aacageegg tgeeeeaga 300 tatteettgg gaacaggggg gteageagtt tategaeete aacageegg tgeeeeaga 300 eactatage atggeaaegt egteeea egeeegee etgeeegee gaeeeaga 300 tatteettgg gaacaggggg gteageagtt tategaeete aacageegg tgeeteeagge 300 eetetaage gttaeeeta egeeeae geageetee teeedeegee eaegeeag 300 eetetaage gttaeeeta egeeeae gtaeteete aacageetgt tgeteetee 300 gettetaage gttaeeeta egeeeae gtaeteete acegeegee acegeeage 300 eetetaage gttaeeetaa egeeeaee gtaeteeteg tegetteeta eteegggeeg 312 eeteatatgt acaeageae geeageete teeeeae eaegeeage 300 eeteeeett eetetggage gteetteeag eatggeegge cagageetee acegteate 300 gegteeeaga gaacaggtee tggaacaae ggtaeaeege etgeteeat 324 teagettatg eaetgeege gteetteeag eatggegge cagageetee acegteate 324 teagettatg eaetgeetee tggaacaae ggtaeaeege etgeteeag 336 eegaagaaga agaagetgee tgaaaete atgeeteege aacageete agetteeagg 346 eeaeggteaa geeaegeete etgaaaeae gggeegeag aacageete agetteeagg 346 eeaeggteaa geeaegeete etaaaeagge atgeeaeege etgeeaaee 346 ggaateeage ageetettge teaaaeagge atgeeaeege etgeeaaea 366 gaaagaggeee eeggegetee eaaeaegee gageaeete teetaaagae taegttaga 377 gaeettatee agegetgeet eteetaege gageaeete ateetaagae taegttaga 377 gaeettatee agegetgeet eteetaege gageaeete ateetaagae taegttaga 377 gaeettatee agegetgeet eteetaege gageaeete ateetaegae aetteetea 384 acaateatee geggeteee eaaeetge gagaaeete gaeaaeett gggaeegae eatteetea 384 acaateatea geegeteee eeegae aetteege ageageetga aetaeetega	0
gccaacttgt tggcagcca gggcagcatt gccgcggcct tggcqttct gcctgacaac 256 accaaccage cagatatcgt gcagctgcgt gacagactct gcagagctca aggcaggte 266 gtgccgggge aggagteete taggagetee tacgagggge ageogetgee caagggegg 270 cccgggccgt ttgetggtea eccgcaggtg tecagagte aaagteagea atattateee 276 caggttagaa ttgeceetae tgteactaee tggagtgaca gaacteeeae tgeeeteee 286 ageoateeae etgeageetg teeetetgae acacagggag ggaateetee aceteeagge 286 tteataatge atggeaaegt tgtecaaat ageoetgee caetgeegae gteeeagge 286 eacatgeaea geoageee acettateeg eageogeage etteeeage 286 tteataatge atggeaaegt tgtecaaat ageoetgee caetgeegae gteeeagea 300 tatteettgg gaacaggggg gteageagtt tategaeete aaeageotgt tgeteetee 300 gettetaage gttaceetaa egeeceaee gtaeteetg tegetteeta eteegggeag 312 eeteatatgt acacageae geegeete teeeetee caageetge teeeteetee 316 eeteetaage gttaceetaa egeegeete teeeetaeet ecagetege teeettee 316 eeteetaage gtaeceeta egeageete teeetaeet ecagetege teetteee 316 eeteetaage gaacaggege gteetteeag eatggeggae caggagetee acegteate 326 teagettatg eaetgeetee tggaacaaea ggtaeaeege etgetgeete 336 gegteecaga gaacaggtee tggaacaea ggtaeaeege etgetgeege 336 eegaagaaga agaagetgee tggaacaea gggedgeage aaeageette ageteaggg 346 eegaagaaga agaagetgee tgagaaette atgeeteetg teeetaee 342 atgaaeeetg ggggagatee ceageeagg eggeeteete geeeteeaga 336 eegaagaaga agaagetgee tgagaaete atgeeteetg teeeeatae 342 atgaaeeetg ggggagatee ceageeag eggeeteete ageteeagg 346 eegaagaaga agaagetgee tagaaeete atgeeteetg teeeeatae 342 atgaaeeetg ggggagatee ceageeag eggeeteete ageeteeaga 336 eeaaggteaa geeegeete etteeegag eegeaeete ageeteega 346 gaaggggeee ceggeetee etteeegag eggeeeete ageeteeaga 346 eeaaggteaa geeegeete etteeegag eggeeeete ageeteeaga 346 gaaggggeee ageeetetge teeaaeegge ageeeeete ageegegeea aceetteea 346 gaaggggeee ageeetetge teeaaeegge ageeeete ateetaagae taegttaga 377 gaeettatee agegetgeet etteeeage ageeeeete ateetaagae taegttaga 377 gaeettatee agegetgeet eteeteage ageaeeete ateetaagae taegttaga 378 geegeeagea aaegeetgga gtgtetgae gaeaaeett aggaagaa etaetetgaa 376 gaegeeagea aa	0
accaaccage cagatategt geagetgegt gaeagaetet geagagetea aggeaggtet 264 gtgeegggge aggagteete taggagetee taegaggge ageegetgee eaaggeegg 270 ceegggeegt ttgetggtea eeegeaggtg teeagagtte aaagteagea atattateee 276 caggttagaa ttgeeetae tgteactaee tggagtgaea gaaeteeeae tgeeeteee 226 ageeateeae etgeageetg teeetegae acacagggag ggaateetee aceteeagg 286 tteataatge atggeaaegt tgtteeaaat ageeetgeee caetgeeage gteteeagge 296 cacatgeaea geeageeae acettateeg eageegae etaecagee gteteeagge 296 cacatgeaea geeageeae acettateeg eageegae etaecagee gteteeage 300 tatteettgg gaacagggg gteageagt tategaeete aceatgeea gaecageag 300 tatteettgg gaacaggggg gteageagt tategaeete aceageeag 300 ceteatatgt acaeageaea geeageetee teeeetae caageetgt tgeteetee 306 gettetaage gttaecetaa egeeegeete teeeetae caageetgt tgeteetee 312 ceteatatgt aceaegeeae geeageetee teeeetae caageetge teetetteee 312 ceteatatg eaetgeetee tggaacaaea ggtaeacege etgetgeeag tgaetgeet 330 gegteecaga gaacaggtee teagaatgt tggaatgate etceegtet gaacaaggta 336 cegaagaaga agaagetgee tgagaaette atgeeteet teeestae 342 atgaaceetg ggggagatee teageaagg aggetgeage aacageette agetteagg 346 ceaeggteaa geeageetee ttgegaaette atgeeteetg teeestae 342 atgaaceetg ggggagatee ceageaeag acegeeaceag eaggegee acegegegee acegteaae 342 atgaaeeetg ggggagatee teageaeag atgeeacege etteesaa 346 gaaaaaata ceaagaage tatecage atgeeaceat teesaacage ageedgeet eageaeaeat 366 gaaaaaatta ceaagaagee tatecagae ageaecee aaceacaga gaagetggae 372 gaeettatee ageetgeet eteeteagae ageaecee aaceacaga gaagetggae 372 gaeettatee ageetgeet eteeteagae ageaecee aaceacagag gaagetggae 376 gaegeeagea aacgeetgga gtetgtae gaeaaecta gggaeeagea acafeetge a 372 gaeettatee agegetgeet eteeteagae ageaecee aaceaagag gaagetggae 376 gaeaaaatta ceaagaagee tatecagae gagaeecea aceaceat 366 gaagaaaatta ceaagaagee tatecagae gaeaaecta gggaeeagae acafeetgae 376 gaegeeagae aacgeetgga gtetgtae gaeaaecta gggaeeagae acafeetgae 376 gaegeeagae aacgeetgga gtetgtae gaeaaecta gggaeeagae acafeeteeaaaafae acaateatea geggteeea eageatge aceageaeeae aceacaeaa 396	0
gtgccggggc aggagteete taggagetee taegaggge ageegetgee caagggegg270cccggggeegt ttgetggtea eccgcaggtg teeagagte aaagteagea atattateee276caggttagaa ttgeeetae tgteactaee tggagtgaea gaacteeeae tgeeeteee282ageeateeeaeetgeageagetgeactaeeageeateeaeetgeageaegtteataatge atggeaaegtgtteeaaaaageeateeaegeeaeaegcacatgeaeageeaeaegcacatgeaeageeaeaeggtteetaagegtaeeaggggggtaeeagagaggtaeeagagggcacatgeaeageeaeaegaegtteetaagegtaeeagagggggtaeeagagaggtaeeagaggggtaeeagagaegtaeeagaeagtaeeagaeageeeaeaeaeaeagtaeeagaeagtaeeagaeaeagtaeeagaeageeeaeaeaaeagtaeeagaeageeeaeaeaaeaaeagtaeeagaeagtaeeagaeaeagtaeeagaeagtaeeaeaaeaaeagtaeeagaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa	0
cccqggccgt ttgctggtca cccgcaggtg tccagagttc aaagtcagca atattatccc 276 caggttagaa ttgcccctac tgtcactacc tggagtgaca gaactccca tgccctcccc 282 agccatccac ctgcagcctg tccctctgac acacagggag ggaatcctcc acctccaggt 286 ttcataatgc atggcaacgt tgttccaaat agccctgcc cactgccgac gtctccagge 294 cacatggaca gccagccacc accttatccg cagccgcagc cttaccagcc agcccagcag 300 tattccttgg gaacaggggg gtcagcagtt tatcgacctc aacagcctgt tgctcctcct 306 gcttctaagc gttaccctaa cgccccatac gtatctcctg tcgcttccta ctccgggcag 312 cctcatatgt acacagcaca gccagcctcc tcccctacct ccagctctgc tcctcttccc 316 cctccccctt cctctggag gtccttccag catggcggac caggagctc accgtcatct 324 tcagctatg cactgcctc tggaacaaca ggtacaccgc ctgctgccag tgagctgcct 330 gcgtcccaga gaacaggtc tcagaatggt tggaatgatc ctcccgctt gaacaaggta 336 ccgaagaaga agaaggtcgc tgagaacttc atgcctcgt ccccttacc 342 atgaaccctg ggggagatcc ccagccacag gggctgcag acaagcctt agcttcagg 346 ccacggtcaa gccagcctc cttcccgcag cggcgcca gcccttccac 354 gggatccage agccagctc cttcccgcag cggcacctag cggcggcca gcccttccac 354 gggatccage agccagctcc cattgggaac accatccagc atgtgcggc 357 gaaaaaatta ccaagaaggc tattccagac gagcaccta ttctaaagac tacgttgag 377 gaccttatcc agcgtgcct ctcctcagct acagaccca aaccaagag gaagctggac 376 gaaggagcag aacggctgc tcccagcac ggcaccta ttctaaagac tacgttgag 377 gaccttatcc agcgtgcct ctcctcagct acagaccca aaccaagag gaagctggac 376 gaagaccag aacgctgga gtgtctgtac gacaaactt gggaccagac actttcca 384 acaatcatca gcggtctcca cagcattgg aggagcattg agacgagaa ctactctgaa 390 gggttgaccg tccacacca catcgtcag aggagcattg agacgagaa ctactctgaa 390	0
caggttagaa ttgcccctac tgtcactacc tggagtgaca gaacteccac tgecetecce agecatecac etgeageetg teetetaga acacagggag ggaateete acetecagge 286 tteataatge atggeaacgt tgttecaaat agecetgeee caetgeegae gtetecagge 294 cacatgeaca gecageeace acettateeg cageegeage ettaceagee gtetecagge 300 tatteettgg gaacaggggg gteageagtt tategaeete aceageetgt tgeteeteet 312 ceteatage gttaccetaa egececatae gtateteetg tegetteeta eteeggeag caetatge acaegeage gteetteeag eatggeggae caggagetee acegteate 312 ceteatatgt acaeageae gecageetee teeeteetee ceteeeteet etggaacaaea ggtacaeege etgetgeeag tgagetgeet 330 gegteecaga gaacaggtee teggaacaaea ggtacaeege etgetgeeag tgagetgeet 330 gegteecaga gaacaggtee tgagaacaea ggtacaeege etgetgeeag tgagetgeet 330 gegteecaga gaacaggtee tgagaactee atgeeteetg teeetetae 342 atgaaeeetg ggggagatee ceageeage tggegeage aceageette agetteegg 346 ceaeggteaa gecaegeete etteega etgeeaeega aceageette agetteegg 346 ceaeggteaa gecaegeete etteega aceageege etgeeggeea gecetteeae 346 gaaagaggeee eeggegetee eatgggaae aceateeage aggeeggee ageetteeae 346 gaaaaaatta eeaagaagee tatteeage gageaeeta etgeeaeaea 346 gaaceetae agegetgeet eteeteage ageaeete aceateeage atgtegage tetgeeaeaa 346 gaaaaaatta eeaagaagee tatteeage gageaeeta aceateeage aggeeggee aceaeeae 347 gaeettatee agegetgeet eteeteage gageaeeta aceateeage aggeeggee etgeeaeaaa 348 aceaateatea geggtetee eteeteage ageaeeee aaeeaeagag gaagetggae 348 gaeettatee agegetgeet eteeteage ageaeeee aaeeaeagag gaagetggae 348 gaeettatee agegetgeet eteeteage ageaeeee aaeeaeagag gaagetggae 348 gaeettatee agegetgeet eteeteage ageaeeee aaeeaagag gaagetggae 348 gaeettatee agegetgeet eteeteage ageaeeee aaeeaagag gaagetggae 348 gaeettatee agegetgeet eteeteage ageaeeee aaeeaagag gaagetggae 348 gaeettatee agegetgeet eteeteagea gageeeeeaaaa 349 gaeettatee agegetgeet eteeteage ageaeeeeaaaa acaateatea geggteteea eaegeageaeaeat aggaeeagaa actaetetgaa 349 gagttgaeeg teeaeaetea eategteage aceageaeet teagtgagae eteetegaa	0
agceatecae etgeageetg teeetetgae acaeagggag ggaateetee aceteeagge 294 tteataatge atggeaaegt tgtteeaaat ageeetgeee caetgeegae gteteeagge 294 caeatgeaea geeageeace acettateeg eageegae ettaeeagee ageeeageag 300 tatteettgg gaacaggggg gteageagtt tategaeete aaeageetgt tgeteeteet 306 gettetaage gttaeeetaa egeeeetae gtateteetg tegetteeta eteeggeag 312 ceteatatgt acaeageaea geeageetee teeeetaeet eagegetge teetetteee 318 ceteectatg eaetgeetee tgegaaeaae ggagegeae eaggagetee acegteatet 324 teagettatg eaetgeetee tggaaeaaea ggtaeaeege etgetgeeag tgagetgeet 330 gegteeeaga gaacaggtee tagaaeaea ggtaeaeege etgetgeeag tgagetgeet 330 eegaagaaga agaagetgee tgagaaette atgeeteet gaaeaagata 336 eegaagaaga agaagetgee tgagaaette atgeeteetg teeeetteeagg 348 eecaeggteaa geeaegeetee etteeegaa gggetgeage aaeageette agetteagg 348 gagateeage ageetettge teaaaeagge atgeeaeetg etgetgeeag 366 gaaagagggeee eeggegetee eattgegaae aceateeage atgtgeagge tetgeeaeaa 366 gaaagaggeee eeggegeee eattgegaae aceateeage atgtgeagge tetgeeaeaea 366 gaaaaaatta eeagaagee tatteeage ageeaeeta tetaaagae taegttgag 372 gaeettatee agegetgeet eteeteage aceateeaga aaeageetga aaeageetgeag 372 gaeettatee agegetgeet eteeteage ageaeaetta gggaeeagae acetteeea 366 gaaagaaaatta eeagaagee tatteeagae gageaeetea teetaaagae taegttgag 372 gaeettatee agegetgeet eteeteage aceateeaga agaeeggae aaeageetgae 376 gaeageeagea aaeeetgga gtgtetgtae gaeaaaetta gggaeeagae aetteeea 366 gaaggagee aaegeetgga gtgtetgtae gaeaaaetta gggaeeagae aetteetea 366 gaeageeagea aaegeetgga gtgtetgtae gaeaaaetta gggaeeagae aetteetea 366	0
ttcataatge atggeaacgt tgttceaaat ageeetgeee caetgeegae gteteeage 294 caeatgeaea geeageeaee acettateeg cageegeage ettaceagee ageeeageag 300 tatteettgg gaacaggggg gteageagtt tategaeete aacageetgt tgeteeteet 306 gettetaage gttaeeetaa egeeegeete teeeeteete aacageetgt tgeteeteet 312 ceteatatgt acaeageaea geeageetee teeeetaeet ceagetetge teetetteee 312 ceteatatgt acaeageaea geeageetee teeeetaeet eagetetge teetetteee 312 teagettatg caetgeetee tggaacaaea ggtaeaeege etgetgeeag tgagetgeet 332 gegteecaga gaacaggtee teagaatgt tggaatgate etceegett gaacagagta 336 cegaagaaga agaagetgee tgagaaette atgeeteetg teeeteetae 342 atgaaeeetg ggggagatee ceageeage etgeteetge aceageette 324 gggateeage ageetettge teaaacagg eggetgeage aacageette agetteagg 348 ceaeggteaa geeaegeete etteeegag etgeteetae 342 atgaaeeetg ggggagatee ceageeage atgeeaeeta eegteate 342 gggateeage ageetettge teaaacagge atgeeaeeta eegteetae 342 gggateeage ageetettge teaaacagge atgeeaeeta eegteetae 346 gaaggggeee eeggegetee eatteeagae gageeaeeta etteegaa geeeaaeeta 366 gaaaaaatta eeagaagee tatteeagae gageaeetea teetaaagae taegttaga 372 gaeettatee agegetgeet eteeteage gageaeetea acageeegaae aacageetgaa 372 gaeettatee agegetgeet eteeteage gageaeetea atteeaagae taegttaga 372 gaeettatee agegetgeet eteeteage gageaeetea aaceaagag gaageeggae 376 gaegeeagea aacgeetgga gtgtetgtae gaeaaaetta gggaeeagae aetteteea 384 acaateatea geggteteea eageatge ageaaeetta gggaeeagea aetteteea 384 acaateatea geggteteea eageatge ageaaeetta gggaeeagae aetteteea 384	0
cacatgcaca gocagocaco acottatoog cagoogcago ottacoagoo agoocagoag 300 tattoottgg gaacaggggg gtoagoagtt tatogacoto aacagootgt tgotootoot 300 gottotaago gttacootaa ogococatao gtatotootg togottoota otoogggag 312 cotoatatgt acacagoaca gocagootoo tocootacot coagottgo tootottoo 312 cotococott oototggago gtoottooag catggoggac caggagotoo acogtoatot 324 toagottatg cactgootoo tggaacaaca ggtacacogo otgotgocag tgagotgoot 330 gogtoccaga gaacaggtoo togagaactao aggotgocag otgotgocag tgagotgoot 330 cocagagaaga agaagotgoo tgagaactto atgootcot tococattao gtacacaato 342 atgaacootg ggggagatoo coagocacag gggotgocag cacggoggoca gocottocac 354 ggaacaggtoa gocagootoo totoocago aggoggoca gocottocac 356 ggaacaggogoco coggogotoo cattgoggaa aacagootto agootacaaca 366 gaaaaaatta coaagaagoo tattocaga gagcacoota ttotaaagac taogttgag 372 gacottatoo agootoga gtgtotgaa gagaacoota acagacoota atoottoga 378 gacottatoo agootoga gtgtotgaa gacaacta gggaacaaca 366 gaacaaatta coagaagoo tattocagoo gagaacoota atoottocaa 378 gacottatoo agootoga gtgtotgaa acagoocoo aaacaagag gaagotggac 378 gacottatoo agootoga gtgtotgaa acagacooca aacacaagag gaagotggac 378 gacottatoo agogtoo tococagoo acagaactta gggaccagac acttoocaa 384 acaatcatoa goggtotoca cagoattgo gagagacattg agaccagaa acttoocaa 384 acaatcatoa goggtotoca cagoattgo gagagacatta gggaccagac acttoocaa 384 acaatcatoa goggtotoca cagoattgog agaacatta gggaccagac acttoocaa 384 acaatcatoa goggtotoca cagoattgog agagacatta gggaccagac acttoocaa 384 acaatcatoa goggtotoca cagoattgog agagacatta gggaccagac acttoocaa 384 acaatcatoa goggtotoca cagoattgog agagacatta ggaacagaga actacootaa 384 acaatcatoa goggtotoca cagoattgog agagacatta gagacagaga actacootaa 384 acaatcatoa goggtotoca cagoattgog agagacatta gagacagac acttoocaa 384 acaatcatoa goggtotoca cagoattgog agagacatta gagacagac acttoocaa 384 acaatcatoa goggtocoa cagoattgog agagacatta gagacagacaa acatcootaa 384	0
tatteettgg gaacaggggg gteageagtt tategacete aacageetgt tgeteeteetgettetaage gttaceetaa egeeceatae gtateteetg tegetteeta eteegggeaggettetaage gttaceetaa egeeceatae gtateteetg tegetteeta eteegggeagcoteatatgt acacageaca geeageetee teeceetaeet ecagetetge teetetteeecoteatatgt acacageae gteetteeag eatggeggae eaggagetee acegteatetgegteetaag gaacaggtee teggaacaaea ggtacacege etgetgeeag tgagetgeettatgaaceetg ggggagatee teagaatggt tggaatgate eteeceate agetteaggatgaaceetg ggggagatee etgegeaeag gggetgeage aacageette agetteagggeggteeage ageetettee etteeceage gegeetee etteeceagegggateeage ageetettee etteeceage ageetee etteeceagegaaggggeee eegegetee eatteeggeae atgeeacegt etteecagegaaaaaatta eeaagaagee tatteeagee gageacetea tteetaagag gaagetggaegaacatatee ageetgeet etteecagee ageetee aaceageetae aceatee ageetgeaegaeettatee ageetgeet etteecagee gageacetea tteetaagag gaagetggaegaeettatee ageetgeet etteecagee gageacetea tteetaagae taegtttgaggaeettatee ageetgeet etteecagee gageacetta gggaeeageae actteeceagaeettatee ageetgeet etteecagee ageetgee aceageaee actteeceagaeettatee ageetgeet etteecagee gageacetea tteetaagae taegtttgaggaeettatee ageetgeet etteetaegee aceageette ageetgeae actteeteegaeettatee ageetgeet etteetaegee ageetgee aceaceaeagaeettatee ageetgeet etteetaegee aceaceaeagaeettatee ageetgeet etteetaegee aceaceaeagaeettatee ageetgeet etteetaegee aceaceaeagaeettatee ageetgeet etteetaegee aceaceaeagaeataatea geggeteetae eageetgee aceaceaeagaeataaea aacgeetgga gtgtetgtae gaeaaaetta gggaeaaaaata etteetaegaaacaateatea geggteetea eageattee acaacaaeaeaea	0
gettetaagegttaccetaaegececataegtatetectgtegettetategettetagettetaagegttaccetaagececeataegtatetectgtegettetategettetaceteetaagegtettetaaggtettetaaggtettetaagtegettetategettetateagettatgcactgeeteeteggaacaacaggtacacegeetgetgeetgetegettetagegteecaaggaacaggteeteggaacaacaggtacacegeetgeetgeetgetegettetaatgaaceetgggggagaateeteggetgeageacageetgeagetegetteagetegetteageatgaaceetgggggagaateeetgeetgeageacageetgeagetegetteagetegetteagegggatecageageeteetgeageetgeetgeagetetteagetegetteagetegetteagegaaaaaattaceaagaageetateecaageaggaeetgeagetegetteagategetteagagaacetateeacageetgeeteteeteagegaacaaaettategetteagategetteagagaacetateeacageetgeeteteeteageacaacageetegetteagategetteagagaacetateeacageetgeeteteeteageacaacageetegetteagategetteagagaacetateeageetgeeteeteageacaacageeteagetegetteagategetteagategetteagagaacetateeageetgeeteageacaacageeteageacaateateagaegetgeeteagategetteagagaacetateeagegetgeeteagaacaateateagggateagaeacaateateagaegetgaetegetteagagaacetateegegtetgeagagaegaeagaeaacaateateagaegaeagaeagaeaaeatteagaeagaeagaegaeagaeagaeaga	0
cctcatatgt acacagcaca gccagcctcc tcccctacct ccagctctgc tcctctccc 316 cctcatatgt acacagcaca gccagcctcc tcccctacct ccagctctgc tcctcttccc 316 cctccccctt cctctggagc gtccttccag catggcggac caggagctcc accgtcatct 324 tcagcttatg cactgcctcc tggaacaaca ggtacaccgc ctgctgccag tgagctgcct 336 gcgtcccaga gaacaggtcc tcagaatggt tggaatgatc ctcccgctt gaacagagta 336 ccgaagaaga agaagctgcc tgagaacttc atgcctcctg tccccattac gtcaccaatc 342 atgaaccctg ggggagatcc ccagccacag gggctgcage aacagccttc agettcaggg 346 ccacggtcaa gccacgcctc cttcccgcag ccgcacctag ccggcggcca gcccttccac 354 gggatccage agectcttge tcaaacagge atgccaccgt ctttctcgaa gcccaacact 366 gaagggggccc ccggcgctcc cattgggaac accatccage atgtgcagge tctgccaaca 366 gaacaaaatta ccaagaagcc tattccagac gagcaccta ttctaaagac tacgtttgag 372 gaccttatce agegctgcet ctcctcaget acagacccc aaaccaagag gaagctggac 376 gacgccagca aacgcctgg gtgtctgtac gacaaactta gggaccagac acttctcca 384 acaatcatca gcggtctcca cagcattge aggagcattg agacgaggaa ctactctgaa 390 gggttgaccg tccacactca catcgtcage accagcact tcagtgagac ctcagccttc 396	0
cctccccctt cctctggage gteetteeag eatggeggae eaggagetee acegteatet teagettatg eactgeetee tggaacaaca ggtacacege etgetgeeag tgagetgeet 330 gegteeeag gaacaggtee teagaatggt tggaatgate eteeegett gaacagagta 336 eegaagaaga agaagetgee tgagaaette atgeeteetg teeeeatae gteaceaate atgaaceetg ggggagatee eeageeag gggetgeage aacageette agetteaggg 348 eeaeggteaa geeaegeete etteeegeag eegeaeetag eeggeggeea geeetteeae 354 gggateeage ageetettge teaaacagge atgeeaeetg etteegaa geeetteeae 354 gagaaggggeee eeggegetee eatteeggaae aceateeage atgtgeagge tetgeeaaea 356 gaaaaaatta eeaagaagee tatteeagee gageaeetea tteaaagae taegttegag 357 gaeettatee agegetgeet eteeteage aceateee aaaceaagag gaagetggae 372 gaeettatee agegetgeet eteeteaget acagaeeee aaaeeaagag gaagetggae 376 gaegeeagea aaegeetgga gtgtetgtae gaeaaaetta gggaeeagae aetteeea 387 acaateatea geggteteea eageattgeg aggageattg agaegaggaa etaeetegaa 386 gaggtgaeeg teeaeetea eategteage aceageaeet teagtgagae eteetegaa 386 acaateatea geggteteea eageattgeg aggageattg agaegaggaa etaeetegaa 386	0
tcagcttatg cactgoctoc tggaacaaca ggtacacogo ctgotgocag tgagotgoct 330 gcgtoccaga gaacaggtoc tcagaatggt tggaatgato otocogottt gaacagagta 336 cogaagaaga agaagotgoc tgagaactto atgoctoctg tooccattao gtoaccaato 342 atgaacootg ggggagatoo ocagocacag gggotgoago aacagootto agottoaggg 348 coacggtoaa gocacgooto ottoocgoag cogoacotag cogogggoca gocottocac 354 gggatocago agootottgo tcaaacaggo atgocacotg ottotooga gocoacaact 360 gaaggggooc coggogotoo cattgggaac accatocago atgtgoaggo totgocaacaa 360 gaaaaaatta coaagaagoo tattocagac gagocacta ttotaaaga taogttgag gacottatoo agogotgoot otootcagot acagacooc aaaccaagag gaagotggac 376 gaaggcoagaa aacgootgga gtgtotgtac gacaaactta gggaccagaa atttotoca 384 acaatoatoa goggtotoc cagoattgo aggagcattg agacgaggaa ctactotgaa 390 gggttgacog tooacactoa catogtoago accagoacot toagtgagac otcagootto	0
gcgtcccagagaacaggtcctcagaatggttggaatgatctccccgctttgaacagagta336ccgaagaagaagaagctgcctgggaacttcatgcctcctgtccccattacgtaccaatc342atgaaccctggggggggagatccccagccacaggggctgcagcaacagccttcagttcaggg348ccacggtcaagccacgcctccttcccgcagccggcgggggagacc354gggatccagcagcctcttgccttcccgcagccggcgggccagccttccac354gggatccagcagcctcttgcctacagaggatgccaccgtctttctcgaagccgaaaggggcccccggcggctcccattgggaacaccatccagcatgtgcaggctctgccaaca366gaaaaaattaccaaggaggctattccagacgagcacctcattctaaagactagttgag372gaccttatccagcgctgcctctcctcagctacaaccaagaggaagctggac376gacgccagcaaacgcctggagtgtctgtacgacaaacttagggaccagacacttctcaa386gacgtcagcaaacgcctggagtgtctgtacgacaaacttagggaccagacacttctcca386gacgtcagcaaacgcctggagtgtctgtacgacaaacttagggaccagacacttctcca386gacgccagcaaacgcctggagtgtctgtacgacaaacttagggaccagac378gacgccagcaaacgcctggagtgtctgtacgacaaacttagggaccagac386gacgtcagcaacaactacagggaccagacacttctcca386gacgccagcaacagcctggagacgacgacaacttaggacaaactta386gacgccagcaacaccagacacttctcca386	0
ccgaagaaga agaagctgcc tgagaacttc atgcctcctg tccccattac gtcaccaatc 342 atgaaccctg ggggagatcc ccagccacag gggctgcagc aacagcettc agettcaggg 348 ccacggtcaa gccacgeete ettecegeag eegeacetag eegegggeea gecetteeae 360 gaaggggeee eeggegetee eattgggaac accatecage atgtgeagge tetgeeaaea 360 gaaaaaatta eeaagaagee tatteeage gageacetea ttetaaagae taegtttgag 372 gacettatee agegetgeet etteetaget acagaeeeee aaeeeagag gaagetggae 378 gaegeeagea aaegeetgga gtgtetgtae gaeaaeetta gggaeeagag aagetggae 378 gaegeeagea aaegeetgga gtgtetgtae gaeaaeetta gggaeeagae aetteeteea 380 gaeateatea geggteteea cageattgeg aggageattg agaegaggaa etaeteegaa 390 gggttgaeeg tceaeaetea categteage accageaeet teagtgagae etaegeette 390	0
atgaacectg ggggagatee eeageeacag gggetgeage aacageette agetteagg 348 ceaeggteaa geeaegeete etteeegeag eegeaeetag eeggeggeea geeetteeae 354 gggateeage ageetettge teaaacagge atgeeaeet etteegaa geeeaaeaet 360 gaaaggggeee eeggegetee eattgggaae aceateeage atgtgeagge tetgeeaaea 366 gaaaaaatta eeaagaagee tatteeage gageaeetea tteetaaagae taegttgag 372 gaeettatee agegetgeet etteeteage gageaeetea aaaeeaagag gaagetggae 378 gaegeeagea aaegeetgga gtgtetgtae gaeaaaetta gggaeeagae aetteetea 386 acaateatea geggteteea cageattge aggageattg agaegaggaa etaeteegaa 390 gggttgaeeg teeacaetea eategteage aceageaet teagtgagae eteageete 396	0
ccacggtcaa gccacgcctc cttcccgcag ccgcacctag ccggcggcca gcccttccac 354 gggatccagc agcctcttgc tcaaacaggc atgccaccgt ctttctcgaa gcccaacact 360 gaaggggccc ccggcgctcc cattgggaac accatccagc atgtgcaggc tctgccaaca 366 gaaaaaatta ccaagaagcc tattccagac gagcacctca ttctaaagac tacgtttgag 372 gaccttatcc agcgctgcct ctcctcagct acagaccccc aaaccaagag gaagctggac 376 gacgccagca aacgcctgga gtgtctgtac gacaaactta gggaccagac actttctcca 384 acaatcatca gcggtctcca cagcattgcg aggagcattg agacgaggaa ctactctgaa 390 gggttgaccg tccacactca catcgtcagc accagcaact tcagtgagac ctcagccttc 396	0
gggatccagc agcctcttgc tcaaacaggc atgccaccgt ctttctcgaa gcccaacact 360 gaaggggccc ccggcgctcc cattgggaac accatccagc atgtgcaggc tctgccaaca 360 gaaaaaatta ccaagaagcc tattccagac gagcacctca ttctaaagac tacgtttgag 372 gaccttatcc agcgctgcct ctcctcagct acagaccccc aaaccaagag gaagctggac 376 gacgccagca aacgcctgga gtgtctgtac gacaaactta gggaccagac actttctcca 380 acaatcatca gcggtctcca cagcattgcg aggagcattg agacgaggaa ctactctgaa 390 gggttgaccg tccacactca catcgtcagc accagcaact tcagtgagac ctcagccttc 390	0
gaaggggccc ccggcgctcc cattgggaac accatccagc atgtgcaggc tctgccaaca 366 gaaaaaatta ccaagaagcc tattccagac gagcacctca ttctaaagac tacgtttgag 372 gaccttatcc agcgctgcct ctcctcagct acagaccccc aaaccaagag gaagctggac 376 gacgccagca aacgcctgga gtgtctgtac gacaaactta gggaccagac actttctcca 386 acaatcatca gcggtctcca cagcattgcg aggagcattg agacgaggaa ctactctgaa 390 gggttgaccg tccacactca catcgtcagc accagcaact tcagtgagac ctcagccttc 396	0
gaaaaaatta ccaagaagcc tattccagac gagcacctca ttctaaagac tacgttgag 372 gaccttatcc agcgctgcct ctcctcagct acagaccccc aaaccaagag gaagctggac 378 gacgccagca aacgcctgga gtgtctgtac gacaaactta gggaccagac actttctcca 384 acaatcatca gcggtctcca cagcattgcg aggagcattg agacgaggaa ctactctgaa 390 gggttgaccg tccacactca catcgtcagc accagcaact tcagtgagac ctcagccttc 396	0
gaccttatcc agcgctgcct ctcctcagct acagaccccc aaaccaagag gaagctggac 378 gacgccagca aacgcctgga gtgtctgtac gacaaactta gggaccagac actttctcca 384 acaatcatca gcggtctcca cagcattgcg aggagcattg agacgaggaa ctactctgaa 390 gggttgaccg tccacactca catcgtcagc accagcaact tcagtgagac ctcagccttc 396	0
<pre>gacgccagca aacgcctgga gtgtctgtac gacaaactta gggaccagac actttctcca 384 acaatcatca gcggtctcca cagcattgcg aggagcattg agacgaggaa ctactctgaa 390 gggttgaccg tccacactca catcgtcagc accagcaact tcagtgagac ctcagccttc 396</pre>	0
acaatcatca gcggtctcca cagcattgcg aggagcattg agacgaggaa ctactctgaa 390 gggttgaccg tccacactca catcgtcagc accagcaact tcagtgagac ctcagccttc 396	0
gggttgaccg tccacactca catcgtcagc accagcaact tcagtgagac ctcagccttc 396	0
	0
atgccagtcc tcaaggttgt gctcagccag gccagtaagc tgggcgtctg agacagctgc 402	0
	0
catgacetee gaeteegeea etteteeaa gaaageeatg etaagaetgg gaeeageeee 408	0
tcattagcat gtttccatgg caccegecae ceaggagett tgacattet geaggeaaae 414	0
tcccctagaa ctgcttgaac cccccctccc accccgcccg tgctttcctt tgttttaatc 420	0
ccctcgccca ttatgatttt cccattctgc aaatagtgtc tttcctggat tacacatagt 426	0
gtggtttcct gagggattct gacaaaatgt ggtttttaaa acttgggtgt actttttagg 432	0
aaaattgcat ctggctgtgt ataaaacaga cctaaaatag atttctttaa tgtcttccct 438	0

accttcttca cgttcatcag attaaagttg taatcccatc tt	4422
<210> SEQ ID NO 25 <211> LENGTH: 2704 <212> TYPE: DNA <213> ORGANISM: Rattus sp.	
<400> SEQUENCE: 25	
gaatteegga ateeggegag gaaatacatg caetegetga gaategeegg egeeaggaeg	60
cagegeeaca aggtgtageg agtgagtggg gtggggcaag aggggaeeea ggagteeeee	120
caggeteeca gegegeetge teetgetett caateetgee eteggggegg aeggagtgae	180
ccccgccccg accatggtag tgttcaatgg ccttcttaag atcaaaatct gcgaggccgt	240
gagettgaag eccaeageet ggtegetgeg ceatgeggtg ggaeeeegge eccagaegtt	300
ccttctggac ccctacattg cccttaacgt ggacgactcg cgcatcggcc aaacagccac	360
caagcagaag accaacagtc cggcctggca cgatgagttc gtcactgatg tgtgcaatgg	420
gcgcaagatc gagctggctg tctttcacga tgctcctatc ggctacgacg acttcgtggc	480
caactgcacc atccagttcg aggagctgct gcagaatggg agccgtcact tcgaggactg	540
gattgatctg gagccagaag gaaaagtcta cgtgatcatc gatctctcgg gatcatcggg	600
cgaagcccct aaagacaatg aagaacgagt gtttagggag cggatgcggc caaggaagcg	660
ccaaggggct gtcaggcgca gggtccacca ggtcaatggc cacaagttca tggccaccta	720
cttgcggcag cccacctact gctcccactg tagggatttc atctggggtg tcataggaaa	780
acagggatat caatgtcaag tttgtacctg cgtcgtccac aaacgatgcc atgagctcat	840
tattacgaag tgcgctgggc taaagaaaca ggaaacccct gacgaggtgg gctcccaacg	900
cttcagcgtc aacatgcccc acaagttcgg gatccacaac tacaaggtcc ccacgttctg	960
tgaccactgt ggctccctgc tctggggcct cttgcggcag ggcctgcagt gtaaagtctg	1020
caaaatgaat gttcaccgtc gatgcgagac caacgtggct cccaattgtg gggtggacgc	1080
cagaggaatt gccaaggtgc tggccgatct tggcgttact ccagacaaaa tcaccaacag	1140
tggccagaga aggaaaaagc tcgctgctgg tgctgagtcc ccacagccgg cttctggaaa	1200
ctccccatca gaagacgacc gatccaagtc agcgcccacc tccccttgtg accaggaact	1260
aaaagaactt gaaaacaaca teeggaagge ettgteattt gacaacegag gagaggagea	1320
ccgagcctcg tcgtctactg atggccagct ggcaagccct ggcgagaacg gtgaagtccg	1380
gcaaggccag gccaagcgct tgggcctgga tgagttcaac ttcatcaagg tgttaggcaa	1440
aggcagcttt ggcaaggtca tgctggccga gctcaagggt aaggatgaag tctatgctgt	1500
gaaggtetta aagaaggaeg teateetgea ggatgaegae gtggaetgea egatgaeaga	1560
gaagaggatt ttggetetgg egeggaaaea eeettateta aeceaaetet attgetgett	1620
ccagaccaag gaccggetet tettegteat ggaatatgta aacggtggag aceteatgtt	1680
ccagattcag cggtcccgaa aattcgatga gcctcgttcc gggttctatg ctgccgaggt	1740
cacatctgct ctcatgtttc tccaccaaca tggagtgatc tacagggatt tgaaactgga	1800
caacateett etagatgeag aaggteacte caagetgget gaetttggga tgtgeaagga	1860
agggattetg aatggegtga caactaceae ettetgtggg acteetgaet acatagetee	1920
agagateetg caggagttgg agtaeggeee eteagtggae tggtgggeee tgggegtget	1980

2040

2100

gatgtacgag atgatggccg ggcagccccc ctttgaagct gacaacgagg acgacttgtt

tgaatccatc cttcacgatg acgttctcta ccctgtctgg cttagcaagg aggctgtcag cateetgaaa gettteatga eeaagaacee geacaagege etgggetgeg tggeageaca 2160 gaacggggaa gatgccatca agcaacatcc attcttcaag gagattgact gggtactgct 2220 ggagcagaag aaaatgaagc cccccttcaa gccgagaatt aaaaccaaga gagatgtcaa 2280 taactttgac caagacttta cccgggaaga gccaatactt acacttgtgg atgaagcaat 2340 cgtgaagcag atcaaccagg aagaattcaa aggcttctcc tactttggtg aagacctgat 2400 gccctgagaa actgcttcac atggagttag ctcactgcaa ggagggtgtt gagacaatcc 2460 cgtgttgcag aggctcagaa tgtctcgaac tattcgtcct ccccagagcc ccagtcccac 2520 atctgctctc ttatttattg catcccctca tcccaggccc tgtccttccc caccctccca 2580 gtgaccagaa ggccctcttt ggtccagact caccaagatc acagatttga actgcgtctg 2640 ctctgtgtgc agtgctaggt ctggagtagc cgtccaccca caaccctgaa gcagcccgga 2700 2704 attc <210> SEQ ID NO 26 <211> LENGTH: 549 <212> TYPE: DNA <213> ORGANISM: Rattus sp. <400> SEOUENCE: 26 agaaaagaat attttattga aacagtttct caattaacaa tggaacaaag tacaatttga 60 120 ttcaaacctg tccaaccage etgaactget aatgaaagaa etcaaacaca caggggggaa ctgtgtagga cctttaagtc tctctgccaa tgtggcaaaa aaaaaaaaa aaaaggtgga 180 gagggggggg ggtggggtag aaaagacaaa acaactgaca tcaggtttgc tttgcccctg 240 cactggggtg gccctacctc ctgctacagg tgcaatactg gaggacaggc actctaggca 300 tggttatagt gggcaagggg ctctccttcc tggcaaagga cactgtcaag ttgaaccctg 360 acccctcttt ctttacccac aaagcttgcc tgagagtgag gtggcatttt tacattcaca 420 ccatgatctc tgtcccacag ggtcttggga aagggggctca cagtagatag cacattttg 480 gtcagcccag ggggaagaag gaaagagcct gaagggtaga ttttacagga actggggatg 540 accaggatg 549 <210> SEQ ID NO 27 <211> LENGTH: 1647 <212> TYPE: DNA <213> ORGANISM: Rattus norvegicus <400> SEOUENCE: 27 cttccgaaaa gtagtccaca ttgagcaggg tggcctggtc aagcctgaga gggatgacac 60 cgagttccag catccatgtt tcctgcgtgg ccaggaacag ctccttgaga atatcaagag 120 180 gaaagtgacc agcgtgtcca ccctgaagag tgaggacata aaaatacgcc aggacagtgt caccaggctg ttgacagatg tgcagctgat gaaggggaaa caggagtgta tggactccaa 240 gctcctggcc atgaagcacg agaacgaggc cctgtggcgg gaggtggcca gccttcggca 300 gaagcatgcc cagcagcaaa aagttgtcaa caagctcatc caattcctga tctcactggt 360 gcagtcgaac cggatcctgg gggtgaaaag aaagatccct ctgatgttga gtgacagcag 420

ctcagcacac tctgtgccca agtatggtcg acagtactcc o	tggagcatg tccatggtcc	480
cggcccatac tcagctccat ctccagccta cagcagctct a	ageetttaet eetetgatge	540
tgtcaccagc tctgggccca taatctccga tatcactgag c	tggctccca ccagcccttt	600
ggcctcccca ggcaggagca tagatgagag gcctctgtcc a	agcagcaccc tggtccgtgt	660
caaggaagag ccccccagcc cacctcatag ccctcgggta c	tggaggcaa gccctgggcg	720
cccagcctcc atggataccc ctttgtcccc aactgccttc a	attgactcca tccttcgaga	780
gagcgaacct acccctgctg cctcaaacac agcccctatg g	Jacacaaccg gagcccaagc	840
ccctgcacac ccagccccct ccacccctga gaagtgcctc a	igogtagoot gootagacaa	900
gaacgagcta agtgatcacc tggatgccat ggactccaac c	tggacaacc tgcagaccat	960
gctgacaagc cacggcttca gtgtggacac cagtgccctg c	tggacctgt tcagcccctc	1020
ggtgaccatg cccgacatga gcctgcctga cctggacagc a	igcctggcca gcattcagga	1080
acttctatct ccccaagagc ctcccaggcc tattgaggca c	jagaatagta acgccgactc	1140
aggaaagcag ctggtgcact acacggctca gcctctgttc c	tgctggacc ctgatgctgt	1200
ggacacaggg agcagtgaac tgcctgtgct ctttgagctg g	jgggagagct cctacttctc	1260
tgagggagat gactacacgg atgatcccac catctctct c	tgacgggca ctgaacccca	1320
caaagccaag gaccccactg tctcctagag gtttcagttg t	caggctggc ttgggcctgg	1380
cccccagcct attcctagga cacggctggt cctggggaga c	aagacagtt gggtagtcca	1440
gggaatccta ggtcaagcca gcacaacccc agtggagcac a	igatgggact tgggcttggg	1500
cagtaccttg gatcaagagg aagatcctga aggctgcata c	ctgctgcct tcaccccage	1560
cccaagtctg ctctctggtc agagcttcac agccacactt g	jgactgaccc tgcaggttgt	1620
tcataaaatt gtattttgat ttttaat		1647
<210> SEQ ID NO 28 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artifi	icial sequence: Primer	
atatgatcgc ctgcttattc a		21
<210> SEQ ID NO 29 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artifi	icial sequence: Primer	
<400> SEQUENCE: 29		
aaaggtaggc aacattttca c		21
<210> SEQ ID NO 30 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artifi	icial sequence: Primer	

-continued

ttgaccacat cgccgaatgc 20 <210> SEQ ID NO 31 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 31 agtgcccaca atgagaccaa tc 22 <210> SEQ ID NO 32 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 32 cccgtccttg tctccag 17 <210> SEQ ID NO 33 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 33 21 agaaaaagag tgcggatgat g <210> SEQ ID NO 34 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 34 agcattttcc agaagagtgg tgtc 24 <210> SEQ ID NO 35 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 35 acaaagacgc tgatggctgc 20 <210> SEQ ID NO 36 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 36 20 gagcaccaaa ccacttcctc

<210> SEQ ID NO 37 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 37 20 ctacaacata agggggtctc <210> SEQ ID NO 38 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 38 aaatccactt caacctaccg ctc 23 <210> SEQ ID NO 39 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 39 24 tcgtctacaa cataaggggg tctc <210> SEQ ID NO 40 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 40 21 tctatgacag cgagtatgat a <210> SEQ ID NO 41 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 41 caagggcact gtggaccaga t 21 <210> SEQ ID NO 42 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 42 taaccaccgc atctcttccc tg 22 <210> SEQ ID NO 43 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial sequence

<pre><220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer</pre>	
<400> SEQUENCE: 43	
tgtgccaagg atttcaaact gg	22
<210> SEQ ID NO 44 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 44	
cagaatggga gccgtcactt c	21
<210> SEQ ID NO 45 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 45	
agcgcacttc gtaataatga g	21
<210> SEQ ID NO 46 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 46	
tttgacaacc gaggagagga gc	22
<210> SEQ ID NO 47 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 47	
cottggtotg gaagcagcaa tag	23
<210> SEQ ID NO 48 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 48	
ggggaactgt gtaggacctt	20
<210> SEQ ID NO 49 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 49	

-c	റ	n	t.	п.	n	11	е	a	
-	~	••	~	-		~	~	~	

atgtaaaaat gccacctcac t 21 <210> SEQ ID NO 50 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 50 ttcaaacctg tccaaccagc c 21 <210> SEQ ID NO 51 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 51 ttgtgggtaa agaaagaggg gtc 23 <210> SEQ ID NO 52 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 52 tegeateegt gtetaeteea te 22 <210> SEQ ID NO 53 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 53 ggaagteett ttetgteace ace 23 <210> SEQ ID NO 54 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 54 cagaaccacc ccatttacct g 21 <210> SEQ ID NO 55 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 55 24 tgtttacatc caaggctctc actg

<210> SEQ ID NO 56 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 56 24 cgaaagagga tgtggatgaa gatg <210> SEQ ID NO 57 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 57 atgtatcgga gtcgcttggt gagg 24 <210> SEQ ID NO 58 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 58 22 aggatgtgga tgaagatgtg cc <210> SEQ ID NO 59 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEOUENCE: 59 24 atgtatcgga gtcgcttggt gagg <210> SEQ ID NO 60 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 60 ggaggatgcc cgagttttac aac 23 <210> SEQ ID NO 61 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 61 aagaggtcca aggatgtgct gtgg 24 <210> SEQ ID NO 62 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial sequence

<pre><220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer</pre>	
<400> SEQUENCE: 62	
aagatggcac tacccacagc ac	22
<210> SEQ ID NO 63 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 63	
tttccttcca cccgttcctg	20
<210> SEQ ID NO 64 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 64	
atcaaggatg ctggaggaag gg	22
<210> SEQ ID NO 65 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 65	
tagttcaggg cactgttcgt gg	22
<pre><210> SEQ ID NO 66 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 66</pre>	
cttgggtatc actgctttga	20
<210> SEQ ID NO 67 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 67	
ataatactcc gcctctgctt c	21
<210> SEQ ID NO 68 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 68	

-c	റ	n	t.	п.	n	11	е	a	
-	~	••	~	-		~	~	~	

tgttctggtg gcgactgcca gacacct 27 <210> SEQ ID NO 69 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 69 tatettttca atecettcaa gaageeg 27 <210> SEQ ID NO 70 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 70 aagaactgct gggggaagat tg 22 <210> SEQ ID NO 71 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 71 20 ttgccgtgag ccttgacctg <210> SEQ ID NO 72 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 72 24 acaactacag cacaggctac gacg <210> SEQ ID NO 73 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 73 agaagagtga aaggcgggag ac 22 <210> SEQ ID NO 74 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 74 21 gacgatccgg gctcccttca c

<210> SEQ ID NO 75 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 75 21 atggatgccg gcttgcgaat g <210> SEQ ID NO 76 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 76 gaccactttg gcagacttca ctg 23 <210> SEQ ID NO 77 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 77 23 ccttccatcc ttcacagata ggg <210> SEQ ID NO 78 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEOUENCE: 78 21 gcctgatatc gaccgaacag c <210> SEQ ID NO 79 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 79 atcatcttcc ttttggcaag c 21 <210> SEQ ID NO 80 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 80 acttccatcc tatccagcct gc 22 <210> SEQ ID NO 81 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial sequence

<pre><220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer</pre>	
<400> SEQUENCE: 81	
caccacaaac acaatgccat ctg	23
<210> SEQ ID NO 82 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 82	
gcaattccaa aacagtcac	19
<210> SEQ ID NO 83 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 83	
tttagcccat ctcctatgat t	21
<210> SEQ ID NO 84 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 84	
aggetaeget gtetaecaga ttee	24
<210> SEQ ID NO 85 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 85	
aacaccetca agcagaagte ace	23
<pre><210> SEQ ID NO 86 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer</pre>	
<400> SEQUENCE: 86	
tggacacggg gttctaca	18
<210> SEQ ID NO 87 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 87	

-continued

caactccttg ggaatctggt a 21 <210> SEQ ID NO 88 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 88 ggagccattg ttcacattac cg 22 <210> SEQ ID NO 89 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 89 taccetgeet tettetetet ggag 24 <210> SEQ ID NO 90 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 90 19 ccgaccagca acacagagc <210> SEQ ID NO 91 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 91 ttcgccgtaa aacatcagca t 21 <210> SEQ ID NO 92 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 92 ggagcagttt tgtgtgtgtg attc 24 <210> SEQ ID NO 93 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 93 25 tgcggtagag taagcataca ggaag

<210> SEQ ID NO 94 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 94 21 gccgaaactc ttcatcattc a <210> SEQ ID NO 95 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 95 gatctgtttc tttgcgtgga a 21 <210> SEQ ID NO 96 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 96 23 tggaactgaa gggtgacatt gag <210> SEQ ID NO 97 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEOUENCE: 97 22 atggcttggc agagagggat tc <210> SEQ ID NO 98 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 98 gaactgaagg gtgacattga g 21 <210> SEQ ID NO 99 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 99 gggatgttta gtttcctcca c 21 <210> SEQ ID NO 100 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial sequence

<220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 100	
ctgacacagg acacggaaca aag	23
<210> SEQ ID NO 101 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 101	
ggtgacactc ttacattgag atgcc	25
<210> SEQ ID NO 102 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 102	
cacagttete gggtggagt	19
<210> SEQ ID NO 103 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 103	
cattgagatg ccctaacagt g	21
<210> SEQ ID NO 104 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 104	
gaccactgga aggaagaaac acc	23
<210> SEQ ID NO 105 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 105	
cagactcacc gaatgacaca ctctc	25
<210> SEQ ID NO 106 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 106	

-continued

gagagtgtgt cattcggtga gtctg	25
gagagegege carreggega georg	25
<210> SEQ ID NO 107 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 107	
cggaagagtc cataggtgtg aagtc	25
<210> SEQ ID NO 108 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer <400> SEQUENCE: 108	
tggctcggaa atacgcagtt g	21
<210> SEQ ID NO 109 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 109	
aggtgtgtgt cctccataca gtgc	24
<210> SEQ ID NO 110 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 110	
ggtggcttca acttctatgc gg	22
<210> SEQ ID NO 111 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial sequence <220> FEATURE: <223> OTHER INFORMATION: Description of artificial sequence: Primer	
<400> SEQUENCE: 111	
ccagggattg gtgaggtttt cc	22

What is claimed is:

1. A method for determining the effect of a candidate compound on hot-flash symptoms, comprising:

- a) contacting a first cell that expresses an estrogen receptor or estrogen related receptor with said candidate compound; and
- b) determining the effect of said candidate compound on said first cell's expression of a panel of genes associated with hot flash symptoms.

2. The method of claim 1, wherein said method further comprises comparing said first cell's expression of said panel of genes associated with hot flash symptoms with a reference expression profile of said panel of genes associated with hot flash symptoms.

3. The method of claim 2, wherein said reference expression profile of said panel of genes is the expression profile of the panel of genes following contacting the cell with a compound selected from the group consisting of estradiol, tibolone, raloxifene, and tamoxifen.

4. The method of claim 1, wherein said method further comprises comparing said first cell's expression of said panel of genes associated with hot flash symptoms with a second cell's expression of said panel of genes associated with hot flash symptoms following contact with a compound that has a known effect on hot flash symptoms.

5. The method of claim 4, wherein said compound that has a known effect on hot flash symptoms is selected from the group that consists of estradiol, tibolone, raloxifene, and tamoxifen.

6. The method of claim 2 or 4, wherein said method comprises determining that said compound decreases the incidence of hot flash symptoms.

7. The method of claim 1, wherein said estrogen receptor is estrogen receptor α .

8. The method of claim 1, wherein said estrogen receptor is estrogen receptor β .

9. The method of claim 1, wherein said cell expresses both estrogen receptor α and estrogen receptor β .

10. The method of claim 1, wherein said cell that expresses the estrogen receptor is selected from the group consisting of a pituitary cell and a hypothalamus cell.

11. The method of claim 10, wherein said cell that expresses the estrogen receptor is selected from the group consisting of a GH3 cell, a GH4 cell, a PR1 cell, a MtT/E-2 cell, an alphaT3-1 cell, a D12 cell, an RCF-8 cell, and a GT1-7 cell.

12. The method of claim 1, wherein said cell's expression of said panel of genes associated with hot flash symptoms is quantified by determining the presence and amount of mRNA expressed from said panel of genes.

13. The method of claim 12 wherein said cell's expression of said panel of genes associated with hot flash symptoms is quantified by a technique selected from the group of reverse transcription real time PCR, quantitative reverse transcription PCR, Northern blot assays, dot blot assays, reverse dot blot assays, RNAse protection assays, 5'-nuclease assays, reporter gene assays, branched DNA assays, bead array assays, and multiplexed array mRNA assays.

14. The method of claim 13, wherein said cell's expression of said panel of genes associated with hot flash symptoms is quantified by a multiplexed array mRNA assay.

15. The method of claim 1, wherein said cell's expression of said panel of genes associated with hot flash symptoms is quantified by determining the presence and amount of protein expressed from said panel of genes.

16. The method of claim 15, wherein said cell's expression of said panel of genes associated with hot flash symptoms is quantified by a technique selected from the group of a western blot assay, an ELISA assay, a cytokine bead array, multiplexed protein detection assays, and an immunofluorescence assay.

17. The method of claim 1, wherein at least one member of said panel of genes is selected from the group consisting of Activin Beta E, Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Argininosuccinate Synthetase, Ribonucleoside Reductase 1, Interleukin-18, ARL gene 4, Calpain, EST196325, CPP32, EST208064, 2-alpha-1 globin, Amiloride Binding Protein, Annexin 1, N27, HBP1, D-binding protein, FE65, Protein Kinase C type I, Glutamate Receptor subunit d1, VAP1, Protein Kinase C subspecies epsilon, EST203549, and Heat Shock Transcription Factor 1. 18. The method of claim 17, wherein at least one member of said panel of genes is selected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon, and wherein expression of at least one member of said panel of genes is upregulated in said cell following said contact with said candidate compound.

19. The method of claim 17, wherein at least one member of said panel of genes is selected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon, and wherein expression of at least one member of said panel of genes is not upregulated in said cell following said contact with said candidate compound.

20. The method of claim 17, wherein at least one member of said panel of genes is selected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon, and wherein expression of at least one member of said panel of genes is downregulated in said cell following said contact with said candidate compound.

21. The method of claim 17, wherein at least one member of said panel of genes is selected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon, and wherein expression of at least one member of said panel of genes is not downregulated in said cell following said contact with said candidate compound.

22. The method of claim 6, wherein said panel of genes comprises Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, EST196325, Annexin 1, N27, and HBP1; wherein expression of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, and EST196325 is upregulated in said cell following said contact with said candidate compound; wherein expression of Annexin 1, N27, and HBP1 is not upregulated in said cell following said contact with sa

23. A method for rapidly determining the effects of a plurality of compounds on hot-flash symptoms, comprising:

- a) separately contacting a sample of cells that express an estrogen receptor or estrogen related receptor with each member of said plurality of compounds; and
- b) assessing the effect of each member of said plurality of compounds on each of said samples of cells' expression of a panel of genes associated with hot flash symptoms, thereby predicting the effect of each of said compounds on hot-flash symptoms.

24. The method of claim 23, wherein said method further comprises comparing said expression of said panel of genes associated with hot flash symptoms by said samples of cells with a reference expression profile of said panel of genes associated with hot flash symptoms.

25. The method of claim 24, wherein said reference expression profile of said panel of genes is the expression profile of the panel of genes following contacting the cell

26. The method of claim 23, wherein said method further comprises comparing said expression of said panel of genes associated with hot flash symptoms by said samples of cells with the expression of said panel of genes associated with hot flash symptoms by a sample of cells following contact with a compound that has a known effect on hot flash symptoms.

27. The method of claim 26, wherein said compound that has a known effect on hot flash symptoms is selected from the group that consists of estradiol, tibolone, raloxifene, and tamoxifen.

28. The method of claim 24 or **26**, wherein said method comprises determining that said compound decreases the incidence of hot flash symptoms.

29. The method of claim 23, wherein said estrogen receptor is estrogen receptor α .

30. The method of claim 23, wherein said estrogen receptor is estrogen receptor β .

31. The method of claim 23, wherein said sample of cells expresses both estrogen receptor α and estrogen receptor β .

32. The method of claim 23, wherein said sample of cells that expresses the estrogen receptor is selected from the group consisting of a pituitary cell and a hypothalamus cell.

33. The method of claim 32, wherein said sample of cells that expresses the estrogen receptor is selected from the group consisting of a GH3 cell, a GH4 cell, a PR1 cell, a MtT/E-2 cell, a alphaT3-1 cell, a D12 cell, an RCF-8 cell, and a GT1-7 cell.

34. The method of claim 23, wherein said expression of said panel of genes associated with hot flash symptoms by said sample of cells is quantified by determining the presence and amount of mRNA expressed from said panel of genes.

35. The method of claim 34, wherein said expression of said panel of genes associated with hot flash symptoms by said sample of cells is quantified by a technique selected from the group of reverse transcription real time PCR, quantitative reverse transcription PCR, Northern blot assays, dot blot assays, reverse dot blot assays, RNAse protection assays, 5'-nuclease assays, reporter gene assays, branched DNA assays, bead array assays, and multiplexed array mRNA assays.

36. The method of claim 35, wherein said expression of said panel of genes associated with hot flash symptoms by said sample of cells is quantified by a multiplexed array mRNA assay.

37. The method of claim 23, wherein said expression of said panel of genes associated with hot flash symptoms by said sample of cells is quantified by determining the presence and amount of protein expressed from said panel of genes.

38. The method of claim 37, wherein said expression of said panel of genes associated with hot flash symptoms by said sample of cells is quantified by a technique selected from the group of a western blot assay, an ELISA assay, a cytokine bead array, multiplexed protein detection assays, and an immunofluorescence assay.

39. The method of claim 23, wherein at least one member of said panel of genes is selected from the group consisting of Activin Beta E, Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Argininosuccinate Synthetase, Ribonucleoside Reductase 1, Interleukin-

18, ARL gene 4, Calpain, EST196325, CPP32, EST208064, 2-alpha-1 globin, Amiloride Binding Protein, Annexin 1, N27, HBP1, D-binding protein, FE65, Protein Kinase C type I, Glutamate Receptor subunit d1, VAP1, Protein Kinase C subspecies epsilon, EST203549, and Heat Shock Transcription Factor 1.

40. The method of claim 39, wherein at least one member of said panel of genes is selected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon, and wherein expression of at least one member of said panel of genes is upregulated in said sample of cells following said contact with said candidate compound.

41. The method of claim 39, wherein at least one member of said panel of genes is selected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon, and wherein expression of at least one member of said panel of genes is not upregulated in said sample of cells following said contact with said candidate compound.

42. The method of claim 39, wherein at least one member of said panel of genes is selected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon, and wherein expression of at least one member of said panel of genes is downregulated in said sample of cells following said contact with said candidate compound.

43. The method of claim 39, wherein at least one member of said panel of genes is selected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon, and wherein expression of at least one member of said panel of genes is not downregulated in said sample of cells following said contact with said candidate compound.

44. The method of claim 28, wherein said panel of genes comprises Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, EST196325, Annexin 1, N27, and HBP1; wherein expression of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, and EST196325 is upregulated in said sample of cells following said contact with said candidate compound; wherein expression of Annexin 1, N27, and HBP1 is not upregulated in said sample of cells following said contact with said candidate compound; and wherein expression of Protein Kinase C subspecies epsilon is not downregulated in said sample of cells following said contact with said candidate compound.

45. An array, comprising:

- a) a non-porous surface; and
- b) a plurality of different oligonucleotides connected with said surface, wherein at least one of said oligonucleotides is specific for a member of a panel of genes associated with hot flash symptoms, and wherein each of said different oligonucleotides is connected with said surface in a different predetermined region of said surface.

46. The array of claim 45, wherein at least one of said oligonucleotides hybridizes under stringent conditions to a member of a panel of genes associated with hot flash symptoms.

47. The array of claim 46, wherein said member of said panel of genes is selected from the group consisting of Activin Beta E, Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Argininosuccinate Synthetase, Ribonucleoside Reductase 1, Interleukin-18, ARL gene 4, Calpain, EST196325, CPP32, EST208064, 2-alpha-1 globin, Amiloride Binding Protein, Annexin 1, N27, HBP1, D-binding protein, FE65, Protein Kinase C type

I, Glutamate Receptor subunit d1, VAP1, Protein Kinase C subspecies epsilon, EST203549, and Heat Shock Transcription Factor 1.

48. The array of claim 47, wherein said member of said panel of genes is selected from the group consisting of Type II Hexokinase, Multi Drug Resistance Gene, Parvalbumin, BAD2, Prolactin, Interleukin-18, Calpain, EST196325, Annexin 1, N27, HBP1, and Protein Kinase C subspecies epsilon.

* * * * *